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Abstract 
 
Airway epithelia are the first targets of influenza A virus (IAV) infection and the first 
cells to respond, contributing to immunity, pathology and recovery. The magnitude 
and quality of epithelial responses may depend on exacerbations like bacterial 
superinfections and be determined by the host genetic background. We therefore 
use a primary mouse tracheal epithelial cell (mTECs) cultures to identify epithelial 
determinants of susceptibility and protection.  
We assessed mTEC responses to IAV-bacterial co-exposure and found that 
the massive in vivo cytokine and chemokine response to co-infection is reflected in 
vitro by strongly increased epithelial responses to a combined viral-bacterial 
stimulus compared to single stimuli. The antiviral transcriptional responses 
dominate the overall response in vivo and in vitro. 
We also compared the epithelial response to IAV between high interferon 
producing, susceptible 129S8 mice, and IAV-resistant moderate interferon 
producers, C57BL/6 mice. We found that 129S8-derived mTECs do not produce 
more interferons in response to IAV but respond more strongly to interferons and 
IAV by induction of cytokines and interferon-stimulated genes. 129S8-derived 
epithelia also proliferate and differentiate less well than C57BL/6 mTECs, 
suggesting reduced repair potential. 
The initial epithelial cell-intrinsic antiviral response and control of IAV 
depends on type I and/or III interferons (IFNαβ or IFNλ). When IFNα and IFNλ 
influenza treatments were compared, IFNα stimulated both innate immune cells 
and mTECs, increasing immunopathology and mortality. IFNλ treatment only 
induced antiviral epithelial responses but not the immune-mediated pathology 
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triggered by IFNα. Therefore, IFNλ treatment helps control IAV and protects without 
inducing immunopathology. 
During recovery, lung epithelial stem cells must proliferate and differentiate 
to repair infection-induced epithelial damage. We found that IFN impaired epithelial 
regeneration by reducing stem cell proliferation and differentiation, likely through 
IFN-induced blockade of epidermal growth factor signalling. Thus antiviral immune 
responses, if mistimed or excessive, may impede post-infection lung repair. 
Together, mTECs help identify determinants of susceptibility and protection. 
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Chapter 1. Introduction 
1.1 Respiratory infections 
1.1.1 Influenza A Virus 
Viral genome and classification 
 
The influenza virus was first isolated in 1933 by Smith, Andrewes and Laidlaw 
(Smith et al. 1933). Influenza viruses belong to the Orthomyxoviridea family of 
enveloped negative-sense RNA viruses. The five genera in this family include 
influenza types A, B, and C, isavirus (infectious salmon anemia virus) and 
thogotovirus. The three influenza genera differ in their host range and pathogenicity. 
The primary natural reservoir host species of Influenza A virus (IAV) include 
shorebirds and wild aquatic waterfowl (Webster et al. 1992; Centers for Disease 
Control and Prevention (CDC) 2016), however IAVs have adapted to stably infect a 
wide variety of avian and mammalian species, whereas influenza B and C virus 
infection is primarily restricted to humans (Palese and Shaw 2007).  
 IAV is enveloped with a host cell-derived lipid membrane and contains eight 
different RNA gene segments, each encoding at least one protein. The envelope is 
covered with projections of three surface proteins: heamagglutinin (HA), 
neuraminidase (NA), and matrix 2 (M2). The internal proteins include the 
nucleoprotein (NP), the matrix protein (M1) and the polymerase complex, which is 
composed of the polymerase basic protein 1 (PB1), polymerase basic protein 2 
(PB2), and polymerase acidic protein (PA). Nonstructural protein NS1 and non-
structural protein NS2, also known as nuclear export protein (NEP) are another set 
of proteins produced by IAV. NS1 has pleiotropic functions including dsRNA 
binding, inhibiting host mRNA processing, enhancement of viral mRNA translation 
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and type I interferon (IFN) antagonism (Palese and Shaw 2007; Gack et al. 2009). 
The protein PB1-F2 is not found in all IAV strains, but is thought to be involved in 
host cell apoptosis (Chen et al. 2001). 
 The antigenic characterization of the HA and NA surface glycoproteins 
allows for the subdivision of the different IAV strains into subtypes. There are 
currently 18 HA and 9 NA subtypes known, meaning theoretically there are 162 
possible HA-NA combinations. The World Health Organization guidelines for the 
nomenclature of IAV include (1) antigenic type (A, B, or C); (2) host (if nonhuman) 
the virus was isolated from; (3) geographic region of the isolate; (4) unique isolation 
reference number; (5) year of isolation; and finally (6) the HA and NA subtypes. For 
example, A/Puerto Rico/8/1934 (H1N1) indicates type A, isolated in Puerto Rico 
with an isolate number 8 in 1934, with HA subtype 1 and NA subtype 1 
(Taubenberger and Kash 2010), which is often abbreviated to PR8.  
 
Viral life cycle 
IAV is spread through aerosol exposure whereby it enters the respiratory tract. The 
first step of IAV infection is the attachment of the viral HA protein to sialic acid (SA) 
which are distal components of the glycosylation of host cell glycoproteins (Figure 
1A). Sialic acids are a derivative of neuraminic acid and often represent terminal 
carbohydrate found in N- and O-linked gylycoproteins. Sialic acid molecules are 
classified by how they are linked to the underlying sugars by the α-2 carbon, with α-
2,3 and α-2,6 being the most common linkages. Different IAVs have HAs with 
varying specificity to SAs. Avian upper airway epithelium expresses predominantly 
α-2,3 SA, whereas the human airway epithelium expresses mostly α-2,6 SA 
(Couceiro et al. 1993). Therefore, IAVs adapted to birds bind preferentially with α-
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2,3 SA, and generally do not infect humans. However, some humans and avian 
hosts have been found to express both types of SAs, although with different tissue 
distributions (Thompson et al. 2006; Wan and Perez 2006). The α2,3 SA has been 
documented to be expressed on human alveolar cells from the lower respiratory 
tract, hence the potential for avian influenza infection of humans (Ibricevic et al. 
2006; Shinya et al. 2006; Nicholls et al. 2007). Pathology of IAV can be attributed 
to this receptor distribution where highly pathogenic IAV strains such as H5N1 do 
not infect the upper respiratory tract where α-2,6 SA is abundant, but rather cause 
pneumonia by binding to α-2,3 SA in alveolar type II cells in the lower lung (Shinya 
et al. 2006). 
 Once the virus has attached to the host cell it is endocytosed by both 
clathrin-mediated and clathrin-independent mechanisms, and cleaved of HA by 
host proteases (Steinhauer 1999) (Figure 1B). Due to the requirement of these host 
proteases, the IAV tissue tropism is generally limited to the respiratory epithelial 
cells (Julkunen et al. 2000), although the infection of macrophages and leucocytes 
has also been documented this does not result in progeny (Manicassamy et al. 
2010). In addition, some highly pathogenic IAV strains have polybasic HA cleavage 
sites, allowing for HA cleavage by a wider range of host proteases and thus IAV 
infection of cells beyond airway epithelium. The acidic pH in the late endosome 
triggers a conformational change in HA resulting in the fusion of the viral and 
endosomal membranes allowing for the release of the viral RNA into the cytoplasm 
(Steinhauer 1999) (Figure 1C, D). The M2 protein plays a critical role in this 
triggering process as it acts as a proton channel allowing H+ ions to enter into the 
virion inducing the conformational change (Pinto and Lamb 2007) (Figure 1C).  
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Following uncoating, the eight RNA segments closely associated with the 
viral NP and the viral polymerase in viral ribonucleoproteins (vRNPs) are 
transported to the nucleus where the RNA undergoes genome replication and 
transcription (O'Neill et al. 1995; Bouvier and Palese 2008). The viral RNA 
polymerase, in combination with components of the host’s transcriptional 
machinery, transcribes viral RNA (vRNA) into mRNA. The viral genome is 
replicated via positive strand complementary RNA (cRNA) synthesis within the 
nucleus (Figure 1E). The mRNA migrates to the cytoplasm to begin viral protein 
translation. The new strands of RNA are also transported to the cytoplasm for the 
formation of the new RNP, where each new strand of RNA is encapsulated by the 
viral nucleoprotein (Baudin et al. 1994). The viral polymerases and NP catalyse the 
genome replication and transcription (Neumann et al. 1999). The proteins M1 and 
NEP also play a crucial role in the trafficking of viral proteins to and from the 
nucleus. The newly produced virus components are then moved to the apical 
plasma membrane of the host where they are assembled and the process of 
budding begins (Figure 1G). The M1 protein is required for the assembly and 
structure of the virion (Bourmakina and García-Sastre 2003) (Figure 1F). For 
efficient budding to occur the NA protein needs to remove the sialic acid from the 
surface glycoproteins, specifically the HA protein. This prevents self-binding of the 
protein and aggregation of the virus (Matrosovich et al. 2004) (Figure 1H). 
HA and NA are the antigenic targets of the humoral immune response to 
IAV, and the antiviral drugs oseltamivir and zanamivir target NA (Figure 1I). These 
viral sialidase inhibitors prevent the release of progeny virions and thereby limit the 
spread of infection. The adamantine class of antiviral drugs target the M2 protein to 
prevent viral replication (Taubenberger and Kash 2010) (Figure 1J). Ribavirin has 
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also been demonstrated to prevent viral replication by acting on the RNA 
polymerase function (Figure 1K). 
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Figure 1 Life cycle of the influenza virus and targets for therapeutic intervention 
IAV adheres to the target host cell using the viral surface glycoprotein 
haemagglutinin, which recognise host glycoconjugate residues (A). The virus is 
then endocytosed (B). A change in pH from the transport of ions into the vacuole 
containing the virus (C) allows for fusion and the release of viral RNA into the 
cytosol (D). The RNA is transported to the nucleus where viral RNA polymerase 
and the host-cell machinery are engaged to produce the necessary viral 
components (D). Viral genome is replicated via cRNA synthesis within the nucleus 
(E). The new viral proteins and RNA come together to form the new RNP where 
they are transported for assembly at the host cell plasma membrane (F). The 
budding process allows for new virion progeny to exit the host cell (G). Viral 
sialidase (NA) cleaves the host sialic acids to completely detach from the host cell 
to seek new host cells to infect (H). Zanamivir and oseltamivir efficiently block the 
sialidase activity of NA and the release of the virus from the host (I). Adamantanes 
target the M2 ion channel of the virus to prevent viral replication (J). Last, Ribavirin 
also prevents viral replication by targeting RNA polymerase.  
Adapted from (Itzstein 2007). Permission to reproduce this figure has been granted 
by Nature publishing group. 
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Antigenic drift and Antigenic shift. 
Influenza viruses have a high mutation rate and have the ability to reassort their 
gene segments, thus potentiating the large diversity in the viral population 
(Manrubia et al. 2005). IAV lacks a proofreading mechanism during the replication 
of viral RNA, which results in errors in transcription leading to this high mutation 
rate, known as antigenic drift (Palese and Shaw 2007). Many of these mutations 
however are deleterious to the virus as it can create premature stop codons, 
changes in the regulator signal that affects replication, or changes to the amino 
acids which render the virus less fit (Pybus et al. 2007). Amino acid mutations in 
the antigenic epitopes of the HA and NA may allow the IAV to evade pre-existing or 
newly forming immunity. Mutations of the HA also makes vaccination difficult as 
vaccine protection is mediated primarily by specific antibodies being produced to 
the specific HA subtype. 
 Co-infections of one host cell with two or more different IAVs can result in 
progeny viruses containing segments from the different parental viruses. This 
generally occurs within pigs, which are known as the mixing vessel for IAV. When 
this re-assortment results in different HA or NA subtypes this is classified as 
antigenic shift (Taubenberger and Kash 2010). When a human host becomes 
exposed to a new HA or NA subtype there is potentially little to no protective 
immunity and the virus can spread rapidly, causing a widespread and potentially 
severe pandemic outbreak.  
 
Epidemics and Pandemics 
The ability of the virus to mutate and reassert its genetic segments allows for the 
outbreak of epidemics and pandemics. Seasonal epidemics are estimated by the 
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World Health Organisation (WHO) to cause three to five million cases of severe 
illness and about 250,000 to 500,000 deaths annually worldwide (WHO 2014). The 
current circulating strains are generally restricted to the IAV strains H1N1 and 
H3N2 (Kreijtz et al. 2011).  
Pandemic viruses have been isolated from 1957 onwards, with the complete 
reconstruction of the 1918 pandemic virus occurring in 2005 (Taubenberger et al. 
2005). There have been five notable pandemics in the past century: 1918 H1N1 
‘Spanish flu’, 1957 H2N2 ‘Asian flu’, 1968 H3N2 ‘Hong Kong flu’, and the most 
recent 2009 H1N1 ‘swine flu’. The 1918-1919 ‘Spanish flu’ was the most severe 
documented pandemic when a novel avian-descended H1N1 virus emerged, 
resulting in an estimated 50 million deaths (Johnson and Mueller 2002; 
Taubenberger et al. 2005; Rabadan et al. 2006). A novel H1N1 virus derived from 
two distinct swine H1N1 viruses caused the recent 2009 ‘swine flu’ pandemic 
(Garten et al. 2009), resulting in approximately 148,000 – 249,000 deaths 
worldwide (Simonsen et al. 2013). 
 
IAV Host Switch 
The mechanisms by which avian IAVs cross the species barrier to infect mammals 
are not fully known. The growing number of human zoonotic infections has been 
associated with a high mortality rate leading to great concern of a possible future 
pandemic. Two subtypes of the HA (H5 and H7) are known to give rise to the highly 
pathogenic avian influenza (HPAI) viruses in poultry (Peiris et al. 2007). Since 1997, 
there have been a total of 720 reported cases of HPAI H5N1 infections in humans, 
predominantly in Southeast Asia (Peiris et al. 2007; Uyeki and Bresee 2007; Qin et 
al. 2015), of which 60% proved to be fatal (Kreijtz et al. 2011). 55 family clusters 
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were found among the reported human HPAI H5N1 cases reported (Qin et al. 
2015). This highlights the possibility of human-to-human H5N1 transmission. In fact, 
household secondary attack rates (SAR) were estimated at 29% (Uyeki and Bresee 
2007), which is similar to the SAR estimates from IAV infections in the United 
States (12.7-30.6%) (Longini et al. 1988). Although overshadowed by the spread of 
H5N1, H5, H7, and H9 subtype HPAI viruses, which are unrelated to the Asian 
H5N1, have also been isolated from infected humans (Alexander 2007; de Wit et 
al. 2008). 
 
 
1.1.2 Streptococcus pneumoniae 
Streptococcus pneumoniae is a gram-positive extracellular bacterium that 
transiently colonises the mucosal surfaces of the upper respiratory tract. It is the 
most common bacterial respiratory pathogen, frequently causing invasive disease 
leading to meningitis, otitis media, sepsis and pneumonia in the young, old and 
immunocompromised. S. pneumoniae-induced disease is the major cause of infant 
mortality, with a mortality rate of approximately 20-25% in children under the age of 
5 in the developing world and 10% worldwide, resulting in more than 1.2 million 
deaths annually worldwide (Berkley et al. 2005). Depending on the age of the host, 
30-60% of survivors develop long term clinical sequelae, such as neurological 
deficits, hearing loss and neuropsychological impairment (Mook-Kanamori et al. 
2011). There are currently 91 known pneumococcal capsular serotypes of S. 
pneumoniae, which vary in their degree of carriage and virulence (Kadioglu et al. 
2008). This variation of serotypes makes vaccination difficult. The 23-valent 
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vaccine, which has a theoretical coverage of 85-90% of the circulating strains, is 
only immunogenic in adults and children over the age of 5. The polysaccharides 
contained within this vaccine induce a severely impaired antibody response in 
children younger than 2 years old (Koskela et al. 1986; O'Brien et al. 1996). 
Fortunately, recent conjugate vaccines are highly immunogenic in children younger 
than 2 years of age, even inducing immunological memory (Eskola and Anttila 
1999). Penicillin is typically used to treat Streptococcus pneumoniae infections, 
however antibiotic resistance is increasing (Henriques-Normark and Tuomanen 
2013). 
 
Mechanism of Colonisation 
S. pneumoniae resides asymptomatically in the human nasopharynx, however 
spread of the bacteria to normally sterile areas of the airway can lead to severe 
complications and disease (Kadioglu et al. 2008). Colonisation generally occurs 
within early childhood. Once inhaled, S. pneumoniae enters the nasal cavity and 
encounters the mucus secretions. A polysaccharide capsule covers the outer 
surface of the pneumococcus. This capsule reduces the entrapment within the 
mucus and prevents phagocytosis of the bacterium, thereby facilitating epithelial 
attachment (Nelson et al. 2006). A thick capsule however, inhibits the ability to 
adhere to the epithelial surface. Most pneumococcal strains therefore display a 
phase variation of the capsular gene. The two bacterial forms can be distinguished 
by their opaque or transparent colony morphologies (Weiser et al. 1994). The 
opaque phenotype is associated with more capsular polysaccharide than the 
transparent form. During initial colonisation, transparent variants display increased 
binding to host tissues in comparison to the opaque variants (Weiser et al. 1994). 
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 The adherence to the epithelial lining of the respiratory tract is essential for 
colonisation. Asymptomatic colonisation requires binding to cell-surface 
carbohydrates (N-acetyl-glycosamine) on resting, non-inflamed epithelia (Bogaert 
et al. 2005). The bacterial surface molecules that bind to these host sugars include: 
lipoteichoic acids, pneumococcal surface adhesion A (PsaA), choline-binding 
protein A (CbpA) and phosphorylcholine (ChoP) (Bogaert et al. 2005; Kadioglu et 
al. 2008). ChoP mediates bacterial adherence by binding to the platelet activating-
factor receptor (PAFR). CbpA shows an increased affinity for immobilised sialic 
acid and lacto-N-neotetraose. Binding of these bacterial components to these host 
receptors induces internalisation of pneumococci and promotes transepithelial 
migrations, resulting in bacterial invasion of the organism (Bogaert et al. 2005). S. 
pneumoniae can also produce three exoglycosidases: a neuraminidase, NanA, a β-
N-acetylglucosaminidase, StrH, and a β-galactosidase, BgaA (King et al. 2009). 
These exoglycosidases may enhance colonisation due to the cleavage of the N-
acetylneuraminic acid, which is the most predominant sialic acid found in 
mammalian mucus. This cleavage reduces the viscosity of the mucus, allowing for 
the bacteria to reach the epithelial surface. These exoglycosidases can also 
remove the terminal sugars found on many human glucoconjugates, which may 
allow for the exposure of adherence receptors (Tong et al. 2000; Kadioglu et al. 
2008). Overall, the bacteria employ all of these mechanisms to penetrate 
through the mucus and bind to the airway epithelial cells to colonize a host. 
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1.1.3 IAV-S. pneumoniae co-infection 
There is increasing clinical evidence that a viral infection followed by a bacterial 
infection results in exacerbated disease, leading to increased morbidity and 
mortality compared to either single pathogen (Madhi et al. 2004; Thorburn et al. 
2006). The IAV pandemics since 1918 have demonstrated this association 
convincingly. During the 1918 ‘Spanish flu’, 95% of fatal cases were attributed to a 
bacterial co-infection (Morens et al. 2008). Of the bacteria isolated from the lungs 
of those that succumbed to disease, Streptococcus pneumoniae was found to be 
the most prevalent (Morens et al. 2008). Staphylococcus aureus, Haemophilus 
influenzae and Streptococcus pyogenes were also all attributed to be the most 
predominant bacteria in separate studies (Brundage and Shanks 2008). Of the 
1957 and 1968 pandemics, where the death toll was less severe compared to the 
1918 pandemic, co-infection was attributed to only 20-44% of deaths (Collins and 
Lehmann 1951; Dauer 1958). Staphylococcus aureus was the most prevalent 
bacterium in the bacterial isolates from these individuals, who were mainly patients 
with chronic medical conditions. This may reflect the use of antibiotics which are 
effective against S. pneumoniae, and the emergence of drug-resistant bacteria 
(Robertson et al. 1958; McCullers 2006). A similar trend was observed during the 
2009 pandemic. In the United States, 13% of the bacteria isolated from post 
mortem lung samples were found to be S. pneumoniae (Louie et al. 2009), and in 
Japan and Argentina, this percentage increased to approximately 50% (Palacios et 
al. 2009; Okada et al. 2011). This trend is not only observed in pandemics but also 
with seasonal outbreaks of IAV. For example, American children hospitalised with 
pneumococcal pneumonia were significantly more likely than control children to 
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have displayed IAV-induced symptoms in the weeks prior to their hospitalisation 
(O'Brien et al. 2000).  
It is therefore of great importance to understand the mechanisms behind the 
induction of exacerbated disease and death during co-infection, and their 
identification will allow for generation of better treatments against co-infections. 
Animal mouse studies have identified a number of these mechanisms, which will be 
discussed further within this Chapter and in Chapter 3. However, the initial and 
main inducers of many of these effects remain to be identified, and airway epithelial 
cells represent prime candidates for this.  
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1.2 The Immune response to IAV 
1.2.1 Innate immune response to IAV 
Recognition of IAV 
The innate immune system is the first line of immune defence against invading 
pathogens. IAV is recognised through pathogen associated molecular patterns 
(PAMPs), which are present within the virus, by pattern recognition receptors 
(PRRs). Recognition of the invading virus induces a rapid, broadly reactive 
response to reduce and control the infection. IAV is recognised by at least 3 distinct 
classes of PRRs: Toll-like receptors (TLR), NOD-like receptors (NLR) and retinoic 
acid-inducible gene I (RIG-I). 
 There are 11 TLRs, with some expressed on the cell surface (TLR1, 2, 4, 5, 
6, 10 and 11) and the others on the luminal side of endosomes (TLR3, 7, 8 and 9), 
which bind to a variety of viral and bacterial PAMPS (Schmolke and García-Sastre 
2010). Specifically for detection of IAV, TLR3, which recognises double-stranded 
RNA (dsRNA) (Guillot et al. 2005), TLR7 and TLR8, which recognise single-
stranded RNA, are utilised by host cells.  
 IAV infected cells do not generate dsRNA (Pichlmair et al. 2006), therefore it 
is thought that activation of TLR3 occurs due to currently unidentified RNA 
structures produced during phagocytosis of dying IAV-infected cells  (Schulz et al. 
2005). TLR3 is constitutively expressed in human epithelial cells and, once 
activated by IAV, induces the activation of the transcription factors IFN regulator 
factor 3 (IRF3) and nuclear factor-κB (NFκB) (Kawai and Akira 2007). Activation of 
these pathways leads to the production of type I and III IFNs and the production of 
proinflammatory cytokines, respectively (Le Goffic et al. 2007).  
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 Plasmacytoid dendritic cells (pDCs) utilise TLR7 to recognise ssRNA 
genomes contained within IAV once they enter the endosome (Diebold 2004; Lund 
et al. 2004). Like TLR3, signalling through this receptor induces the activation of 
NFκB and IFN-regulator factor 7 (IRF7), which again are responsible for the 
expression of proinflammatory cytokines and type I and III IFNs. TLR7 was also 
implicated in eliciting a robust antibody response to IAV (Heer et al. 2007). TLR8, 
which is expressed by human monocytes and macrophages, can induce the 
proinflammatory cytokine IL-12 but not IFNα, a type I IFN, following activation 
(Ablasser et al. 2009). However, the exact relevance of this receptor during IAV 
infection remains to be elucidated. 
 Activation of the NLR pathways induces formation of inflammasome 
complexes resulting in the autocatalytic activation of pro-caspase 1, which can elicit 
pyroptosis of infected cells (Bergsbaken et al. 2009) and generate mature IL-1β 
and IL-18. The NLRP3 system can be activated by numerous stimuli including a 
variety of pathogens, stress and host cell damage (Martinon et al. 2009). The 
involvement of the inflammasome signalling after IAV infection in the innate 
immune response has been demonstrated (Allen et al. 2009; Thomas et al. 2009). 
However, the study by Allen et al. inoculated mice with IAV along with alum, which 
is well known for inducing the NLRP3 inflammasome (Li et al. 2008). Therefore the 
study by Allen and colleagues does not fully demonstrate that it is IAV alone that is 
inducing the inflammasome signalling. Monocytes, DCs, neutrophils, macrophages 
(Guarda et al. 2011), and bronchial epithelial cells (Pothlichet et al. 2013) have all 
been shown to undergo NLRP3 signalling. One study showed the inflammasome 
recognition of IAV is essential for the adaptive immune response to infection 
(Ichinohe et al. 2009). 
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 RIG-I activation is crucial for IAV detection, and type I and III IFN production 
in infected epithelial cells, conventional dendritic cells (cDCs) and alveolar 
macrophages (Kato et al. 2005). RIG-I recognises the 5’-triphosphorylated viral 
ssRNA, the 5’ pattern of viral genomic RNA, within the cytosol of infected cells 
(Hornung et al. 2006; Pichlmair et al. 2006; Baum et al. 2010; Rehwinkel et al. 
2010). Upon recognition of IAV, a conformation change enables the caspase-
recruitment domains to bind to the signalling adaptor: mitochondrial antiviral 
signalling protein (MAVS) (Jiang et al. 2011; Kowalinski et al. 2011). MAVS 
subsequently activates IRF3, IRF7 and NFκB, initiating the IFN and inflammatory 
response to infection. NS1 protein can bind to viral RNA, masking it from PRRs 
recognition. NS1 proteins can also block RIG-I binding to the tripartite-motif-
containing protein 25 (TRIM25), therefore suppressing RIG-I signalling and IFN 
production (Gack et al. 2009). The evolution of IAV to antagonise RIG-I and IFN 
signalling by NS1 demonstrates the importance of the RIG-I mediated recognition 
of IAV and the IFN antiviral response to IAV (Pichlmair et al. 2006; Palese and 
Shaw 2007; Gack et al. 2009).  
 
IFNαβ and IFNλ response 
IFNs were discovered and named for their ability to ‘interfere’ with viral replication. 
There are three distinct families of IFNs: type I, type II and type III. The type I IFN 
family is a multi-gene cytokine family consisting of 13 partially homologous IFNα 
subtypes (11 in mice), a single IFNβ, and several other family members (IFNε, 
IFNδ, IFNκ, IFNω, and IFNζ). The type II IFN family contains IFNγ. The final family 
of type III IFNs comprises of IFNλ1 (IL-29), IFNλ2 (IL28A), IFNλ3 (IL28B) and the 
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recently discovered IFNλ4 (Pestka et al. 2004; Prokunina-Olsson et al. 2013; 
O’Brien et al. 2014).  
 As mentioned, type I IFNs are induced after IAV detection by PRRs. Almost 
all cells in the body have the capacity to produce and respond to type I IFNs. pDCs 
were found to be the most potent type I IFN producer (Ganguly et al. 2013). Type I 
IFNs are classified as antiviral cytokines, capable of inhibiting replication and 
spread of viruses (Isaacs and Lindenmann 1957; Müller et al. 1994). All type I IFNs 
signal exclusively through the ubiquitously expressed heterodimeric 
transmembrane receptor, IFNαβR. This receptor is composed of the subunits 
IFNAR1 and IFNAR2 (McNab et al. 2015). IFNα and IFNβ are more broadly 
expressed than the other family members, and therefore many studies concentrate 
on the actions of these two subtypes. IFNαβ can act in an autocrine and paracrine 
manner by binding to the IFNαβR on the infected cell or to neighboring cells 
(Randall and Goodbourn 2008). Engagement of the receptor activates janus kinase 
1 (JAK1) and tyrosine kinase 2 (TYK2). JAK1 and TYK2 then act to phosphorylate 
signal transducers and activators of the transcription 1 and 2 (STAT1 and STAT2) 
present in the cytosol, leading to dimerization and binding to IRF9 to form the 
trimeric transcription factor ISGF3 (Murray 2007). The ISGF3 complex binds to 
IFN-stimulated response elements which triggers the expression of several 
hundred interferon stimulated genes (ISGs) (Ivashkiv and Donlin 2014; Schneider 
et al. 2014)  
 Many of these ISGs have been attributed with a direct antiviral role, by 
inhibiting viral replication and limiting viral spread, including the MX, IFITM, OAS 
and RSAD protein families. MX proteins were amongst the first ISGs to be 
identified that restrict IAV infection (Staeheli et al. 1986). Humans express MXA 
Chapter 2 Materials and Methods 
 
36 
 
and MXB, however it is only the MXA protein, which is present in the cytosol, that 
has potent antiviral activity towards IAV, along with many other viruses (Pavlovic et 
al. 1995; Hefti et al. 1999; Turan 2004). In contrast, the MXB protein, present at the 
cytoplasmic face of nuclear pore complexes, does not inhibit IAV infection but can 
restrict human immunodeficiency virus-1 (HIV-1) (Liu, Pan, et al. 2013). IFITM 
proteins, which are constitutively expressed by respiratory epithelial cells, 
macrophages, and endothelial cells, also restrict IAV replication by blocking virus to 
host cell membrane fusion (Huang et al. 2011). Furthermore, IFITM3 was found to 
have a role in limiting host damage resulting from IAV infection (Everitt et al. 2012). 
Humans can have natural hypomorphic mutations in the ifitm3 gene which 
associates with increased morbidity and mortality following IAV infections (Everitt et 
al. 2012). The OAS (2’-5’-oligoadenylate synthase) family acts together with 
ribonuclease L (RNase L) to degrade viral RNA present in the cytosol (Iwasaki and 
Pillai 2014). Finally, overexpression of RSAD2 (viperin) blocks the release of IAV 
from host cells by inhibiting the formation of lipid rafts (Wang et al. 2007). 
 Type I IFNs not only induce a cell-intrinsic antiviral response but are also 
involved in activating or inhibiting the response of myeloid cells, NK cells, B cells 
and T cells, depending on the response context. Type I IFN production can activate 
immature committed dendritic cells (DCs), enhancing the cell surface expression of 
major histocompatibility complex (MHC) along with the co-stimulatory molecules 
CD80 and CD86, to increase the ability to stimulate T cells and thereby viral 
clearance (Montoya et al. 2002). It has also been observed that type I IFN can 
promote the DC capability to cross-present antigens and migrate to the lymph 
nodes during viral infections (Parlato et al. 2001; Le Bon et al. 2003). NK cells were 
found to have increased function and survival following stimulation with type I IFNs. 
Chapter 2 Materials and Methods 
 
37 
 
Following IAV infection, the type I IFNs produced induce the cytolytic effector 
function and the production of IFNγ by NK cells (Nguyen et al. 2002). B cell 
activation and antibody responses were increased following type I IFN stimulation 
early in IAV infection, however late in infection the role of type I IFNs on B cells is 
negligible (Price et al. 2000; Swanson et al. 2010). A stimulatory and inhibitory role 
of type I IFNs have also been described for both CD4+ and CD8+ T cell survival, 
proliferation, cytokine production, cytotoxic function and memory formation (McNab 
et al. 2015). 
 Although type I IFNs are associated with a protective antiviral response, the 
immunomodulatory effects, along with triggering inflammation and tissue damage, 
may sometimes supersede their protective actions resulting in exacerbated disease. 
IAV mediated lung tissue damage may be due to the viral cytotoxic effects, or to 
the immune response. If the immune response is left unchecked it can potentially 
cause pathology to the host. This was observed in patients infected with highly 
pathogenic influenza strains, where high proinflammatory cytokines associated with 
tissue damage and disease severity (Peiris et al. 2004; de Jong et al. 2006). Two 
studies have delved specifically into the role of type I IFNs during influenza 
infection with both associating high type I IFN concentrations with increased 
disease severity (Boon et al. 2009; Davidson et al. 2014). Type I IFNs have been 
demonstrated to regulate not only cellular survival but also have the potential to 
induce cell death pathways (Leaman et al. 2003). The apoptosis inducing ligand, 
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is upregulated on 
many cells following type I IFN stimulation during IAV infection (Herold et al. 2008). 
This member of the TNF superfamily (TNFSF10) of cytokines can act as a surface-
bound or secreted protein that upon binding with its receptors (TRAIL-R1 and 
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TRAIL-R2 in humans, and DR5 in mice) induces apoptosis of the cells in a 
caspase-dependent manner (Walczak et al. 1997; Holoch and Griffith 2009; 
Benedict and Ware 2012). In IAV infection, type I IFN mediated upregulation of 
TRAIL on inflammatory monocytes, and DR5 on airway epithelial cells resulted in 
epithelial cell death and lung damage leading to host morbidity and mortality 
(Herold et al. 2008; Davidson et al. 2014). FASL, another apoptosis inducing ligand, 
which can bind to its receptor FAS to induce apoptosis, was found to be induced 
following type I IFN stimulation during IAV infection, and also correlated with lung 
damage and disease severity (Fujikura et al. 2013). Overall, the immunomodulatory 
effects of type I IFNs on immune cells which act in parallel to the induction of ISGs, 
shows the potential of type I IFNs to over-activate the immune system during IAV 
infection, inducing immunopathology. However, induction of ISGs with the potential 
to be pathogenic, such as TRAIL, requires 100-fold higher IFN concentrations than 
that of antiviral ISGs such as MX (Leaman et al. 2003; Thomas et al. 2011; 
Davidson et al. 2015). 
 Type III IFNs were discovered in 2002 (Kotenko et al. 2002; Sheppard et al. 
2002). Like type I IFNs, type III IFNs induce the same JAK/STAT signalling 
pathway to activate transcription of the same set of ISGs (Sheppard et al. 2002; 
Crotta et al. 2013). However, type III IFNs bind to a completely separate receptor, 
IFNλR, which is composed of IFNλR1 and IL-10 receptor chain 2 (IL-10R2). This 
receptor, unlike the IFNαβR, is restricted to mucosal surfaces such as the airway 
epithelium or the gut (Sommereyns et al. 2008; Mordstein et al. 2010). Due to this 
receptor distribution, type III IFNs cannot stimulate the immune cells of the host. 
Infection of mice deficient in IFNAR, IFNλR, or both receptors, with a variety of 
viruses has established redundancy between these two types of IFN. Only when 
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there was absence of both receptors was a dramatic loss of viral control and host 
mortality observed (Mordstein et al. 2008; Crotta et al. 2013). This is only true for 
viruses for which tissue tropism is restricted to epithelial cells such as IAV. IAV can 
only productively infect epithelial cells, whereas many other virus such as the 
measles virus can productively infect both epithelial and immune cells (Tahara et 
al. 2008). In this case loss of IFNAR may be detrimental. Type III IFNs may 
therefore have evolved to induce an antiviral state within the epithelial cells, the first 
host target of infection for many viruses, without triggering the immune system, 
which as previously discussed can induce immunopathology. 
 
 
1.2.2 Overview of adaptive immune response to IAV 
The innate immune response is crucial for the recognition and initial control of IAV. 
It is the adaptive immune response however that is essential to fully clear the 
infection. The lung antigen-presenting cells (APCs) such as DCs are recruited, 
activated, and uptake antigen following IAV detection. These cells then migrate out 
of the infected lungs to the draining lymph nodes (Holt et al. 2008). The 
accumulation of APCs in the draining lymph node concentrates viral antigens 
where virus-specific naïve T cells reside, thus promoting the encounter with their 
cognate antigens and their subsequent priming (Khanna et al. 2008). Virus specific 
CD8+ T cells recognise infected cells via influenza peptide-MHC class I (MHCI) 
complexes on the cell surface (Thomas et al. 2006). Once IAV is detected, 
activated CD8+ T cells lyse the infected cells through perforin, FAS-, or TRAIL- 
dependent mechanisms (Topham et al. 1997; Brincks et al. 2008). Human studies 
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have revealed that IAV-specific CD8+ T cells react to the viral NP and M1 proteins 
(Gotch et al. 1987; Jameson et al. 1998). These proteins are highly conserved 
between IAV strains, therefore allowing for a higher degree of cross-protection by 
CD8+ T cells between the different strains. Due to this selective pressure, many 
amino acid substitutions occurring during the evolution of the H3N2 strain 
associated with decreased recognition by virus-specific CD8+ T cells (Boon et al. 
2004; Berkhoff et al. 2007).  
The primary role of CD4+ T cells in IAV infection is to provide cognate help 
to B cells through TCR:MHCII interactions, promoting activation of B cells, class 
switching, and affinity maturation of the antibodies they produce. This T-cell help 
promotes the antibody response against IAV (Topham et al. 1996; Topham and 
Doherty 1998). Most protective antibodies induced by IAV infection however are 
mainly directed to the highly variable head region of HA and are therefore often 
strain specific (Caton et al. 1982; Laursen and Wilson 2013). These antibodies can 
mark the infected cell for destruction by phagocytic cells, known as antibody-
dependent cell-mediated cytotoxicity (ADCC) (Hashimoto et al. 1983). HA specific 
antibodies can also neutralise the ability of IAV to attach to and infect the host cells 
(neutralising antibodies). The high variability of the HA head region is immune-
driven and makes generation of effective vaccines difficult, as they cannot induce 
broadly neutralising antibodies. Several cross-reactive antibodies against IAV have 
been documented. HA-stalk reactive antibodies can bind to highly conserved 
epitopes in the membrane-proximal stalk region of the HA molecule to neutralise 
many different HA subtypes (Ekiert et al. 2009; 2011; Tan et al. 2012; DiLillo et al. 
2014; Tan et al. 2014). These broadly neutralising antibodies work either by 
preventing fusion with the host cell (Ekiert et al. 2009), by preventing IAV from 
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escaping from within the endosome (Tan et al. 2012), or by hindering virus budding 
(Tan et al. 2014). Additionally, antibodies to NA, M2, and NP have been shown to 
also have broad neutralising or ADCC-inducing capacity against IAV (Zebedee and 
Lamb 1988; Mozdzanowska et al. 1999; Carragher et al. 2008). 
CD4+ T cells, CD8+ T cells, antibodies, and memory B cells are all therefore 
essential for clearance and immunological memory against IAV. As previously 
discussed, antigenic drift can allow for IAV to evade the adaptive responses due to 
reduced affinity of the antibodies and CD8+ T cells. Antigenic shift is another 
mechanism by which IAV evades the adaptive immune response, as the host may 
have no pre-existing antibodies or T cells able to recognise the completely novel 
IAV strain. 
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1.3 The Immune response to S. pneumoniae 
1.3.1 Overview of innate immune response to S. pneumoniae 
Like IAV, PAMPS of S. pneumoniae are detected by the PRRs of the host, 
including TLRs, NLRs, and C-type lectins. TLR2 recognises the cell wall 
peptidoglycan and lipoteichoic acid (LTA) of S. pneumoniae (Yoshimura et al. 
1999; Han et al. 2003; Schroder et al. 2003). However, studies on the role of TLR2 
in pneumococcal pneumonia have shown only a modest contribution of this 
receptor in the defence against the pathogen (Knapp et al. 2004). In contrast, TLR2 
was found to play a detrimental role during infection by impairing the epithelial 
barrier integrity and promoting pneumococcal translocation (Clarke et al. 2011). 
TLR4, a receptor that is traditionally associated with the recognition of gram-
negative bacteria, can directly interact with the pneumolysin of S. pneumoniae 
(Srivastava et al. 2005). The importance of TLR4 in the detection of the bacterium 
appears to be restricted to the airway surfaces, as one study found no difference in 
blood bacterial loads, and survival in TLR4 deficient mice following infection 
(Benton et al. 1997). TLR9 detects unmethylated cytosine-phosphate-guanosine 
(CpG) motifs which are abundant in prokaryotic DNA (Bauer et al. 2001). Studies 
have shown only a mild increase in disease severity when any one of these three 
TLRs were missing (Knapp et al. 2004; van Rossum et al. 2005), but mice lacking 
the adaptor molecule myeloid differentiation factor 88 (MyD88) were highly 
susceptible to infection (Albiger et al. 2005). MyD88 is a key adaptor molecule in 
the signalling cascade downstream of nearly all TLRs, except TLR3 (Premkumar et 
al. 2010), and of the interleukin-1 receptor (IL-1R) and IL-18R. TLRs therefore play 
an important but a partially redundant role in the recognition of S. pneumoniae. 
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 Nod1 and Nod2 recognize microbial products to activate a NFκB dependent 
proinflammatory cytokine response (Chen et al. 2009). Nod1 detects peptidoglycan 
fragments which are mainly produced by gram-negative bacteria, whereas Nod2 
detects peptidoglycans of most bacteria, including S. pneumoniae (Opitz et al. 
2004). This recognition of S. pneumoniae by Nod2 requires phagocytosis and 
lysozyme-dependent digestion of the bacteria by macrophages. The subsequent 
delivery of pneumococcal peptidoglycan fragments into the cytosol of the host 
induces Nod2 activation (Opitz et al. 2004; Davis et al. 2011). NLRP3 has also 
been attributed with the response to S. pneumoniae. The NLRP3 pathway was 
shown to be involved in the pneumolysin mediated proinflammatory cytokine 
production in macrophages and DCs (McNeela et al. 2010; Witzenrath et al. 2011). 
 The C-type lectin SIGN-R1 is expressed by macrophages and can bind to 
capsular polysaccharide of the bacteria (Kang et al. 2004). The absence of SIGN-
R1 results in sepsis and increased mortality following S. pneumoniae infection of 
mice (Lanoue et al. 2004; Koppel et al. 2005). Another macrophage receptor, 
MARCO can also bind to the bacteria to facilitate phagocytosis, although the 
bacterial ligands recognised by MARCO have yet to be identified (Arredouani et al. 
2004). 
Activation of these PRRs induces the expression of inflammatory mediators 
including TNF-α, IL-6, CXCL1, CXCL2, CCL2, IL-1β, and IFNαβ through the 
stimulation of NFκB and IRF3/7. These cytokines then activate and recruit immune 
cells such as neutrophils and macrophages, which phagocytose or kill the bacteria 
in an effort to clear the infection.  
 Like in IAV, type I IFNs can have both a protective and a detrimental role 
within bacterial infections. In studies utilizing the Ifnar-/- mice, infection with S. 
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pneumoniae resulted in increased bacterial growth and mortality compared to the 
wild-type controls (Weigent et al. 1986; Parker et al. 2014). Type I IFN signalling 
during S. pneumoniae infection contributes to the optimal secretion of TNF-α and 
inducible nitric oxide synthase (iNOS) from macrophages, and other antimicrobial 
effectors such as indoleamine 2,3-dioxygenase (IDO), granulocyte-binding proteins 
and proinflammatory cytokines (McNab et al. 2015). In contrast, type I IFNs may 
impair the host response to the bacteria by inducing extensive cell apoptosis such 
as TRAIL-DR5 interaction (Halaas et al. 2004), inducing IL-10 and IL-1 receptor 
antagonist to suppress the proinflammatory cytokine production, and reducing the 
responsiveness of immune cells to IFNγ (McNab et al. 2015). 
 The complement pathway is thought to be one of the most important 
immune response for the clearance of S. pneumoniae. C-reactive protein (CRP) 
binds to ChoP on the bacterium, which then binds to C1q of the complement 
system, activating the classical pathway of complement (Brown et al. 2002). 
Furthermore, the CRP concentrations found in the airway can inhibit the 
pneumococcal adherence to PAFR on the epithelial surface (Gould and Weiser 
2002). The subsequent deposition and activation of the complement component, 
C3, on the surface of the bacteria results in the complement cascade leading to 
opsonphagocytosis of the bacterium and the induction of inflammation. As the 
complement system is critical in the immune response to the bacterium, 
pneumococcus has evolved several mechanisms to evade this response. The 
capsule limits the accessibility for the cell-bound complement and reduces the 
amount that can be deposited (Abeyta et al. 2003). PhpA on the surface of S. 
pneumoniae can degrade C3, thus preventing the complement-mediated clearance 
of the bacteria (Angel et al. 1994; Zhang et al. 2001). Two more surface proteins: 
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PspA and PspC, can also contribute to resistance from complement (Ren et al. 
2004). Furthermore, pneumolysin has been found to protect from complement 
deposition and complement-mediated clearance (Yuste et al. 2005), however the 
mechanisms for how this protective response is initiated is unknown. 
 
 
1.3.2 Overview of adaptive response to S. pneumoniae 
The complement pathway can also be initiated by antibody binding. Antibody 
mediated complement-dependent opsonophagocytosis is thought to be the main 
method of S. pneumoniae control (Mold et al. 2002). The presence of serotype-
specific IgG against the capsule of S. pneumoniae correlates with protection, which 
is the immune status that the 23-valent vaccine attempts to generate. Antibodies to 
the capsular polysaccharide of S. pneumoniae can agglutinate the bacteria and 
mark them up for phagocytosis (Musher et al. 1993). Preformed ‘natural antibodies’, 
which are produced without prior S. pneumoniae infection, but in response to the 
normal gut flora, can be protective against pneumococcal challenge (Mold et al. 
2002). Furthermore, CD4+ T cells have been found to be recruited rapidly to 
infected areas of the host in a pneumolysin-dependent manner, and contribute to 
bacterial clearance through induction of mucosal antibodies and a Th1 response 
(Kemp et al. 2002; van Rossum et al. 2005; Zhang et al. 2006). 
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1.4 Immune response to IAV-S. pneumoniae co-infection 
IAV infection followed by bacterial infection, such as with S. pneumoniae, results in 
exacerbated disease leading to a more severe outcome in comparison to either 
single infection. Mechanistic studies of IAV-S. pneumoniae co-infections have 
implicated the primary viral infection predisposing the host to the secondary 
bacterial infection. Lung damage and dysfunction, increased epithelial adhesion, 
immune impairment and a strong proinflammatory cytokine response have all been 
attributed to the synergistic effects of co-infection. Mouse models of co-infection 
have also shown that the susceptibility to secondary infection occurs between 3 to 
14 days post IAV infection, with the greatest susceptibility occurring at day 7 
(McCullers and Rehg 2002). 
 
 
1.4.1 Lung damage and dysfunction 
Epithelial cell damage and reduced function 
The primary IAV infection can cause many changes within the lung, which can 
facilitate the secondary bacterial invasion. IAV strains that express the pro-
apoptotic viral peptide PB1-F2 induce lung damage and inflammation and 
associate with a more severe outcome following a co-infection (McAuley et al. 
2007). This outcome depends on the sequence of PB1-F2, therefore disease 
severity correlates with the variant PB1-F2 present in the IAV strain. (Weeks-
Gorospe et al. 2012; Alymova et al. 2013).  
IAV infection creates epithelial damage leading to the sloughing of host cells 
into the airways. This along with increased mucus production provides an 
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environment rich in nutrients ideal for rapid bacterial growth (Siegel et al. 2014). 
The ciliated cells of the lung can also be affected by IAV infection, resulting in 
decreased ciliar beat frequency and uncoordinated movement (Levandowski et al. 
1985; Pittet et al. 2010). This may reduce the mechanical clearance of the 
secondary pneumococcus, thus further potentiating S. pneumoniae colonization 
within the lung (Figure 2A).  
 
Increased epithelial adhesion 
Virus-mediated cytotoxicity or immune-mediated epithelial cell apoptosis leads to 
damage to the epithelium, exposing the extracellular matrix molecules and the 
basement membrane elements which bacteria can adhere to (McCullers 2004). 
This may allow for increased pneumococcal binding to the lung epithelium. Primary 
IAV infection was shown to increase the capability of S. pneumoniae to bind to 
mouse tracheal epithelial cells (Plotkowski et al. 1986) and a human alveolar cell 
line (McCullers 2004). Within the lungs of humans that succumbed to pandemic 
IAV, increased bacterial adherence was also observed (Morens et al. 2008; 
Centers for Disease Control and Prevention (CDC) 2009). 
 Most seasonal strains of IAV do not cause extensive lung damage but can 
still facilitate bacterial co-infections, although not as severe in comparison to the 
induction by high pathogenic IAV strains (Guarner and Falcón-Escobedo 2009). 
This suggests that other, potentially receptor-mediated, mechanisms are at play 
beyond the apoptosis-inducing mechanisms of high pathogenic IAV strains. The 
neuraminidase of the virus can cleave host SAs, which may expose the bacterial 
adhesion receptors. Furthermore, the viral neuraminidase can disrupt the sialylated 
mucins of the host that may have otherwise acted as decoy receptors for the 
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bacteria (McCullers and Bartmess 2003). S. pneumoniae also processes a 
neuraminidase to cleave the protective mucins and access the epithelial surface. 
The presences of IAV in the lungs before the inhaled bacteria may therefore 
generate an environment permissive for colonisation and unchecked outgrowth of 
the bacteria. The epithelial receptor PAFR may be one of these bacterial binding 
sites exposed following viral infection, allowing for binding by the virulence factor 
ChoP of S. pneumoniae. Pafr-/- mice had a moderately reduced bacterial load and 
were slightly protected (van der Sluijs et al. 2010).  
Not only may there be increased lung damage and neuraminidase-mediated 
exposure of binding partners, but the repair and regeneration of the epithelial cell 
layer may also be affected. Kash and colleagues found that following co-infection 
there was a reduction in epithelial stem cells, proliferation, and reduction of the 
epithelial growth factors: hepatocyte growth factor (HGF) and fibroblast growth 
factor (FGF). The loss of these factors results in decreased repair responses (Kash 
et al. 2011). This may also lead to increased binding by S. pneumoniae as areas of 
incomplete repair have the basement membrane of the epithelia exposed, leaving 
components such as laminin or type I and type IV collagen accessible for S. 
pneumoniae adhesion (Kostrzynska and Wadström 1992). 
 
 
1.4.2 Immune impairment and immune deviation 
The bacterial infection is usually controlled and eliminated by multiple immune 
mechanisms during single infection. Following IAV infection however, this anti-
bacterial response may be impaired. It was suggested that IAV infection can lead to 
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prolonged desensitization of TLRs for up to 6 weeks, resulting in augmented 
detection of and increased susceptibility to S. pneumoniae (Didierlaurent et al. 
2008), but this increased susceptibility was only mentioned in the text of this paper 
and not shown in a data graph. Furthermore, the IAV induced apoptosis of cells 
results in the exposure of the inhibitory signal molecule CD200. CD200 can bind to 
its cognate receptor CD200R on myeloid cells, such as DCs and alveolar 
macrophages (Barclay et al. 2002), which results in reduced responsiveness of 
these myeloid cells to the bacteria (Goulding et al. 2011) (Figure 2B). This reduced 
ability to detect and respond to the bacteria means mice may control bacteria less 
well and succumb to disease. 
 Macrophages are important for the control and elimination of S. pneumoniae 
(Davis et al. 2011). These macrophages may become impaired following IAV due 
to reduction in numbers and decreased ability to phagocytose the bacteria. IAV 
specifically depletes the airway resident macrophages from the lung, which 
normally clear bacteria early in infection (Ghoneim et al. 2013). As these alveolar 
macrophages take up to 2 weeks to replenish (Ghoneim et al. 2013), there is a 
deficit of an early antibacterial response in the lung, thus facilitating an unchecked 
growth of the bacteria. Following co-infection the IFNγ production by T and NK cells 
provokes a decreased ability of any non-depleted macrophages to bind and 
phagocytose S. pneumoniae. IFNγ acts to downregulate the alveolar macrophage 
scavenger receptor MARCO resulting in decreased antibacterial function (Sun and 
Metzger 2008) (Figure 2C). The role of IFNγ in the impairment of the immune 
response during co-infection was confirmed in studies using linezolid treatment, 
which reduces IFNγ production. This treatment improved the survival of the hosts 
(Breslow-Deckman et al. 2013).  
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High concentrations of the antiviral cytokines, type I IFNs, can also 
compromise the immune response to the secondary bacterial infection by 
suppressing the anti-bacterial functions of macrophages and neutrophils 
(Shahangian et al. 2009; Li et al. 2012). Type I IFNs act to impair the recruitment of 
monocytes through suppression of the chemoattractant CCL2 during co-infection 
(Nakamura et al. 2011) (Figure 2D). Overall, the decreased ability of the 
macrophages to respond to infection may be increasing the susceptibility to 
secondary infection permitting a bacterial outgrowth. 
 Type I IFNs can also inhibit the recruitment of neutrophils by suppression of 
neutrophil chemoattractants such as CXCL1 and CXCL2 (Shahangian et al. 2009; 
Schliehe et al. 2014). Type I IFN production following IAV infection was found to 
induce Setdb2 protein, which correlated with repression of the CXCL1 gene. 
Setdb2 was found to have a negative effect upon early neutrophil recruitment, 
pathogen clearance and tissue integrity during IAV – S. pneumoniae co-infection. 
(Schliehe et al. 2014). Type I IFNs can also transiently reduce IL-17 production by 
γδT cells resulting in fewer recruited neutrophils (Li et al. 2012). Regardless of this 
effect by type I IFNs, it is found that neutrophil numbers are increased overall 
during co-infection (LeVine et al. 2001). This contradiction may be due to the 
outgrowth of bacteria driving the neutrophil recruitment which many override an 
initial IFN-induced impairment. Damjanovic and associates showed increased 
neutrophil numbers along with increased myeloperoxidase activity in the lungs of 
co-infected lungs mice, but with a marginally decreased phagocytic capacity in vitro 
(Damjanovic et al. 2013). In contrast, LeVine and others showed reduced 
myeloperoxidase activity of the neutrophils (LeVine et al. 2001). This discrepancy 
could be due to different IAV and S. pneumoniae strains, and the dosing used in 
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these two studies.  The exact role of neutrophils during co-infection is not fully 
known. One study showed that antibiotic-induced lysis of bacteria resulted in an 
influx of neutrophils into the co-infected lungs, which caused extensive lung 
damage and mortality (Karlström et al. 2011). However this study also employed 
antibiotics that did not induce this influx of neutrophils and protected against 
mortality. The authors argue that the lysis of the bacterium by certain antibiotics 
elicits a ‘proinflammatory burst’, exacerbating disease (Karlström et al. 2011). 
Nonetheless this study along with the study by Schliehe et al. highlights the impact 
neutrophils can have on lung damage if they are recruited in high numbers.  
Many studies have delved into whether neutrophils were protective during 
co-infection. Studies that depleted neutrophils during co-infection did not show 
exacerbated disease (Bogaert et al. 2010; Damjanovic et al. 2013). McNamee and 
colleagues showed that depletion of neutrophils when S. pneumoniae was given 3 
days after IAV infection however did exacerbate disease, whereas no effect was 
seen when the pneumococcus was given 6 days post influenza (McNamee and 
Harmsen 2006). This study suggests that this is due to an increase in neutrophil 
impairment during IAV infection, thus they become non-protective late in infection. 
This study however depleted neutrophils with the low specificity RB6 antibody and 
also simultaneously treated IAV-infected mice with LPS aerosolization. This poor in 
vivo depletion and the potentially confounding LPS aerosolization make 
interpretation of these results difficult. It may be interpreted that neutrophil 
depletion is detrimental at 3 d.p.i due to the lower level of bacterial loads, whereas 
the effect of neutrophil depletion at 6 d.p.i cannot exacerbate disease further with 
the already high level of bacterial load within the lung. 
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Ellis and associates did describe a protective role for neutrophils. Blockade 
of neutrophils resulted in bacterial outgrowth and increased mortality (Ellis et al. 
2015). Different timings and methods of infection along with different viral and 
bacterial strains may explain the differences between all these studies. It is 
therefore unclear whether the protective action of neutrophils is essential during co-
infection and whether their impairment greatly exacerbates disease.  
 The immunosuppressive effects of type I IFNs induced by the primary 
infection are in contrast with studies that used IFNα as a treatment against co-
infection. Treatment with this type I IFN increased the neutrophil and macrophage 
response, and survival of the mouse (Damjanovic et al. 2014). Overall it remains to 
be fully elucidated whether the role of type I IFNs during co-infections are beneficial 
or detrimental to the outcome of the response and infection. The timing and 
duration of IFN production may also make a difference to this outcome.  
 
 
1.4.3 Enhanced proinflammatory responses 
IAV and S. pneumoniae stimulate many of the same PRRs and induce similar 
effector molecules, therefore it is plausible that in the presence of both pathogens a 
synergistic response may occur. The apoptotic and inflammatory properties of the 
viral PB1-F2, may synergise with the pneumolysin of S. pneumoniae to induce 
exacerbated cell death and inflammation, leading to a ‘cytokine storm’ (McCullers 
2014). Many studies have observed this synergistic increase in an inflammatory 
response even in the absence of PB1-F2 and pneumolysin, thus showing that this 
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cytokine storm may not solely be due to the synergism of these two pathogen 
proteins. 
Increased TNF-α, IL-1β, CXCL1, CXCL2, IL-12 and IFN-γ have all been 
observed (LeVine et al. 2001; Seki et al. 2004; Smith et al. 2007; Damjanovic et al. 
2013; Ellis et al. 2015). These increased proinflammatory cytokines and 
chemokines correlate with the increase in neutrophils mentioned previously 
(LeVine et al. 2001). As discussed, high concentrations of proinflammatory 
cytokines and chemokines may cause localised damage to the lung to the lung. 
These results appear to contradict the notion that an immune impairment is the 
mechanism for increased susceptibility to co-infection. It is possible that initial 
impairment in specific antibacterial function leads to bacterial outgrowth, which then 
drives an excessive immune response. Conversely, the combination of two 
pathogen triggers may lead to synergistic activation of immune cells or epithelia 
which in turn leads to massive immune cell recruitment, more cytokines and tissue 
damage. Which of these hypotheses is true is as yet unclear. 
 
 
The responses of the airway epithelial cells, the first host targets of these two 
infections, have not been previously considered. The airway epithelial cells may 
contribute to the ‘cytokine storm’ and many of the other effects described in 
response to the combined stimulus. Inversely, the epithelial response may be 
impaired by initial exposure to IAV or IFNs. Delving into the role of the airway 
epithelium in co-infection will allow us to answer the question whether and by which 
mechanisms epithelial responses contribute to exacerbation of disease in this 
condition.  
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Figure 2 Immune response to IAV-S. pneumoniae co-infection 
Viral replication within the airway epithelial cells decreases mucociliary velocity, 
thereby adversely affecting the clearance of S. pneumoniae (A). IAV infection also 
results in increased apoptosis of DCs and epithelial cells. Apoptotic cells increase 
their surface expression of CD200, which can subsequently bind to CD200R on 
myeloid cells, such as DCs and macrophages. Binding to the CD200R results in 
sustained desensitization to the bacteria (B). IAV infection induces the production 
of IFNγ by T-cells as well as endogenous IFNγ by APCs. IFNγ downregulates the 
scavenger receptor MARCO on alveolar macrophages, which leads to inhibition of 
their phagocytosis abilities of the bacteria (C). Production of type I IFNs following 
IAV infection can inhibit the recruitment of monocytes and neutrophils (D). 
Figure adapted from (Short et al. 2012). Permission to reproduce this figure has 
been granted by Nature Publishing Group. 
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1.5 Host genetics and IAV 
Differences in influenza severity or protection from influenza can be attributed to 
varying degrees of recall responses by the adaptive immune system to new and 
‘recognized’ viral strains, depending on precedent vaccination or infection, or to the 
strain’s virulence. However, apart from immunological memory there may also be a 
role for variations of host-intrinsic responses to the virus to explain differences in 
influenza severity (Horby et al. 2010).  
 Apart from host medical conditions such as disease- or pregnancy-related 
immunosuppression or risk factors for severe influenza such as heart defects, the 
host genetic background contributes prognosis of disease in influenza. Two studies 
delved into the role of familial aggregation in the susceptibility to mortality from 
influenza infection. Albright et al. utilized a database of 4855 influenza associated 
deaths in Utah between 1903 and 2004 (Albright et al. 2008). They found that 
genetically close (length of genetic path is less than 3) and distant relatives of 
individuals who succumbed to disease had a significantly increased risk of 
influenza-induced death themselves. A conflicting report by Gottfresson et al. 
concluded that of the 455 deaths from the 1918 ‘Spanish flu’ in Iceland over a 6-
week period, there was no statistically significant indication of a heritable 
predisposition to death (Gottfredsson et al. 2008). The Gottfresson et al. study 
however had a drastically lower cohort and a limited time period compared to the 
Albright et al. study. This would greatly impact on the generation of statistically 
significant outcomes. The Albright et al. study therefore is more reliable and as 
such indicates the contribution of a heritable component to the outcome of disease. 
 The more recent spread of the HPAI avian H5N1 has also highlighted the 
family clustering of infections and speculation that host genetics may therefore play 
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a role (Ungchusak et al. 2005; Kandun et al. 2006; Sedyaningsih et al. 2007; Wang 
et al. 2008). This is highly debated, with the possibility of this person-to-person 
transmission being attributed to close contact rather than host genetic factors 
(Pitzer et al. 2007). The totality of the epidemiological data rather supports the host 
genetic contribution to disease. In fact, up until 2010, 50 of the 54 H5N1 familial 
clusters were among blood relatives (Horby et al. 2010). A more recent study 
showed that of the 720 H5N1 infections reported since 1997 until 2nd November 
2014, 144 cases were found in family clusters (55 clusters) (Qin et al. 2015). This 
study also identified 36 out of 460 cases of H7N9 infections were found in familial 
clusters (16 clusters). The increased proportion of family clusters found with H5N1 
than with H7N9, could be due to a higher risk of infection by H5N1. The authors 
however exclude this, as there is a much faster rate of accumulation of human 
H7N9 cases compared to H5N1 cases. Another possible explanation is that the 
detection of H5N1 clusters is easier than H7N9 clusters. This explanation was ruled 
out due to the widespread availability of molecular diagnostic methods following the 
emergence of H7N9 in 2013. Thirdly, person-to-person transmission may be more 
common for H5N1 than with H7N9, but the authors found no evidence to support 
within their analysis. This leaves the final explanation of familial susceptibility to 
H5N1 as the only reasonable explanation for the higher incidences of clusters. This 
is corroborated by the overall relative risk of infection between blood-related 
contacts compared to unrelated individuals of 8.96 for H5N1 and 0.8 for H7N9. The 
authors however state that this relative rate of infection may be unrepresentative of 
the true number, as it could only be calculated where full data was available: 16 out 
of the 55 family clusters for H5N1, and 11 out of the 16 cluster for H7N1. They also 
suggest that a large number of mild cases of H7N9 infections go unreported, which 
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has also been reported by Yu et al. (Yu et al. 2013).  
 It is well established that the human leucocyte antigen (HLA) locus plays an 
essential role in inducing cell mediated lysis of IAV infected cells (McMichael et al. 
1977). HLA also influences antigen presentation to T cells and drives specificity of 
the cytotoxic T lymphocyte (CTL) response to IAV (Belz et al. 2000; Boon et al. 
2002). As of yet, no polymorphisms in the HLA loci have been found to associate 
with susceptibility to influenza infection. 
 Mutations in IRF7 (Ciancanelli et al. 2015), IFITM3 (Everitt et al. 2012; 
Wang et al. 2014), CD55 (Zhou et al. 2012), and the mutations and polymorphisms 
of TLR3 (Esposito et al. 2012), have all been associated with susceptibility to IAV. 
Polymorphisms in IL-1α, IL-1β, TNF and IL-6 genes have also been correlated with 
increased susceptibility to H1N1 infection (Liu, Li, et al. 2013; García-Ramírez et al. 
2015). A study focusing on 91 severe 2009 ‘swine flu’ H1N1 cases and 98 exposed 
but asymptomatic controls found four single nucleotide polymorphisms (SNPs), 
which associated with disease severity (Zúñiga et al. 2012). Three of these SNPs 
were found within the genes for: complement binding protein (C1QBP), an 
immunoglobulin Fc receptor (FCGR2A) and a protein that facilitates entry of 
replication protein A into the nucleus (RPAIN). The final SNP is within an unknown 
gene: rs9856661.  
HCV patients can also be classified according to SNPs in their IFNλ locus, 
where patients whose genome can code for the IFNλ4 protein have a reduced 
antiviral response to IFNα treatment and lower rates of spontaneous clearance of 
HCV, but with higher baseline ISG levels compared to individuals who do not have 
a functional IFNλ4 gene (Prokunina-Olsson et al. 2013). A negative feedback 
mechanism through prolonged signalling and induction of USP18 has been 
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hypothesised as the mechanism for which IFNλ4 antagonises other IFNs (Egli et al. 
2014). As approximately 40% of Caucasians are thought to express IFNλ4, it would 
be of interest to assess if this SNP alters the IFNλ protectiveness in IAV infection.  
 The use of animal models has also indicated the genetic contribution to 
disease susceptibility. There have been several studies utilizing a range of inbred 
laboratory mouse strains to analyze their responses to IAV (Toth and Williams 
1999; Boon et al. 2009; Srivastava et al. 2009; Alberts et al. 2010; Boon et al. 
2011; Davidson et al. 2014). These studies showed that mice diverged in the 
outcome of disease dependent on their strain resulting in those that are susceptible 
and those that are resistant. Crossing a resistant strain with a susceptible strain 
resulted in intermediate levels of resistance (Srivastava et al. 2009), suggesting a 
codominant or polygenic contribution to influenza protection in these strains. 
Furthermore, some of these studies correlated increased proinflammatory 
responses to susceptibility (Boon et al. 2009; 2011). One study identified type I IFN 
directly correlated with exacerbated disease (Davidson et al. 2014). When Toth and 
Williams compared a resistant strain to a susceptible strain infected with a low 
pathogenic IAV strain (H3N2 X31), they found a quantitative trait locus (QTL) on 
chromosome 6 which associated with influenza-induced slow-wave sleep patterns 
(Toth and Williams 1999). 
 In 1962, the resistance of certain inbred mouse strains was reported 
(Lindenmann 1962) and was subsequently contributed to the Mx1 gene (Staeheli et 
al. 1988). Mx1 is able to inhibit influenza virus replication and protect the host 
during infection (Tumpey et al. 2007). Mice that are missing this gene or have 
nonsense point mutations are susceptible to IAV (Staeheli et al. 1988). The human 
homologue, MxA, along with the ISGs OAS1 and PKR, has been described and 
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associated with HCV outcome, but as of yet has not been associated with IAV 
severity (Knapp et al. 2003). 
 Host genetic contribution to IAV susceptibility has been well documented. 
However, the differences at the level of the airway epithelium have not yet been 
identified. The airway epithelium is the first host target of infection and the first to 
respond. Any defects in the ability of the epithelium to respond appropriately to 
infection may be detrimental for the host. The response of the epithelium from IAV-
susceptible and resistant strains may therefore further clarify the contribution of 
host genetics to the outcome of IAV-induced disease.  
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1.6 Airway epithelial cells 
1.6.1 Function 
The respiratory system of all vertebrates has evolved to facilitate the vital exchange 
of gases between the organism and the outside environment. In humans, the 
branched structure of the airways allows for this bidirectional exchange of 
approximately six litres of air per minute (Rackley and Stripp 2012). The respiratory 
tract develops into a highly branched tree-like system. This design is highly 
conserved between vertebrates but can differ slightly due to the different sizes of 
the lungs (Rock et al. 2010). In general, the lung can be divided into two sections: 
upper respiratory tract and the lower respiratory tract (Figure 3). 
The upper respiratory tract includes the nasopharynx, the trachea and the 
bronchi. The lower respiratory tract includes the bronchioles and the alveolar sacs. 
The proximal conducting airways are lined by a pseudostratified columnar 
epithelium whose main function is to transport air to and from the lower respiratory 
tract. It is also the first line of defence against any harmful contaminants within this 
inhaled air. This airway epithelium can act as a physical and a chemical barrier to 
pathogens by preventing the colonization and spread of the pathogen into the 
organism. The airway epithelium produces mucus, which traps and immobilises the 
pathogen, and the ciliated cells work in a coordinated wave of ciliar beats to 
mechanically move the mucus and therefore the pathogens out of the airways 
(Wolff 1986). This mucociliary transport is facilitated by the presence of two distinct 
layers of surface mucous. The layer closest to the airway epithelium is less viscous 
to allow for the free movement of cilia, and the overlying layer is more viscous to 
trap the particles and pathogens (Randell and Boucher 2006). Antimicrobial 
peptides are also produced and are secreted into these mucus layers to directly 
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destroy microbes. The epithelium monitors the external environment for these 
pathogens by using PRRs. If a pathogen is detected, the epithelium can release 
cytokines and chemokines for direct anti-pathogen action and to induce the 
recruitment and activation of the innate and adaptive immune response, to 
effectively eliminate the infection. These innate immune responses along with the 
tight adhesions between epithelial cells and the underlying stroma ensure that 
almost completely sterile, hydrated gases reach the peripheral alveoli for gas 
exchange. This defence function depends on the proper distribution and 
maintenance of the different epithelial cell types. 
The alveolar epithelium of the lower lung allows for the essential process of 
gas exchange. The epithelium consists of type 1 and type 2 alveolar epithelial cells. 
The type 2 alveolar epithelial cells are cuboidal and contain abundant lamellar 
bodies, the secretory vesicles (Figure 3A). These cells secrete the surfactant-
associated proteins (SPC-A –B –C -D) along with extracellular proteins and lipids 
which decrease the alveolar surface tension and contribute to host defence 
(Whitsett et al. 2010). These cells are also thought to contribute to the homeostasis 
of the lung through the absorption and secretion of fluid (Bove et al. 2010) and can 
act as progenitor cells for the other alveolar epithelial cells (Adamson and Bowden 
1975). The type I alveolar cells are squamous or flat and constitute to approx. 95% 
of the surface area of the lower lung (Williams 2003). It is these type 1 alveolar 
cells that are essential for gas exchange (Figure 3B). 
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1.6.2 Structure of the upper respiratory epithelium 
In mice, the largest airway is the trachea, which is lined with a pseudostratified 
columnar epithelium. This epithelium is composed of basal (Figure 3C), ciliated 
(Figure 3D) and secretory (goblet and club) cells (Figure 3E). It is these secretory 
and ciliated cells that make up the mucociliary defence mechanism described. This 
heterogeneous population also make up the human trachea, however mucin-
secreting goblet cells are more abundant in humans than within the mouse. In 
humans, this pseudostratified epithelium can also extend into the bronchioles, 
whereas they are restricted to the trachea in mice (Mercer et al. 1994; Rock et al. 
2010).  
In both humans and mice the basal cells, so called due to their proximity to 
the underlying basal lamina, act as the stem cell of the lung capable of self-
replenishing and differentiating into the two other cell types: ciliated and secretory. 
Basal cells constitute approximately 30% of the total epithelial population (Hong 
2003; Hackett et al. 2008; Rock et al. 2009). They form a mostly continuous 
monolayer but can also be found in clusters or individually (Nakajima et al. 1998), 
and form desmosomal contacts with neighbouring columnar cells. 
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Figure 3 The cellular subsets of the upper and lower respiratory tract 
The lung respiratory tract is split into two: upper respiratory tract and lower 
respiratory tract. The alveolar type 2 cells (A) secret surfactant to facilitate the gas 
exchange by the alveolar type 1 cells (B). The upper respiratory tract is made up of 
basal cells (C), ciliated cells (D) and secretory cells (E). The upper respiratory tract 
guides the inhaled air to the lower respiratory tract. The mucus production traps 
any inhaled particles. The cilia beat moves the mucus and trapped particles out of 
the airways. 
Figure adapted from (Whitsett and Alenghat 2015). Permission to reproduce this 
figure has been granted by Nature publishing group. 
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1.6.3 Damage and regeneration 
Epithelial cells of the lung are largely quiescent and turn over at a very slow rate, 
approximately every 100 days (Blenkinsopp 1967). Damage to the epithelium can 
be caused by bacterial or viral infections, harmful pollutants, inflammation, allergic 
reactions, physical trauma, cancer, or by unknown origins (idiopathic fibrosis). The 
epithelium must recover from this damage to return to homeostasis. The repair 
mechanisms are initiated immediately following damage to the epithelium with the 
proliferation of basal cells and progenitor cells which migrate and spread over the 
open wound. Once the denuded area is covered these stem cells differentiate into 
the missing cell types to re-establish the integrity and functional organization of the 
epithelial layer (Zahm et al. 1991; Puchelle et al. 2006; Rock et al. 2009). 
Due to the difficulty of examining the in vivo repair mechanisms of the 
alveolar epithelium, less is known about it (Crosby and Waters 2010). Two studies 
however identified a ‘stem cell like’ population from the upper respiratory tract that 
migrates to the lower respiratory tract to repair the damaged epithelium, by 
covering the wound and differentiating into the alveolar cell types (Vaughan et al. 
2014; Zuo et al. 2014). These stem cell like population express KRT5 protein and 
the transcription factor Trp63. These molecules are highly expressed in basal cells 
(Rock et al. 2009). Another study found that it was these cells that were 
preferentially infected following IAV infection, which significantly impacts the repair 
of the lower lung (Quantius et al. 2016).  
 The migration and spreading of the cells to cover the damaged area occurs 
within the first 12-24 hours following injury. The proliferation and differentiation of 
basal cells begins within 15-25 hours and continues for days or even weeks 
(Horiba and Fukuda 1994; Dupuit et al. 2000). Although basal cells are believed to 
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be the primary cell type capable of long-term self-renewal and differentiation, the 
club cells of the lung, which are normally quiescent, are believed to be able to 
dedifferentiate and also function as progenitor cells following damage, to replenish 
ciliated cells (Donnelly et al. 1982; Breuer et al. 1990; Watson et al. 2015). Once 
the ciliated cells are replenished, the club cells return to quiescence.  
 The damage to the epithelium and the ensuing inflammatory response 
results in the production of soluble factors from endothelial cells, fibroblasts, 
alveolar macrophages and the lung epithelium, which participate in the repair 
process (Crosby and Waters 2010; Herold et al. 2011). Of these soluble factors the 
epidermal growth factor (EGF) family and the fibroblast growth factor (FGF) family 
are believed to be important for epithelial repair. Several members of the EGF 
family have been shown to have roles in epithelial repair: EGF, transforming growth 
factor alpha (TGF-α), and amphiregulin (Kheradmand et al. 1994; Van Winkle et al. 
1997; Monticelli et al. 2011). Innate lymphoid cells were found to produce 
amphiregulin in response to IAV infection to restore the airway epithelial integrity 
and tissue homeostasis (Monticelli et al. 2011). Three members of the FGF family 
have been attributed to epithelial repair in the lungs: keratinocyte growth factor 
(KGF), hepatocyte growth factor (HGF), and FGF-10 (Atabai et al. 2002; Crosby 
and Waters 2010; Herold et al. 2011). Administration of Fgf10 was found to 
counteract IAV-induced repair failure and restored barrier function in the lower lung 
(Quantius et al. 2016). Granulocyte macrophage colony-stimulating factor (GM-
CSF) and IL-22, although not conventional epithelial growth factors, have also been 
implicated in epithelial repair following IAV-induced lung damage (Pociask et al. 
2013; Rösler and Herold 2016).  
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1.6.4 Airway remodelling 
The ability of the epithelium to repair is extremely important, however an 
exaggerated response to chronic stimuli (Kim et al. 2008), repeated injury (Cao et 
al. 2016), or an aberrant response to naïve stimuli may result in airway remodelling. 
The immune response to infections has also been shown to induce airway 
remodelling, with some cytokines altering the cell fate choices, contributing to 
goblet cell metaplasia (Danahay et al. 2015). Loss of growth factors, such as 
amphiregulin, or cells which produce these factors can also result in airway 
remodelling (Monticelli et al. 2011). This remodelling results in variations in tissue 
architecture, cell composition and matrix properties, which may affect the 
pulmonary mechanisms and gas exchange capacity of the lung (Crosby and 
Waters 2010). Pathological changes in the cellular composition (remodelling) and 
physiological function of the airways are common features of respiratory diseases, 
which include chronic asthma, chronic obstructive pulmonary disease (COPD), 
cystic fibrosis, and idiopathic pulmonary fibrosis (IPF) (Thorley and Tetley 2007; 
Crosby and Waters 2010; Rock and Hogan 2011). 
 
Asthma 
Asthma is a common long-term disorder of the lung. Hallmarks of asthma include 
goblet cell hyperplasia and overproduction of mucus along with repeated epithelial 
shedding, airway wall fibrosis, thickening of the basal lamina, angiogenesis, and 
hyperplasia of the submucosal gland (Tang et al. 2006). Asthma suffers also 
experience exacerbations of virus induced disease (Kurai et al. 2013). Asthma is 
believed to be partly caused by allergen-specific T helper 2 (Th2) cells which 
produce the cytokines: IL-4, IL-5, IL-9, IL-10 and IL-13 (Cohn et al. 2004). Induction 
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of these cytokines, apart from IL-10, correlates with airway inflammation, including 
eosinophilia, mast cell activation and goblet cell metaplasia (Lee et al. 1997; 
Temann et al. 1997; Curran and Cohn 2010). It is also thought that a defect in 
epithelial repair may result in this airway remodelling. This defect is proposed to be 
present from birth as these clinical manifestations have been observed early in life 
(Pohunek et al. 2005). One study has shown that epithelial growth factor receptor 
(EGFR) may be altered in asthma and thus affect the repair capabilities of the 
epithelia (Puddicombe et al. 2000). Basal cells are present in the areas of goblet 
cell hyperplasia (Rock et al. 2010), therefore it is possible that changes in their 
ability to proliferate and differentiate may contribute to the ability of the lung to 
repair.  
 
COPD 
COPD is a major cause of morbidity and mortality, with around 6% of men and 4% 
of women suffering from COPD in the UK (Barnes 1998). It is predicted by the 
World Health Organization (WHO) to become the third leading cause of death 
worldwide by 2030 (Rock et al. 2010). Patients suffering from COPD experience 
disease exacerbation and death following influenza infection (Bauer et al. 2010; 
Kurai et al. 2013), and even more so in co-infection (Sethi 2006). Smoking is one of 
the most important causative factors in the development of COPD, inducing chronic 
bronchitis, small airways disease, and emphysema (Thorley and Tetley 2007; Kang 
et al. 2008), leading to narrowing of the airways, shortness of breath (dyspnea) and 
persistent cough that brings up thickened, discoloured mucus. The airway 
epithelium is the first target of cigarette smoke and other inhaled toxins. The 
epithelium adapts to protect the lung from theses toxins, however in those that 
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develop COPD the changes within the epithelium become irreversible affecting the 
structure and function of the lung. Patients afflicted with COPD also have a higher 
risk of developing lung cancer than smokers without COPD (Mannino et al. 2003). 
This progression is thought to start with epithelial hyperplasia, turning to metaplasia, 
to dysplasia, carcinoma in situ and subsequent malignancy (Banerjee 2009; Rock 
et al. 2010). Again changes in basal cell proliferation and differentiation capabilities 
may induce this remodelled state of the lung. Hyperproliferating basal cells were 
observed in these metaplasia areas in COPD patients, which were found to 
produce IL-1β. This IL-1β production promotes airway wall fibrosis (Araya et al. 
2007). Although IL-13 is synonymous with Th2-mediated allergy, causing asthma, 
IL-13 driven chronic lung disease has also been implicated in COPD following viral 
infections of the lung (Kim et al. 2008). 
 
Cystic fibrosis 
Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane 
conductance regulator gene (CFTR). A disrupted ion transport within the columnar 
epithelial cells is the primary defect within the lungs of these patients (Boucher 
2007). Along with the resulting dehydration of the lung, chronic bacterial infection, 
goblet cell hyperplasia, impaired mucin clearance, increased proinflammatory 
cytokine secretion, extensive leukocyte influx, airway epithelial damage and 
bronchiectasis are also observed (Rock et al. 2010). Furthermore, 
hyperproliferative basal cells were observed in these patients, contributing to the 
chronic repair process (Voynow et al. 2005). These chronic infections, repeated 
damage, and repair of the lung change the overall lung cellular composition and 
function. In turn, this altered lung architecture facilitates further infections.  
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Idiopathic pulmonary fibrosis 
Idiopathic pulmonary fibrosis (IPF) is a type of interstitial lung disease (ILD). IPF is 
a severely debilitating chronic and ultimately fatal lung disease. Idiopathic means 
the cause of this condition is unknown. It is generally thought that chronic epithelial 
injury and disrupted repair leads to disordered communication between the 
epithelium and the surrounding stroma. This leads to mesenchymal 
hyperproliferation and fibrogenesis of the lung (Pardo and Selman 2002). It is 
currently unknown which cell types are the fibrogenic population, although resident 
fibroblasts, bone marrow-derived stem cells and alveolar epithelial cells have been 
proposed (Willis et al. 2006; Rock and Hogan 2011). Again this altered lung 
architecture leaves the host vulnerable to infections, which induce further damage, 
and induction of repair mechanisms resulting in fibrosis and loss of lung function. 
 
 
It is clear that chronic infections and repair leads to severe lung disease and 
remodelling leaving the host vulnerable to subsequent infections, thus resulting in a 
vicious circle. Changes to the basal cell proliferative rate or disruption in the 
amount of ciliated and secretory cells could theoretically lead to pathological airway 
remodelling. Excessive basal cell proliferation could lead to basal cell hyperplasia 
at the expense of differentiation. On the other hand, inappropriate cell fate choices 
may lead to goblet cell hyperplasia or ciliopathies at the expense of ciliated cells. 
Ciliopathies comprise a group of disorders where a lack of, or abnormal formation 
or function of ciliated cells are observed (Waters and Beales 2011). A failure to 
proliferate, increased apoptosis along with this inappropriate commitment to 
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differentiation could also contribute to epithelial remodelling (Rock et al. 2010). In 
summary it is clear that in many cases repeated repair can cause considerable 
changes to the structure and function of the lung. Therefore, in the airway 
epithelium, a tight balance of the basal cell proliferation and differentiation is 
required, and any change in the ability of basal cell proliferation or differentiation 
may impact severity and long-term outcome of infection. 
 
 
1.6.5 Mouse tracheal epithelial cells 
Most pathogens infect the upper respiratory tract and as such the mouse trachea 
becomes a highly useful experimental model. The mouse trachea is very similar to 
the human trachea, bronchi, and bronchioles. Therefore, the culture of primary 
mouse tracheal epithelial cells (mTEC) provides a potent tool for the study of the 
composition and response of airway epithelial cells (AECs) in respiratory tract 
development and during infections. Utilising this primary culture also allows for the 
generation of genetically different epithelial cells from different inbred strains of 
mice and genetically altered mice, to determine the contribution of host genetics to 
the development and response of the AECs. 
To generate these mTEC cultures, epithelial cells are digested out of the 
mouse trachea and plated on transwells in the presence of a growth medium. Only 
a fraction of the seeded cells attach to the transwell membrane as differentiated 
cells die, leaving a few remaining basal cells, which proliferate until they are 
confluent. The media from the upper chamber of the transwell is then removed to 
expose the basal cells to air. This air liquid interphase (ALI) stimulates the basal 
Chapter 2 Materials and Methods 
 
71 
 
cells to differentiate into secretory and ciliated cells (Ostrowski and Nettesheim 
2009) (Figure 4). The full growth and differentiation of this culture takes about 14 
days (You et al. 2002).  
Using these mTECs will allow us to focus on the contribution of epithelial 
cells in infectious settings as outlined previously. We will be able to study epithelial 
responses during viral-bacterial stimulation, the effect of host genetics on the 
response to IAV. mTECs will also allow us to determine the effectiveness of a 
therapeutic treatment against IAV, and the impacts of IFNs during repair. 
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Figure 4 Generation of an mTEC culture 
Epithelial cells are digested out of a mouse trachea and seeded onto a semi-
permeable transwell along with growth medium. The cells are grown to confluence 
(trans-epithelial electric resistance (TEER) >1000mΩ/cm2). The upper medium is 
removed from the upper chamber to expose the cells to air (air liquid interphase 
(ALI)). This exposure to air induces the differentiation of the cells to resemble the 
tracheal airway epithelium.  
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1.7 Study Rationale 
We aim to study the protective and pathological processes related to influenza 
infection from a strictly airway epithelial perspective. The airway epithelium 
represents the first host target of many infections and is ultimately the first line of 
host defence, responding by producing cytokines and chemokines to modulate the 
immune response and repair the damage induced by any harmful particles inhaled. 
Severe IAV induced disease is characterised by a ‘cytokine storm’ and lung 
damage. It is intriguing to note that in studies of severe influenza, mortality does 
not correlate with viral load but with the magnitude of the immune activation 
(Hayden et al. 1998; Peiris et al. 2004). IAV infection can induce morbidity and 
mortality of the host, however a number of factors can determine disease outcome, 
such as secondary bacterial infections, host genetics and disrupted repair. The 
airway epithelium response to infection may therefore play a critical role in outcome 
of disease. 
Secondary bacterial infections represent the majority of deaths following IAV 
pandemics (Madhi et al. 2004; Thorburn et al. 2006; Morens et al. 2008). This trend 
is also common in seasonal IAV epidemics (O'Brien et al. 1996; Metersky et al. 
2012). Research into the immune response to IAV-S. pneumoniae co-infection has 
been extensively undertaken, however several aspects remain elusive. The 
massive proinflammatory response is well documented in co-infected lungs (LeVine 
et al. 2001; Seki et al. 2004; Smith et al. 2007; Damjanovic et al. 2013; Ellis et al. 
2015). The primary and main producers of these proinflammatory cytokines 
remains unidentified. As the airway epithelium is the first host target of viral 
infection and the first cell type exposed to invading bacteria, and can respond by 
producing proinflammatory cytokines, we have utilised the mTEC system to 
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determine the AECs response to viral and bacterial stimuli both separately and 
together. Using this system allows us to determine if the AECs can orchestrate a 
synergistic response to co-infection, which may contribute to, if not be the sole 
responsible determinant of the increased morbidity and mortality observed in co-
infections.  
Type I IFNs are the prototypical antiviral cytokines and are thought to be 
exclusively protective during IAV infection. Work within our lab has however shown 
that a high IFN response correlates with increased disease severity and lung 
damage (Davidson et al. 2014). It is intriguing that in different in-bred mouse strains 
a divergent response to IAV infection occurs, which may be an indicator of a 
differing epithelial makeup and response. We hypothesise that the airway 
epithelium from the high IFN, IAV-susceptible mouse strain is driving the high 
proinflammatory response seen in vivo, and will also have reduced potential for 
repair following injury.  
Owing to our study on the pathogenic potential of type I IFNs (Davidson et 
al. 2014), we then assessed the potential of type I IFNs (IFNα) and type III IFNs 
(IFNλ) as a treatment for IAV infection. Isolation and stimulation of both mouse and 
human cell types and epithelial cells, will allow for the determination of the cell 
specific effect of these IFNs. We hypothesise that owing to the expression of the 
IFNλ receptor on airway epithelial cells only, IFNλ will be a better treatment option 
than IFNα against IAV, as it will not induce the immunopathology seen with IFNα.  
As discussed, the presence of high type I IFNs can be detrimental during 
IAV infection whereas IFNλ is beneficial. However, what effect these IFNs can have 
when IAV infection is cleared and the lung epithelia are repairing has not been fully 
investigated. The antiproliferative effect of type I IFNs is well known (Paucker et al. 
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1963; Bekisz et al. 2010), whereas the antiproliferative effects of type III IFNs are 
only recently being appreciated (Brand 2005; Maher et al. 2014). The effect of type 
I and type III IFNs have not been assessed on repairing epithelia of the lung. We 
hypothesise that IFNs will have a negative effect on proliferation and differentiation. 
We aim to determine which mechanism is behind this antiproliferative effect. We 
will utilise both type I and III IFNs to establish which IFNs are eliciting this effect. 
In conclusion, the following 4 questions will be addressed in this thesis: 
 
1. Do airway epithelial responses to combined viral-bacterial stimuli explain or 
contribute to the severe immunopathology observed in IAV-S. pneumoniae 
co-infection? 
2. Do the host genetic differences in anti-IAV responses observed in C57BL/6 
versus 129 mice manifest in airway epithelia? 
3. How do the different response patterns of immune and epithelial cells to 
IFNα versus IFNλ explain their different therapeutic potential in IAV 
infection? 
4. How do IFNs impact on airway epithelial repair? 
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Chapter 2. Materials & Methods 
Mice  
129S8 and C57BL/6 mice were bred at the Francis Crick Institute, Mill Hill 
Laboratory under specific pathogen-free conditions. B6.A2G-Mx1 congenic mice 
carrying the functional Mx1 alleles on the C57BL/6 background (Staeheli et al. 
1985) were a kind gift from Dr P. Staeheli (Freiburg University). All mice were kept 
in specific pathogen-free isolators until use for experiments. Clinical symptoms 
during influenza infection were scored based upon presentation of hunched 
posture, piloerection, reduced movement and labored breathing. All protocols for 
experiments with animals were approved by the Home Office, UK, Animals 
(Scientific Procedures) Act 1986.  
 
Primary mouse tracheal epithelial cell culture (mTEC) 
Isolation and culture of primary mTEC were performed as previously described 
(You et al. 2002). In summary, tracheas from mice were obtained and cells isolated 
by enzymatic treatment were seeded onto 0.4 mm pore size clear polyester 
membrane (Corning) coated with a collagen solution. At confluence, media was 
removed from the upper chamber of the transwell to establish an air-liquid interface 
(ALI). Fully differentiated, 7-10 days-old post ALI cultures were used for 
experiments. For replated experiments the cells were dissociated from the 
transwells using Trypsin-EDTA (0.25%) (ThermoFisher) supplemented with 10mM 
EDTA (ThermoFisher). The cells were washed and resuspended in growth 
medium. The cells were counted and then plated as before in or without the 
presence of IFNs. The time taken to reach confluence (R>1000 mΩ/cm2) was 
recorded. MTEC cultures will also be referred to as airway epithelial cells (AEC) 
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throughout this thesis. 
 
A549 culture 
Human lung carcinoma epithelial-like cell line A549 was obtained from Dr. J. 
McCauley (Francis Crick Institute, Mill Hill Labs (FCI-MH)) and cultured in RPMI 
medium supplemented with 10% fetal bovine serum in a T75 culture flask at 37°C. 
At approximately 70-95% confluency cells were detached from the flask by Tryspin-
EDTA treatment, pelleted and reseeded at 1 x 106 cells/well, in a 24-well plate  
 
Influenza Virus 
Influenza A virus X31 strain (H3N2), a reassortant with the A/PR/8/34 (H1N1) 
backbone, and PR8 (A/PR/8/34, H1N1), kind gifts from Dr. J. Skehel (FCI-MH), 
were grown in 10 day embryonated chicken eggs which are free of bacterial, 
mycoplasma, and endotoxin contamination. Alternatively, the virus was grown in 
Madin-Darby Canine Kidney (MDCK) cells, a kind gift from Dr J. McCauley (FCI-
MH). All viruses were stored at -70°C and titrated on MDCK cells by 50% tissue 
culture infective dose (TCID50), according to the Spearman-Karber method.  
 
Virus infection in vitro 
The apical sides of the mTECs were washed extensively to remove accumulated 
mucus before inoculation with X31 at a MOI of 0.1. After incubation at 37°C for 4 
hours, the virus inoculum was removed. Cells were then lysed to extract RNA. For 
the A549 cells the media was removed and cells were inoculated with IAV at a MOI 
of 0.3 in media without sera. After 4 hours the inoculum was removed and 
complete media re-added. The cells were lysed after 24 or 48 hours. 
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Virus infection and treatment in vivo 
Mice were anesthetized by inhalation of isofluorane and infected via the intranasal 
route with X31 (8x102-2.4x104 TCID50/30µl) diluted in phosphate-buffered saline 
(PBS). Virus quantification was carried out by quantitative real-time PCR (RT-
qPCR) on complementary deoxyribonucleic acid (cDNA) for the matrix gene, as 
previously described (Ward et al. 2004). In Chapter 4, C57BL/6 mice were infected 
with X31 as described and treated with EdU (1 mg/mouse) (ThermoFisher) or PBS 
on days 7-9 post infection. Lungs were collected on day 10 post infection. In 
Chapter 5, B6.A2G-Mx mice were infected with PR8 (3x104-1x105 TCID50/30µl). 
B6.A2G-Mx mice were treated with 1.45µg/50µL of IFNα or 2.6µg/50µL IFNλ either 
at -1dpi (pre-treatment experiment) or days 2, 4 and 5 post infection (treatment 
during infection experiments). Mice were infected and treated under light 
isoflurane-induced anaesthesia intranasally. All anaesthesia was performed with 
animals kept on a heat mat to regulate body temperature.  
 
Streptococcus pneumoniae 
D39, a kind gift from Dr. M. Coles, (University of York) was grown from 
cryopreservative beads (Technical Services Consultants) in brain-heart infusion 
broth under microaerophillic conditions to autolytic phase overnight, then 
subcultured to an optical density of 0.4 at OD 590/600, centrifuged and re-
suspended in PBS immediately prior to infection both in vivo and in vitro. To heat 
kill the bacteria, it was placed at 80°C for 10 minutes, and killing of bacteria 
confirmed by plating. TIGR4, a kind gift from Dr. K. Okkenhaug (Babraham), was 
passaged through mice. Colonies were collected from spleens of infected mice and 
incubated in brain-heart infusion broth under microerophilic conditions to autolytic 
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phase overnight, then sub-cultured in brain-heart infusion broth to an optical 
density of 0.5-0.7 (OD600) before being centrifuged and re-suspended in PBS + 
10% glycerol to an optical density of 1.0 (OD600). Aliquots were snap frozen and 
stored at -70oC for a maximum of 10 months before re-passage through mice.  
 
Bacterial infection 
For in vitro co-exposure experiments, 24 hours after primary virus infection, the 
apical side of the cells were washed extensively to remove accumulated mucins 
before inoculation with live or heat killed (HK) S. pneumoniae at 106
 
CFU/well, or 
TIGR4 at 108 CFU/well. After incubation at 37°C for 23.5h, the antibiotic: penicillin 
streptomycin was added and aliquots of the supernatants were collected before 
and after for plating on blood agar plates to determine growth and subsequent 
death of bacteria. Cells were then lysed to extract RNA 24h post bacterial 
inoculation. For in vivo co-infection experiments, mice were anesthetized by 
inhalation of isofluorane and infected via the intranasal route with 30µl of the 
bacteria diluted in PBS. 
 
Toll like receptors 
Toll-like receptor 2 agonist, Pam3CSK4 (Enzo) and toll-like receptor 4 agonist, LPS 
(Enzo) was given apically to the AEC cultures 24 hours after IAV infection. Cells 
were then lysed to extract RNA 24h post TLR agonist treatment. 
 
Recombinant IFN proteins 
IFNα: Mammalian IFNα4 for mouse studies (Lot: 5983) and human universal type I 
IFN (5831) was purchased from PBL Assay Science (Chapter 5 and 6) 
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IFNβ: Mouse IFNβ was purchased from PBL Interferon source (Lot: 5118) (Chapter 
4 and 6). 
IFNλ: A codon optimized cDNA encoding the mature form (without the signal 
peptide) of mouse IFNλ2 was purchased (Eurofins) and expressed in E. Coli, 
purified under denaturizing condition and refolded in vitro as described previously 
(Dellgren et al. 2009), a kind gift from Dr R. Hartmann (Aarhus University). The 
human IFNλ3 was made as described in (Dellgren et al. 2009) (Chapter 5). For 
Chapter 4 and 6, IFNλ2 (Lot: 4635-ML) and IFNλ3 (Lot: 1789-ML) were used jointly 
as the IFNλ stimulus and were purchased from R&D systems. 
 
IFN titration on AECs and subsequent generation of an IFNα:IFNλ conversion ratio 
mTEC cultures were stimulated for 4hrs with serial dilutions of IFNα, IFNβ or IFNλ 
or medium control. For Chapter 5 mouse IFNα was compared to mouse IFNλ with a 
serial dilution ranging from ranging from 100 – 3 U/ml IFNα vs. 1-0.03 ng/ml IFNλ, 
and 100 – 0.16 U/ml human IFNα vs. 100 -0.03 ng/ml human IFNλ. In Chapter 6, 
IFNα and IFNβ were compared using the range 100 - 3 U/ml, and IFNβ and IFNλ 
were compared using 30 – 0.24 (U/ml and ng/ml respectively). The induction of 
stated ISGs was assessed by RT-qPCR. For each gene, data was pooled from 2-8 
independent titrations. Prism 6 software was used for four-parameter logistic 
regression analysis, to generate a dose response curve and obtain half-maximal 
effective concentrations (EC50) for each gene assessed for each treatment. An 
IFNα:IFNλ (Chapter 5), and IFNα:IFNβ:IFNλ (Chapter 6) conversion ratio was then 
generated by for example: dividing the IFNα EC50 for an ISG by the IFNλ EC50 for 
the same gene (Chapter 5). The final conversion ratio of 0.558 was determined by 
the geometric mean of the ratios obtained for all ISGs assessed and applied to 
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treat mice and cells with equipotent amounts of IFNα and IFNλ (Chapter 5). The 
conversion ratio for human IFNα:IFNλ of 17.5 was applied to the human cells 
(Chapter 5). For Chapter 6, this conversion ratio was 2:1:1 IFNα:IFNβ:IFNλ 
(U/ml:U/ml:ng/ml). 
 
Stimulation of mouse cells 
In Chapter 4, equipotent doses of 30 U/ml of IFNβ and 30 ng/ml IFNλ were added 
to the upper and basalolateral side of the mTEC cultures for 4 hours. The cells 
were washed and lysed for analysis.  
In Chapter 5, equipotent doses of IFNα and IFNλ were added to the apical and 
basolateral sides of the cultures for 4 hours. The cells were then lysed for analysis. 
Spleens were excised from B6.A2G-Mx1 mice. Spleens were then were directly 
mashed through a 70µM cell strainer and washed with flow cytometry buffer. Red 
blood cells were lysed using ammonium chloride and cells were seeded into a 96-
well U-bottom plate at 1x106/well. Whole splenocyte cultures were stimulated with 
IFNα4 (100 U/ml), IFNλ2 (1.4 ng/ml) or left as media control for specified time 
points. After stimulation cells were collected for analysis by RT-qPCR and 
multiplex.  
In Chapter 6, AECs were grown in the presence of IFNα, IFNβ, IFNλ or media 
control ranging from 270 – 5 U/ml (IFNα and IFNβ) and 270 – 5 ng/ml (IFNλ), 
throughout the full term of culture.  
 
IFN Stimulation of human cells 
The human biological samples were sourced ethically and their research use was 
in accord with the terms of the informed consents. Primary human bronchial 
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epithelial cells were purchased from Lonza and cultured as per manufacture’s 
instructions. In brief, cells were expanded in a T-75 flask to 60% confluence then 
harvested for seeding onto transwells at 50,000 cells per insert. At confluence, 
liquid was removed from the upper chamber to establish ALI. Fully differentiated, 
15-20 day-old post ALI cultures were routinely used for experiments. Peripheral 
blood mononuclear cells (PBMCs) were prepared from peripheral blood by Ficoll-
Paque density gradient centrifugation, and cultured at 2x105 cells per well. For 
analysis of cytokine secretion, primary human bronchial epithelial cell and PBMC 
cultures were stimulated with human universal type I IFN (21 U/ml) and human 
IFNλ (1.2 ng/ml) or media controls for 24hrs. 
 
Separation of CD45+ and CD45- cells from whole lung 
Whole lungs were excised and processed into single cell suspension using 
gentleMACS (Miltenyi), following the manufacturer’s instructions. Cells were then 
incubated with biotin-conjugated CD45 (Biolegend) for 15 mins at 4oC in MACs 
buffer (2mM EDTA, 2% FCS in PBS). Cells were washed x1 with MACS buffer and 
incubated with anti-biotin microbeads (Miltenyi) in MACS buffer for 15 mins at 4oC. 
Cells were washed, suspended in MACs buffer and separated by MACS cell 
separation (LS columns), as per manufacturer’s instructions. The CD45+ and 
CD45- fractions were collected and processed for RNA extraction. 
 
RNA extraction 
Before RNA extraction, mTEC cultures were washed extensively with PBS. RNA 
was isolated from MTEC cultures by directly lysing the cells in the transwells, using 
the Qiagen RNeasy mini kit, according to the manufacturer’s instructions. Whole 
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lungs were collected in TRIzol (Invitrogen) and homogenized using Polutron PT 10-
35 GT (Kinematica). One microgram total RNA was reverse transcribed using the 
ThermoScript RT-PCR System kit (Invitrogen). The cDNA served as template for 
the amplification of genes of interest and the housekeeping gene (Hprt1) by real-
time PCR, using TaqMan Gene Expression Assays (Applied Biosystems), universal 
PCR Master Mix (Applied Biosystems) and the ABI-PRISM 7900 sequence 
detection system (Applied Biosystems). The increase in mRNA expression was 
determined using the ΔCt method. The fold increase in mRNA expression was 
determined using the ΔΔCt method relatively to the values in mock treated 
samples, after normalization to Hprt1 gene expression.  
 
Scratch Assay 
After the mTEC culture was fully grown (d14 after plating), a pipette tip (size p2) 
was used to induce a ‘scratch’ transversely across the mTEC culture. The 
transepithelial electrical resistance (TEER) was measured until the culture reaches 
back to confluence and the scratch is considered repaired. To quantify the 
proliferative rate of the cells following a scratch, the mTEC cultures were pulsed 
with EdU for 24 or 48 hours then taken for quantification by Flow Cytometry. 
 
Immunohistology 
For staining of cilia in the mTEC cultures, cells were fixed within the transwell with 
4% paraformaldehyde in PBS for 60 mins. Cells were then washed with PBS, then 
treated with 0.1% Triton-X (Roche) in PBS for 15 mins, washed again with PBS 
and blocked with 0.5% BSA for 30 mins. β-tubulin (Sigma) was added in PBS/BSA 
for 1 hour. Cells were washed for 5 mins in PBS x3. The cells were then treated 
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with anti-mouse Alexa 488 for 1 hour in PBS/BSA and cells were once again 
washed for 5 mins in PBS x3. Cells were then stained with DAPI for 10 mins and 
washed. The transwell membrane is cut out and placed on a glass slide, covered 
with a mounting medium (Vectashield, Vector Laboratories) and a coverslip. 
Tracheas were excised, mounted in paraffin and cut into slices and mounted on 
glass slides. To process the samples for staining, the wax was melted and washed 
with xylene, and then in decreasing concentrations of alcohol to rehydrate the 
samples. To expose the antigens, the glass slides were heated in 10 mM NaCit 
and stained as with the mTEC cultures. All slides were run on a VS120 virtual slide 
microscope. 
 
Microarray data analysis 
RNA was hybridized to Illumina.SingleColor.Mouse WG-6_V2_0_R0_1127 
microarrays. Raw data were processed using GeneSpring GX version 11.5 (Agilent 
Technologies). After background subtraction, each probe was attributed a flag to 
denote its signal intensity detection P-value. Flags were used to filter out probe 
sets that did not result in a ‘present’ or ‘marginal’ call in at least 50% of the 
samples, in any one out of three experimental conditions. The signal intensity of 
each probe was first normalized on the median intensity of that probe across the 
control group and then represented as log2/log4 fold change relative to the 
controls. Subsequent statistical analysis was a 1-way ANOVA to identify genes 
significantly differentially expressed relative to controls (≥2 fold change; P<0.01, 
Benjamini-Hochberg multiple test correction) which were further analysed by a 
further 2 fold change to identify genes significantly differentially expressed in co-
exposure versus single exposure (Chapter 3), or IFN treatment (Chapter 6). The 
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subset of genes most differentially expressed were analysed by Ingenuity Pathway 
Analysis.  
 
Quantification of protein  
Bronchioalveolar lavage (BAL) fluid was recovered from treated mice, centrifuged 
at 1,300rpm, 5min at 4oC and supernatant collected. Cell culture supernatants were 
harvested from the apical side of the cultures. IL-28A/B was measured using the IL-
28A/B ELISA Duo kit (R&D Systems), IFNβ and IFNα with their respective Verikine 
ELISA kit (PBL Interferon Source). CXCL1 and CXCL2 with their respective ELISA 
Duo kit (R&D Systems), IL-6 and TNF-α were measured with their respective 
ELISA Ready-SET-Go!® (eBioscience). Milliplex Map Kit was used to quantify the 
protein of samples as per manufacturer’s instructions and read on a Luminex 100 
(E-Bioscience). For immunoblots of total lysates, mTECs were lysed in RIPA buffer 
(Appendix, Table 1). Detection of p-EGFR (Cell Signaling Technology), T-EGFR 
(ThermoFisher) and β-actin (Cell Signaling Technology) protein by western blot and 
quantification of the protein was undertaken by ImageJ analysis. 
 
Flow cytometry  
mTECs: The different cell subsets of mTECs were quantified by flow cytometry. In 
brief, mTECs were dissociated from the transwells using Trypsin-EDTA. The cells 
were pelleted and washed with PBS x2. Cells were preincubated with anti-FcγRIII/II 
(Fc block) in PBS prior to a 20 min incubation with the fluorochrome-labelled 
antibodies (Appendix, Table 2). Cells were then washed with PBS x2 counter 
stained with LIVE/DEAD® Fixable Dead Cell Stain (Life Technologies) for 15 mins. 
Whole lungs: Lungs were excised from infected and EdU treated mice or untreated 
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mice, digested with 20µg/ml Liberase TL (Roche) and 50µg/ml DNAse 1 (30 
minutes at 37°C) and homogenized using gentleMACS (Miltenyi), following the 
manufacturer’s instructions. Lungs were then passed through a 70µM cell strainer 
and washed with flow cytometry buffer (10% BSA in PBS). Red blood cells were 
lysed using ammonium chloride and cells were seeded into a 96-well U-bottom 
plate at 1x106 cells/well. Cells were preincubated with anti-FcγRIII/II (Fc block) in 
PBS prior to a 20 min incubation with the fluorochrome-labelled antibodies 
(Appendix, Table 3). Cells were then washed with PBS x2 counter stained with 
LIVE/DEAD® Fixable Dead Cell Stain (Life Technologies) for 15 mins. For 
intracellular staining of EdU, the Click-iT® EdU Alexa Fluor® 488 (ThermoFisher) 
imaging protocol was followed. All samples were resuspended in the PBS buffer (or 
permeabilization buffer if intracellular staining) and analyzed using a LSR II or BD 
LSRFortessa X-20 (Becton Dickinson).  
 
Statistical analysis 
Data shown as the means ± SEM. Data sets were analysed by 2-way ANOVA, 2-
way ANOVA with Bonferroni post tests, Log-rank (Mantel-Cox) Test (survival) or 
Student-t test. GraphPad Prism 6 (GraphPad Software, San Diego, CA) was used 
for data analysis and preparation of graphs. P-values less than 0.05 were 
considered as statistically significant 
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Chapter 3. IAV and S. pneumoniae show limited 
synergy in inducing epithelial responses 
 
3.1 Background 
A major complication following IAV infection is the increased susceptibility of the 
host to infection with bacteria such as Streptococcus pneumoniae. Combination of 
these divergent stimuli synergizes leading to increased induction of lung damage, 
morbidity and mortality (McCullers and Rehg 2002; Brundage and Shanks 2008). It 
is not fully understood what the cause of this increased lung damage, morbidity and 
mortality is.  
The lung relies heavily on the innate immune response to protect the host 
from invading pathogens. S. pneumoniae must be able to evade the host response 
mechanisms to infect the host. Additionally, the primary viral infection may 
predispose the host to a more severe manifestation of the secondary bacterial 
infection by direct viral-mediated lung damage, impairment of the antibacterial 
immune response, or induction of immunopathology. Many of the innate immune 
responses to co-infections have been analysed in vivo. However, the specific role 
of the airway epithelium in these responses has not been previously considered. 
The airway epithelium is at the forefront of the host’s defence since it acts as a 
physical barrier to infection and is the first to respond. It can produce antiviral and 
antibacterial effector proteins, and cytokines and chemokines to recruit and activate 
immune cells, contributing to the elimination of the invading pathogens. With regard 
to the epithelial response during co-infection, many parameters may be altered, 
leading to increased susceptibility to co-infection: increased epithelial damage, 
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decreased mucociliary function, decreased production of antimicrobial peptides 
(AMPs), and impaired or enhanced cytokine and chemokine production.  
One of the hallmarks of IAV infection is lung epithelial damage. This lung 
damage can be caused directly by the virus via the viral cytotoxic peptide PB1-F2 
(McAuley et al. 2009), but can also be induced by the antiviral immune response. 
One such component of the antiviral response, type I IFNs, is associated with 
immunopathology and lung damage when produced in high amounts (Herold et al. 
2008; Högner et al. 2013; Davidson et al. 2014). Type I IFNs induce DR5 on airway 
epithelia following IAV infection, and interaction with its corresponding ligand TRAIL 
from monocytes leads to apoptosis of the epithelium (Holoch and Griffith 2009; 
Benedict and Ware 2012; Davidson et al. 2014; Ellis et al. 2015) in order to 
eliminate virally infected cells. As a synergistic increase in type I IFNs following co-
infection has been observed (Nakamura et al. 2011), this highlights the possibility 
that a synergistic increase in type I IFNs is contributing to the amplified lung 
damage observed within co-infected lungs. Another death receptor, FAS, which 
can be induced by type I IFN, can also bind its ligand FASL to induce apoptosis 
(Waring and Müllbacher 1999; Fujikura et al. 2013). It is not yet known how these 
death receptors are affected following co-infection, and whether the combination of 
the viral and bacterial stimuli results in increased expression on AECs. 
This lung damage following IAV infection has been shown to increase 
mucus production and decrease ciliar beat frequency (McCullers and Rehg 2002). 
This severely impacts the mucociliary clearance function of the airway epithelium to 
trap and remove pathogens, and thus provides an ideal environment for bacterial 
binding, colonization and dissemination (Plotkowski et al. 1986; Pittet et al. 2010; 
Goulding et al. 2011).  
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AMPs can be produced by the epithelia to help control bacteria through 
direct bacterial killing or inhibiting binding (Bals 2000; Nisapakultorn et al. 2001; 
Wiesner and Vilcinskas 2010). How these are affected by the primary IAV infection, 
the antiviral immune response, or during co-infection is as of yet unknown. 
The primary antiviral response can result in immune impairment. This can 
be mediated through the desensitization of TLR signalling in innate immune cells 
(Didierlaurent et al. 2008), and result in the reduced production of CCL2, required 
for the recruitment of monocytes (Nakamura et al. 2011), CXCL1 and CXCL2, 
required for the recruitment of neutrophils (Shahangian et al. 2009). This immune 
impairment may help reduce the possibility of over-activating the immune response 
that may lead to immunopathology resulting in increased lung damage. 
Unfortunately, this can contribute to bacterial escape from the immune response, 
resulting in outgrowth and bacterial-induced damage. Whether the epithelial 
production of chemokines in response to bacteria is impaired following primary 
infection remains to be elucidated.   
 Although there are reports of impaired antibacterial responses following IAV 
infection, a massive proinflammatory cytokine production has been documented 
within the lungs of co-infected mice, which correlates with mortality (LeVine et al. 
2001; Seki et al. 2004; Damjanovic et al. 2013; Ellis et al. 2015). A high 
concentration of proinflammatory cytokines within the lung can be directly toxic, as 
they can induce cell death, and they can further drive inflammation, by recruiting 
and activating innate immune cells, all contributing to pathology in the lung. This 
increased damage could allow for enhanced bacterial outgrowth (Ellis et al. 2015) 
and dissemination that could ultimately lead to sepsis and death of the host. It is 
therefore possible that the epithelial response to the combined viral and bacterial 
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stimuli is greater than the response to single stimuli, resulting in an excessive 
proinflammatory cytokine production.  
Overall, there are multiple factors contributing to bacterial susceptibility 
following influenza infection. It is clear that the host response to the viral and 
bacterial infection plays a pivotal role in the progression of the disease. Since the 
airway epithelium initiates and contributes to the host response to co-infection, 
epithelia may play a vital role in determining the outcome of disease. It is therefore 
important to study the epithelial reaction to sequential viral and bacterial stimuli and 
compare this to single stimuli.  
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3.2 Hypothesis and Aims 
As the upper airway epithelial cells are direct targets of many respiratory pathogens, 
and communicate with the immune system, their responses may underlie the 
symptoms observed in influenza – Streptococcus pneumoniae co-infection, 
namely: lack of bacterial control, increased lung damage, and massive pulmonary 
inflammation. To understand the role of epithelia in each of these processes, 
primary airway epithelia were grown in vitro to study in isolation the epithelial 
responses to IAV – bacterial co-stimulus compared to responses to both single 
stimuli. 
 
I hypothesize that: 
Compared to single stimuli, co-stimulation of AECs will result in: 
• A suppression of AMPs, which would allow for the outgrowth of bacteria 
• Increased production of type I and III IFNs, resulting in increased ISG 
induction 
• Upregulation of apoptosis related genes, contributing to increased lung 
epithelial cell death  
• Massive proinflammatory cytokine and chemokine induction 
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3.3 Results 
3.3.1 Selection of infection stimuli 
The main inducer of the effects observed during co-infection in vivo has not yet 
been identified. Given that airway epithelial cells (AECs) are the first host target of 
both IAV and S. pneumoniae, they may be an important driver of these effects. 
Primary mouse tracheal epithelial cell (mTECs) cultures are a useful experimental 
system of isolating AECs from the rest of the immune system to determine their 
responses through the induction of AMPs, IFNs, ISGs, apoptosis inducing ligands 
and proinflammatory cytokines and chemokines. mTECs were derived from 
C57BL/6 mice, given that the majority of the literature utilise this in-bred strain, 
allowing for direct comparisons. Many studies on co-infection in vivo infect with 
A/Puerto Rico/8/1934 (H1N1) (PR8) (Bouvier and Lowen 2010). PR8 induces 
severe lung damage, morbidity and mortality in mice unlike many other human 
isolates of influenza. Therefore, in order to study the effect of co-infection on the 
epithelia without a severe initial viral infection, a milder influenza strain was chosen 
– X31. X31 is a re-assortment of the PR8 strain with the HA and NA of A/Hong 
Kong/1/1968 (H3N2) (Tam et al. 2013). This strain induces only moderate disease 
allowing for assessment of synergy with the secondary bacterial infection.  
The common laboratory strain of Streptococcus pneumoniae, D39, is used 
in many mouse models of infection (Chiavolini et al. 2008) and in co-infections 
(Goulding et al. 2011). It is a mild strain of S. pneumoniae, where its virulence 
depends on the strain of mice, route of administration and dosage administrated. 
Live D39, and heat-killed (HK) D39 which would act as a bacterial stimulus without 
the ability to proliferate and damage the epithelia, or overgrow in tissue culture, 
were used. In lieu of the bacterium and as a clean positive control, Toll-like 
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receptor agonists were also used - Pam3CSK4, a TLR2 agonist, and 
lipopolysaccharide (LPS), a TLR4 agonist. The virus was placed on the cells for 24 
hours, then the bacterial stimulus was added for a further 24 hours. A synergistic 
effect of a co-infection must be greater than the sum of the induction from the virus 
and the bacterial stimulation alone.  
To assess whether AECs respond to viral and bacterial stimulation, the 
known virus-induced type III IFN, IFNλ (IL-28A), and the known bacterial- and 
virus-induced CXCL2 were analysed (Figure 5). The virus induced IL-28A as 
expected, whereas the bacterial agonist, Pam3CSK4, did not (Figure 5A), which 
confirms these AEC cultures can respond to virus infection. Pam3CSK4 did 
however upregulate CXCL2 as expected, along with the virus, confirming the 
epithelia can also respond to bacterial stimulation (Figure 5B).  
  
Chapter 3 Results 
 
94 
 
 
Figure 5 AECs respond accordingly to viral and bacterial stimulation 
C57BL/6 epithelia were infected with X31 at a MOI of 0.1 or exposed to 
Pam3CSK4 (1 µg/ml) for 24 hours. cDNA from the cultures were analysed for 
IL28A induction and CXCL2 induction. Significance was assessed by unpaired t-
test where *** P<0.001, **** P<0.0001. Graphs show mean ± SEM. Data pooled 
from four independent experiments, n=6-24. 
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3.3.2 AMP production by AECs is minimally induced by bacteria 
AMPs produced by AECs can directly kill invading bacteria, and lack thereof may 
allow for increased colonisation of the lung. How their induction is affected during 
co-exposure is unknown. We hypothesise that preceding viral infection suppresses 
AMP production, thus contributing to lack of bacterial control in co-infection. Six 
antimicrobial peptides were chosen: Defb1, Defb2, Defb3, CAMP, Reg3g and 
S100a8, to asses their induction and possible suppression following co-infection. It 
is surprising to see that bacterial stimulation alone does not induce any of these 
AMPs significantly higher than the media control (Figure 6). There is a statistically 
significant induction of Defb1 when X31 is combined with LPS (1 µg/ml) compared 
to either single stimulus. Although not statistically significant, expression of Defb1 
increases when the lower concentration of LPS is used following IAV infection, and 
with both concentrations of Pam3CSK4. Defb3 displays a marginal increase 
following X31 + HK S. pneumoniae, and an increase in Reg3g when X31 is 
combined with Pam3CSK4 (1 µg/ml), LPS, or live S. pneumoniae. These increases 
are in contrast to the suppression that was hypothesized. Since bacterial 
stimulation alone does not seem to induce antimicrobial peptides, their subsequent 
suppression following co-exposure is therefore difficult to determine. In addition, a 
statistically significant increased induction in the presence of combined stimuli was 
observed in one case, which is difficult to reconcile with in vivo observations of 
reduced bacterial control.  
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Figure 6 The induction of AMPs by bacterial stimuli is minimal and generally 
remains unmodified by viral co-stimulus 
C57BL/6 epithelia were infected with X31 at a MOI of 0.1 for 24 hours then 
stimulated with either Pam3CSK4, LPS, HK or live S. pneumoniae (106 CFU/well) 
for a further 24 hours. cDNA from the cultures were analysed for antimicrobial 
peptides. Significance was assessed by unpaired t-test where * indicates co-
stimulus:single bacterial stimulus, ^ indicates co-stimulus:X31. * P<0.05. 
Significance only displayed if co-stimulus is greater than each single stimulus. 
Graphs show mean ± SEM. Data pooled from four independent experiments, n=3-
16. 
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3.3.3 IAV infection dominates the induction of type I and III IFNs, and 
subsequently ISG induction 
Since type I IFN production has been associated with many immune impairment 
and pathogenic effects, type I and III IFNs were quantified. Viral infection of AECs 
induces the production of IFNα, IFNβ and IFNλ. However, bacterial stimulation 
alone rarely induces any IFNs (Figure 7). IFNa4 messenger levels never exceed 
the media control for the virus or bacterial stimulants (Figure 7A). There is an 
induction of IFN protein by the viral infected epithelia as expected, and by both heat 
killed and live S. pneumoniae treatments, however this is not significant (Figure 
7B). Messenger levels of IFNb1 and IL28A (IFNλ) can be observed by X31 and live 
S. pneumoniae treatment, however protein is detected only following X31 infection.  
  
Chapter 3 Results 
 
98 
 
 
Figure 7 Viral but not bacterial stimulation of AECs induces an IFN response 
C57BL/6 epithelia were treated with X31 (MOI: 0.1), Pam3CSK4, LPS, HK or live S. 
pneumoniae (D39, 106
 
CFU/well) for 24 hours. cDNA from the cultures were 
analysed for IFNa4, IFNb1 and IL28A (A). Supernatants were collected and 
analysed for IFNα, IFNβ, and IFNλ (B) Significance compared to media control and 
assessed by unpaired t-test where * P<0.05, ** P<0.01, *** P<0.001. Graphs show 
mean ± SEM. Data pooled from six independent experiments, n=3-24. 
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When the two stimuli are joined there is no great synergy observed. Only 
messenger levels of IFNa4 when X31 and live S. pneumoniae are combined, and 
both messenger and protein levels of IFNλ when X31 and 0.1 µg/ml of LPS are 
combined, result in a statistically significant increase compared to the single stimuli 
(Figure 8). IFNa4 messenger levels, although not statistically significant shows an 
increase when IAV is combined with HK S. pneumoniae (Figure 8A), and in IFNα 
protein levels when X31 is combined with HK and live S. pneumoniae (Figure 8B). 
There is an increase in IFNβ protein levels following IAV, and HK or live S. 
pneumoniae combination (Figure 8B). An increase in IFNλ protein levels can also 
be observed when the virus is combined with Pam3CS4, LPS, HK or live S. 
pneumoniae (Figure 8B). However, the majority of these increases are not 
statistically significant, therefore it is predominantly the antiviral response that 
drives the induction of type I and III IFNs. This is not surprising in the light of Figure 
7 where the bacteria alone rarely induced IFNs to begin with, but it is in 
disagreement with in vivo findings by Nakamara et al. (Nakamura et al. 2011). 
This may be due to the altered order of administration as the bacteria were given 
before IAV within this study.  
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Figure 8 A viral-bacterial co-stimulation of AECs results in only marginal 
increases in the production of IFNs  
C57BL/6 epithelia were infected with X31 at a MOI of 0.1 for 24 hours then with 
either Pam3CSK4, LPS, Heat killed (HK) or live S. pneumoniae (D39, 106 
CFU/well) for a further 24 hours. cDNA from the cultures were analysed for IFNa4, 
IFNb1 and IL-28A (A). Supernatants were collected and analysed for IFNα, IFNβ 
and IFNλ (B) Significance was assessed by unpaired t-test where * indicates co-
stimulus:single bacterial stimulus, ^ indicates co-stimulus:X31. * P<0.05, *** 
P<0.001, **** P<0.0001. Significance only displayed if co-stimulus is greater than 
each single stimulus. Graphs show mean ± SEM. Data pooled from six 
independent experiments, n=3-24. 
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Given the lack of type I or type III IFN induction by the bacterial stimulus 
alone and only marginal increases following a co-stimulus, it is therefore not 
surprising to see little to no induction of ISGs by the bacterial stimulation alone 
(Figure 9). No significant synergy or suppression is observed when the virus is 
combined with the bacterial stimuli. There appears to be a non-significant 
suppression of Rsad2 and Oasl2 when the virus is combined with HK or live S. 
pneumoniae. This suppression also appears for ifi203 when X31 is combined with 
both concentrations of Pam3CSK4 and LPS, but again this is not significant. There 
is however an increase in Oasl2 following X31 + Pam3CSK4 and X31 + LPS 
stimulation, but yet again these are not significant (Figure 9). Overall, the levels of 
induction are in general similar to the inductions by the virus alone, which further 
confirms that viral infection dominates the epithelial response thus far. 
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Figure 9 IAV infection of AECs induces ISGs, which are unchanged following a 
co-stimulation 
C57BL/6 epithelia were infected with X31 at a MOI of 0.1 for 24 hours then with 
either Pam3CSK4, LPS, HK or live S. pneumoniae (D39, 106 CFU/well for a 
further 24 hours. cDNA from the cultures were analysed for interferon 
stimulated genes: Rsad2, ifi203 and Oasl2. No significance for any co-
stimulation:single stimulation. Graphs show mean ± SEM. Data pooled from five 
independent experiments, n=3-24. 
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3.3.4 Death receptors are not induced in isolated mTEC cultures  
Given the data of lung damage facilitating bacterial colonisation and pathology in 
co-infected lungs (McAuley et al. 2009; Ellis et al. 2015), apoptosis-related genes 
were quantified. Lung damage observed in vivo correlated with an increase in DR5 
on AECs (Ellis et al. 2015). DR5 can be induced on airway epithelia by type I IFNs, 
an antiviral cytokine, which can bind to its receptor TRAIL, another ISG, to induce 
apoptosis of the DR5 expressing cell. However, upon testing DR5 messenger 
levels on AECs in vitro, it was found that the virus alone did not induce it, nor do 
bacterial stimulation alone, or the combination (Figure 10). Viral and bacterial 
stimulation induces TRAIL, which is significantly increased following co-stimulation 
of IAV with Pam3CSK4 or LPS, compared to both single stimuli. There is no 
statistically significant increase over single stimuli when either the HK or live S. 
pneumoniae are used. HK and live S. pneumoniae marginally increase expression 
of FAS, another death receptor, however this is not significant. Following X31 and 
live S. pneumoniae co-stimulation there appears to be a suppression of FAS, but 
this is also not significant. Viral stimulation alone drives the induction of its ligand 
FASL, whereas bacterial stimulation alone does not. There is a significantly 
increased induction of FASL when the virus and the higher concentration of LPS 
are combined in comparison to the two single stimuli. Overall, the apoptosis-related 
receptors are not induced. This may indicate the type I IFN amounts produced 
within these cultures are not sufficient to induce these death receptors, or that other 
cytokines or cell interactions, not present in our mTEC system, are required on top 
of IFNs to upregulate death receptors on epithelia. However, the epithelia can 
significantly increase the ligands following co-infection compared to single stimuli, 
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which suggests that epithelial cells may contribute to the induction of apoptosis of 
the epithelium when the death receptors are present.  
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Figure 10 Co-stimulation of AECs does not induce death receptors more strongly 
than in the corresponding single infections 
C57BL/6 epithelia were infected with X31 at a MOI of 0.1 for 24 hours then with 
either Pam3CSK4, LPS, HK or live S. pneumoniae (D39, 106 CFU/well) for a 
further 24 hours. cDNA from the cultures were analysed for apoptosis related 
genes, Death receptors: DR5 and FAS with their corresponding ligands: TRAIL 
and FASL respectively. Significance was assessed by unpaired t-test where * 
indicates co-stimulus:single bacterial stimulus, ^ indicates co-stimulus:X31. ** 
P<0.01, *** P<0.001. Significance only displayed if co-stimulus is greater than 
either single stimulus. Graphs show mean ± SEM. 
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3.3.5 Co-stimulation of AECs results in increased induction of 
proinflammatory cytokines and chemokines 
Cytokines and chemokines can be protective during infections, but excessive 
amounts can be pathogenic and therefore detrimental to the lung. Co-stimulation of 
AECs induces statistically significant increases in messenger and protein levels of 
the proinflammatory cytokines CXCL1, CXCL2 and TNF-α when Pam3CSK4 and 
LPS are used as the bacterial stimulus (Figure 11). Combination of the virus and 
HK S. pneumoniae also induces a significant increase in messenger levels of 
CXCL2, however this appears to be an additive effect (Figure 11A). An additive 
effect, where the sum of the two stimuli alone equals the induction by the 
combination, also appears to be responsible for the increase in messenger IL-6 
levels when X31 and live S. pneumoniae are combined (Figure 11A). Protein levels 
of IL-6 however display a significant increase when X31 is combined with the lower 
concentration of Pam3CSK4, and with both concentrations of LPS. An additive 
induction of IL-6 can be observed following the combination of virus and the higher 
concentration of Pam3CSK4, but this is not significant in comparison to single 
stimuli (Figure 11B). Interestingly, there appears to be a reduction in IL-6 protein, 
which does not correlate with a decrease in messenger levels following viral and 
live S. pneumoniae stimulation. There is a significant increase in protein levels of 
TNF-α following X31 and live S. pneumoniae co-stimulation. However, this is not as 
great as when LPS is used as the secondary stimulus (Figure 11B). Overall, co-
exposure of epithelia leads to a synergistic increase in a range of proinflammatory 
cytokines and chemokines. This indicates that the airway epithelia are contributing 
to the recruitment of neutrophils and other innate immune cells crucial for 
controlling and eliminating the bacteria. Virus-dependent suppression of these 
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chemoattractants, as has been described in the literature for other cell types, was 
not observed in mTECs. 
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Figure 11 Co-stimulation with bacterial agonists on AECs results in greater 
proinflammatory cytokine induction compared to the two single stimuli. 
C57BL/6 epithelia were infected with X31 at a MOI of 0.1 for 24 hours then with 
Pam3CSK4, LPS, HK or live S. pneumoniae (D39, 106 CFU/well) for a further 
24 hours. cDNA from the cultures were analysed for CXCL1, TNF-α, IL-6 and 
CXCL2 (A). Supernatants were collected and analysed for CXCL1, TNF-α, IL-6 
and CXCL2 ELISA and cytokine multiplex (B). Significance was assessed by 
unpaired t-test where * indicates co-stimulus:single bacterial stimulus, ^ 
indicates co-stimulus:X31. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. 
Significance only displayed if co-stimulus is greater than either single stimulus. 
Graphs show mean ± SEM. Data pooled from seven independent experiments, 
n=3-40. 
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Using a hypothesis driven approach to analyse the cytokine and chemokine 
response may not be giving an overall view of the synergistic increases in cytokine 
levels. Therefore, a cytokine multiplex was performed. The fold changes of 
cytokines induced by co-stimulus over the corresponding single stimulus were 
calculated and graphed (Figure 12 and 14). Considering the TLR agonists as the 
secondary stimulus, it is clear to see that there is a greater fold induction of 
cytokines by the virus than the bacteria (Figure 12A, C). We took the top six most 
upregulated, and any downregulated cytokines and combined them into a Venn 
diagram (Figure 12B, D). In general we see that bacterial stimulation upregulates 
known bacterially induced cytokines such as CXCL2, and G-CSF. The virus is also 
upregulating known cytokines such as CXCL10 and CCL5. Although we find very 
little overlap, it is interesting to see that TNF-α is induced more strongly by co-
stimulation with either Pam3CSK4 or LPS than by either single stimulus. CCL3 is 
also commonly suppressed by co-exposure compared to exposure to either single 
stimulus (Figure 12B, D). Furthermore, CXCL1 and IL-6 is more greatly induced by 
co-stimulation with LPS than either single stimuli (Figure 12D).  
To ensure that the fold increases reported in Figure 12 are not simply due to 
very small cytokine amounts skewing the ratios, and to calculate statistical 
significance, we also looked at the absolute protein levels of the cytokines induced. 
Of the cytokines that overlap, TNF-α, and CXCL1 show the most striking and 
statistically significant increases by X31 and LPS co-stimulation over single stimuli 
(Figure 13A). IL-6 is also significantly increased although not as striking as with 
TNF-α and CXCL1 (Figure 13A). These increases also confirm the findings in 
Figure 12 obtained by individual ELISAs. Looking at the protein levels of the other 
most induced cytokines we find that for CXCL10 and G-CSF there are no 
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significant increases following co-exposure is observed (Figure 13B). However, 
there are significant increases in CCL2 and CXCL2 protein levels following co-
exposure in comparison to both single stimuli, also confirming results from Figure 
12. The suppression of CCL3 in co-stimulation was not significant versus either 
single stimulus (Figure 13C) 
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Figure 12 Only a small subset of cytokines are consistently induced or 
suppressed following X31 and TLR agonist co-exposure 
C57BL/6 epithelia were infected with X31 at a MOI of 0.1 for 24 hours then 
exposed to either Pam3CSK4 or LPS (1 µg/ml) for a further 24 hours. 
Supernatants from the cultures were analysed by cytokine multiplex. Co-
stimulation induced cytokine amounts were calculated as fold changes over the 
corresponding single stimulus (A, C). The six most upregulated, and cytokines 
that were downregulated were put into a Venn diagram for when Pam3CSK4 
(B), or LPS (D) is used. Graphs show mean ± SEM. Data representative of 2 
independent experiments, n=3-4. 
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Figure 13 Absolute values show significant increases following co-exposure 
C57BL/6 epithelia were infected with X31 at a MOI of 0.1 for 24 hours then 
exposed to either Pam3CSK4 or LPS (1 µg/ml) for a further 24 hours. Supernatants 
from the cultures were analysed by cytokine multiplex. Absolute values of the most 
upregulated overlapping cytokines (A), a subset of cytokines differentially regulated 
(B), and the overlapping downregulated cytokine (C) in Figure 12B and D. 
Significance was assessed by unpaired t-test where * indicates co-stimulus:single 
bacterial stimulus, ^ indicates co-stimulus:X31. * P<0.05, ** P<0.01, *** P<0.001, 
**** P<0.0001. Significance only displayed if co-stimulus is greater than either 
single stimulus. Data representative of 2 independent experiments, n=3-4. 
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 When S. pneumoniae is used as the secondary stimulus we again see a 
greater increase in cytokine fold changes by the virus than by either the HK or live 
S. pneumoniae (Figure 14A, C). This confirms that the virus represents a stronger 
stimulus for the epithelium than either the bacteria or bacterial stimulus do. It is 
interesting to note that the S. pneumoniae infection induces a different set of top 
cytokines compared to PAM3CSK4 or LPS. However we still detect induction of 
common antiviral cytokines, CXCL10 and IFNγ, and common antibacterial 
cytokines, CXCL1, and G-CSF (Figure 14B, D). Interestingly, CCL5 is commonly 
up regulated by co-stimulation with IAV and either HK or live S. pneumoniae in 
comparison to the single stimuli (Figure 14B, D). TNF-α is also most up regulated 
when live S. pneumoniae is used as the secondary stimulus as was expected 
based on the results obtained with bacterial TLR agonists in Figure 12 (Figure 14B). 
IL-6 on the other hand is more upregulated by IAV co-exposure with HK S. 
pneumoniae (Figure 14D). VEGF is commonly down regulated during X31 and live 
S. pneumoniae co-stimulation (Figure 14B), which was also down regulated by 
Pam3CSK4 (Figure 14B).  
 Assessing absolute protein levels we find that apart from TNF-α, there is no 
significant increase by co-stimulation in comparison to the two single stimuli for 
CCL5 and IL-6. IL-6 again appears to be suppressed when X31 is combined with 
live S. pneumoniae. TNF-α is significantly increased by X31 and live S. 
pneumoniae co-exposure (Figure 15A). A subset of the top induced cytokines 
(Figure 15B) and those downregulated (Figure 15C) in Figure 14 also do not show 
any significant increase by co-exposure in comparison to both single stimuli, apart 
from G-CSF when X31 is combined with live S. pneumoniae. 
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 The cytokines are not filtered on statistical significance before generating 
fold changes. This is why some cytokines come out as highly induced yet are not 
significantly changed in protein levels. Overall, Figures 12-15 show epithelia 
respond separately to viral and bacterial stimulation and the cytokine profiles are 
relatively separated, with those cytokines that are induced mainly by the viral 
infection and those which are induced mainly by bacterial stimulation. There are a 
few exceptions of cytokines that are synergistically induced by co-exposure: TNF-α 
by virus plus TLR agonists or bacteria; IL-6, CXCL2, CCL2 and CXCL1 only by 
virus plus TLR agonists, and CCL5 only by virus plus bacterial exposure. As these 
synergistically induced cytokines and chemokines have great proinflammatory 
potential, it would be interesting to test whether increased amounts of these 
cytokines contribute to immunopathology in vivo.  
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Figure 14 Only a small subset of cytokines overlap following X31 and S. 
pneumoniae co-exposure 
C57BL/6 epithelia were infected with X31 at a MOI of 0.1 for 24 hours then with 
either HK or live S. pneumoniae (D39, 106 CFU/well) for a further 24 hours. 
Supernatants from the cultures were analysed by cytokine multiplex. Co-
infected results were calculated as fold changes over the corresponding single 
infection (A, C). The six most upregulated, and cytokines that were 
downregulated were put into a Venn diagram for when live D39 (B), or HK D39 
is used (D). Graphs show mean ± SEM. Data is representative of four independent 
experiments, n=3-4. 
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Figure 15 Absolute values for cytokines differentially regulated following IAV and 
S. pneumoniae co-exposure 
C57BL/6 epithelia were infected with X31 at a MOI of 0.1 for 24 hours then with 
either HK or live S. pneumoniae (D39, 106 CFU/well) for a further 24 hours. 
Supernatants from the cultures were analysed by cytokine multiplex. Absolute 
values of the most upregulated overlapping cytokines (A), a subset of cytokines 
differentially regulated (B) and downregulated (C) in Figure 14B and D. 
Significance was assessed by unpaired t-test where * indicates co-stimulus:single 
bacterial stimulus, ^ indicates co-stimulus:X31. * P<0.05, ** P<0.01, *** P<0.001, 
**** P<0.0001. Significance only displayed if co-stimulus is greater than either 
single stimulus. Data representative of 2 independent experiments, n=3-4. 
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3.3.6 IAV infection dominates the transcriptional response of the AECs  
Expression profiling allows a global analysis of the transcriptional response of 
epithelia to exposure to virus or bacteria or both. We therefore performed 
microarray analysis on media control AECs, and AECs infected with X31 +/- LPS, 
Pam3CSK4, or live S. pneumoniae. Samples were normalized to the average of 
the media control group and filtered for a fold change of 2 (p<0.01) yielding 2731 
genes differentially expressed in the experiment utilising LPS as the secondary 
stimulus (Figure 16A), and 1095 genes when live S. pneumoniae was used as the 
secondary stimulus (Figure 17A).  
Concentrating on when LPS was used as the secondary bacterial stimulus, 
it is clear to see that the antiviral response dominates the overall transcriptional 
response (Figure 16A). This gene set was further filtered for a 2-fold change of X31 
+ LPS stimulation over X31 stimulation alone (Figure 16B) and X31 + LPS 
compared to LPS stimulation alone (Figure 16C). Co-stimulation leads to an 
additional 567 differentially expressed genes compared to virus stimulus alone, 
which is far fewer than the 2240 genes induced by co-stimulation over bacterial 
stimulus alone, which is a consequence of the stronger gene induction by virus 
exposure. A set of 505 genes were further upregulated upon costimulation as 
compared to both the virus and bacterial single stimulus (Figure 16D, E. Appendix 
Table 4). Genes of note that are differentially expressed are the cytokines: CXCL1, 
CXCL2, IL-6, IL-1α, TNF; the antimicrobial peptides: S100a9, S100a8, Slpi, and the 
apoptosis related gene: Tnfrsf19 (Appendix, Table 4). This list of 505 genes is 
represented as a heatmap (Figure 16E) and was used for Ingenuity Pathway 
Analysis (IPA) where the top 6 canonical pathways are represented (Figure 16F). It 
is unsurprising that the highest pathway is related to LPS signalling since LPS is 
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the secondary stimulus here, and that granulocyte recruitment processes are 
found, given the chemoattractants we have detected. It is also interesting that aryl 
hydrocarbon receptor related pathways appear twice among the top six pathways. 	 	
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Figure 16 The antiviral response dominates the overall transcriptional response 
to co-stimulation with TLR agonists 
C57BL/6 epithelia were infected with X31 at a MOI of 0.1 for 24 hours, then 
exposed to either Pam3CSK4 or LPS for a further 24 hours. RNA was collected 
for global analysis by Illumina.SingleColor.Mouse WG-6_V2_0_R0_1127 
microarrays. Samples (n=3) were normalized to the median of the vehicle 
control group and filtered for a fold change of 2 (A). This was subsequently 
filtered for 2-fold change of co-stimulation with LPS versus X31 (B), or versus 
Veh Ctrl
X31
Pam3CSK4
LPS
X31 + Pam3CSK4
X31 + LPS
A B C
D
E F
2731 genes
567 genes 567 genes
505 genes
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LPS alone (C). A Venn diagram was generated using the gene set from B and 
C to generate a list of genes differentially expressed in co-stimulation versus 
either single stimulation (D).  The 505 genes commonly differentially expressed 
are displayed in a heatmap (E), with the six top canonical pathways associated 
with this gene-set as determined by Ingenuity Pathway Analysis (F). One-way 
ANOVA, P<0.01, Benjamini-Hochberg multiple test correction was carried out 
for all. Samples were analysed under the supervision of Dr Stefania Crotta. 
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 The dominance of the antiviral response within the overall transcriptional 
response of the AECs is also clear to see when live S. pneumoniae was used as 
the secondary stimulus (Figure 17A). This gene set was further filtered for a 2-fold 
change of X31 + live S. pneumoniae co-exposure compared to X31 single 
exposure (Figure 17B), and X31 + live S. pneumoniae co-exposure compared to S. 
pneumoniae single exposure (Figure 17C). Co-exposure induced 90 genes above 
X31 stimulus alone, which is again far fewer than the 1007 genes induced by co-
exposure in comparison to the bacterial stimulus alone. It is surprising to see that 
live S. pneumoniae exposure alone or as a co-stimulus had very little impact on 
epithelial responses. This could be due to the fact that D39 is a mild strain of S. 
pneumoniae. There is also the possibility that D39 may shield its PAMPs from the 
PRRs on the epithelia, even though bacterial TLR agonists had equally little impact 
on epithelia, as shown previously. A set of only 80 genes were differentially 
expressed by co-exposure to either virus or bacteria alone (Figure 17D, E. 
Appendix Table 5). Genes of note that were differentially expressed are the 
cytokines: CXCL2, CXCL1, and the antimicrobial peptide: Slpi (Appendix, Table 5). 
These 80 genes are also displayed as a heatmap (Figure 17E) and were taken for 
IPA (Figure 17F). The top six canonical pathways are represented. Interestingly, 
within these top six pathways is: ‘The role of hypercytokinemia/hypoxytokinemia in 
the pathogenesis of Influenza’ which further confirms the predominant role of the 
virus in the overall response from the AECs, and suggests that the genes induced 
by co-exposure may contribute to pathology. 
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Figure 17 The antiviral response also dominates the overall transcriptional 
response following co-stimulation with live S. pneumoniae 
C57BL/6 epithelia were infected with X31 at a MOI of 0.1 for 24 hours then with 
live D39 for a further 24 hours. RNA was collected for global analysis by 
Illumina.SingleColor.Mouse WG-6_V2_0_R0_1127 microarrays. Samples (n=3) 
were normalized to the median of the vehicle control group and filtered for a fold 
change of 2 (A). This was subsequently filtered for 2-fold change of co-
stimulation versus X31 (B), or a 2-fold change of co-stimulation vs. D39 alone 
A B C
D
E
Veh Ctrl
X31
D39
X31 + D39
F
1095 genes
90 genes 1007 genes
80 genes
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(C). A Venn diagram was generated using the gene set from B and C to 
generate a list of genes differentially expressed in co-stimulation versus either 
single stimulation (D). The 80 genes most changed when X31 and D39 are 
used are displayed in a heatmap (E), with the 6 top canonical pathways 
associated with this gene set as determined by Ingenuity Pathway Analysis (L). 
One-way ANOVA, P<0.01, Benjamini-Hochberg multiple test correction was 
carried out for all. Samples were analysed under the supervision of Dr Stefania 
Crotta. 
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 The mTEC system lacks any of the resident or recruited innate immune cells, 
which can also respond to infection by the release of cytokines, chemokines and 
other innate immune factors. Since, we see the virally induced genes dominating 
the overall AECs response to co-stimulation, whole lungs may be able to portray 
whether this represents the in vivo situation and whether the presence of the innate 
immune cells change the picture we find for co-exposed epithelia. Mice were either 
singularly infected or co-infected with X31 and D39. The primary X31 virus was 
given for 5 days before treatment with either PBS or D39 for 48 hours. Whole lungs 
were taken and processed for microarray. Samples were normalized to the average 
of the vehicle control group and filtered for a fold change of 4 by any of the stimuli, 
yielding 3173 genes differentially expressed (Figure 18A). It is evident yet again 
that the antiviral response dominates the whole lung transcriptional response. This 
gene set was further filtered for a 2-fold change in X31 + S. pneumoniae compared 
to X31 infection alone (Figure 18B), and X31 + S. pneumoniae challenge compared 
to S. pneumoniae infection alone (Figure 18C). Co-infection resulted in 418 genes 
differentially expressed compared to virus infection alone, which is once more far 
less than the 2721 genes differentially expressed by the co-infection over S. 
pneumoniae alone. A set of 362 genes were differentially expressed overall by both 
X31 and S. pneumoniae infection (Figure 18D, E. Appendix Table 6). Genes of 
note that are differentially expressed are the cytokines: CXCL2, CXCL1 and TNFα 
(Appendix, Table 6). All 362 genes are expressed as a heatmap (Figure 18E), and 
this set of genes was assessed by IPA. The top twelve canonical pathways are 
represented (Figure 18F). Many of these pathways are found in Figures 16 and 17. 
In fact ‘The role of hypercytokinemia/hypoxytokinemia in the pathogenesis of 
influenza’ is also found as one of the top pathways induced in vivo and in AECs, 
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further corroborating the strong cytokine induction and confirming that the overall 
response of the lung during co-infection is driven mainly by the antiviral response. 
However the differentially expressed gene list here, 362 genes are far larger than 
the 80 genes differentially expressed by AECs and suggest that the response from 
the innate immune cells contributes many gene products that the AECs do not 
induce. 
 When the three lists of genes that were differentially expressed in the three 
co-exposure scenarios were combined into a Venn diagram, it was surprising to 
find only six genes common between all three (Figure 18G, H). Interestingly, 
CXCL2, present twice within the gene list, and CXCL1 are both induced by all three 
co-exposure scenarios, which concretely confirms the findings from Figures 11-15. 
This indicates that the AEC response mirrors the in vivo response of the lung to co-
infection and suggests that airway epithelia can initiate and contribute to the innate 
immune response during co-infection by producing proinflammatory cytokines and 
chemokines, essential for the recruitment of neutrophils needed to control and 
eliminate the bacteria but also potentially pathogenic. However, we cannot estimate 
how much of these cytokines and chemokines are produced in vivo by AECs and 
how important the contribution of innate immune cells are. Most likely, cross talk 
between the innate immune cells and the AECs and positive feed back loops 
through recruited immune cells producing more chemoattractants will enhance and 
amplify the initial epithelial response in vivo. 
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Figure 18 The antiviral response also dominates the transcriptional response by 
co-infected whole lungs 
C57BL/6 mice were infected with 8x103 TCID50 X31 or vehicle control (PBS), 
then 5 days later with 2x107 CFU S. pneumoniae (D39) or PBS. Whole lungs 
were collected 48 hours later. RNA was collected and prepared for global 
analysis by Illumina.SingleColor.Mouse WG-6_V2_0_R0_1127 microarrays. 
Samples (n=10) were normalized to the median of the vehicle control group and 
filtered for a fold change of 4 (A). This was subsequently filtered for 2-fold 
changes in co-stimulation versus X31 (B), or a 2-fold change in co-stimulation 
vs. D39 alone (C). A Venn diagram was generated using the gene set from B 
Veh Ctrl
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X31 + D39
A B C
D
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and C to produce a list of genes which are commonly upregulated in co-
infection compared to single infections (D). These 362 genes most changed 
when X31 and D39 are used in vivo are displayed in a heatmap (E), with the 
twelve top canonical pathways associated with this gene-set as assessed by 
Ingenuity Pathway Analysis (F). The three sets of changed genes in a co-
stimulus (E, Figure 16E and Figure 17E) were generated into a Venn diagram 
showing only four genes differentially expressed by all three (G, H). One-way 
ANOVA, P<0.01, Benjamini-Hochberg multiple test correction was carried out 
for all. Samples were collected with Dr Gregory Ellis and were analysed under 
the supervision of Dr Stefania Crotta. 
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3.3.7 A more virulent bacterium does not induce the synergy expected 
Since the transcriptional profile showed very little gene induction by the bacterium 
we used, a more virulent strain of S. pneumoniae, TIGR4, was utilised to see if that 
would lead to stronger antibacterial responses and induce the expected synergy. 
The five hypothesis driven readouts: AMPs, type I and III IFNs, ISGs, apoptosis 
related genes, and proinflammatory cytokines, were tested. In contrast to Figure 6, 
live TIGR4 induces the antimicrobial peptides: Defb3, Defb2, and S100a8, which 
have marginal increases following co-infection (Figure 19A).  
The virus induces messenger levels of the three IFNs tested (Figure 19B). 
Interestingly, live TIGR4 induces IFNa4 that increases following co-stimulation, 
however this is not significant. Furthermore, live TIGR4 induces messenger levels 
of IFNb1 and IL28A. For IL28A, there is an increase following X31 with HK TIGR4 
and live TIGR4, but this too is not significant. 
The virus induces the three ISGs tested: Rsad2, Ifi203 and Oasl2, as 
expected (Figure 19C). Interestingly, the induction of IFNs by live TIGR4 alone 
does not correlate with an induction of the three ISGs. Similarly, the combination of 
X31 and live TIGR4, which resulted in induction of type I and III IFN, induced 
Rsad2 and ifi203, however very little induction of Oasl2 is found. Intriguingly, there 
appears to be suppression in the expression of Rsad2 and Oasl2 during co-
stimulation in comparison to the virus alone.  
There is an increase in DR5 and TRAIL induction following X31 and HK 
TIGR4 co-stimulation, but this is not significant (Figure 19D). TRAIL expression 
appears to be suppressed during X31 and live TIGR co-stimulation in comparison 
to X31 alone. Virus infection alone induced, although not significantly, the death 
receptor FAS with no further increase observed following co-stimulation, 
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corroborating Figure 10. It’s corresponding ligand FASL however, shows an 
increased induction following X31 and live TIGR4 co-stimulation, but this is again 
not significant. 
For the cytokines CXCL1 and TNF-α, there is a small induction by the 
bacteria alone (Figure 19E). CXCL1 is increased when X31 is combined with either 
HK TIGR4 or live TIGR4. An increase in TNF-α when X31 and HK TIGR4 are 
combined can also be observed. These increases are again not significant. 
Overall, live TIGR4 stimulation of the AECs alone induces a greater 
response than was observed using D39. This however did not translate into 
stronger synergy or detectable suppressive effects when combined with X31. As 
these initial results did not promise to find stronger synergy, this bacterial strain 
was not tested further. 
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Figure 19 Exposure to a more virulent bacterium induces more genes than D39 
but does not synergise strongly with X31 exposure 
C57BL/6 epithelia were infected with X31 at a MOI of 0.1 for 24 hours then with 
HK or live TIGR4 (108) for a further 24 hours. cDNA from the cultures were 
analysed for antimicrobial peptides (A), IFNs (B), ISGs (C), apoptosis related 
genes (D) and cytokines (E). Significance was assessed by unpaired t-test where 
* P<0.05. No significance for any co-stimulation:single stimulation. Graphs show 
mean ± SEM, n=3. 
  
Chapter 3 Results 
 
132 
 
3.4 Conclusions and Discussion 
It is well documented that viral and bacterial co-infection is associated with strong 
inflammation, lung damage, high cytokine levels and massive immune cell 
recruitment into the lung, leading to increased morbidity and mortality (Morens et 
al. 2008; Centers for Disease Control and Prevention (CDC) 2009; Cillóniz et al. 
2012; Li et al. 2012; Niemann et al. 2012). Airway epithelia are one of the first and 
most important targets for viral and bacterial contact and invasion, and are able to 
produce a vast range of inflammatory cytokines and chemokines, essential for the 
activation and recruitment of immune cells that can help control and clear infection. 
We therefore tested the hypothesis of whether co-exposure of airway epithelia to 
the two infectious agents would lead to massive increases in the epithelial 
response compared to exposure to both single pathogens. This would allow us to 
understand better whether or not the strong immune response found in co-infection 
may be orchestrated by the airway epithelia. We found that the antiviral response 
drives the overall response of the AECs during viral and bacterial co-exposure. We 
did however show increased induction of proinflammatory cytokines and 
chemokines following co-exposure in relation to the two single stimuli. Although this 
airway epithelial response to co-exposure may contribute to the overall innate 
immune response, it is unlikely that it is the epithelium alone that drives the 
massive proinflammatory cytokine signature observed in vivo during co-infection. 
The exposure timings employed in our in vitro model greatly differ from 
those used in vivo. We infect the mTECs with X31 for 24 hours, and then they are 
co-exposed with TLR agonists or bacteria for a further 24 hours before samples 
were taken. In vivo, bacteria are given 5 days after the primary IAV infection, with 
samples taken 24 hours later and onwards. A huge antiviral response occurs within 
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these first 5 days, which allows the lung to potentially clear the first viral infection 
before the second bacterial one is given. The bacteria therefore enter into an 
already inflamed lung. We could not do this in vitro, as the virus would kill most, if 
not all of the AECs within 5 days. Our system is therefore rather a co-exposure as 
the virus and bacterial stimuli are given concurrently, which may or may not occur 
in vivo. This may be one reason for why we did not confirm many of our 
hypotheses. 
 We first hypothesized that the primary viral infection would suppress the 
production of AMPs, which could contribute to the bacterial outgrowth observed in 
co-infected mouse lungs (Ellis et al. 2015). We found that surprisingly the bacterial 
stimulation alone rarely induced any of the antimicrobial peptides, which made 
subsequent inductions or suppression difficult to determine. This may be due to the 
bacteria shielding their PAMPs, which may only become visible once phagocytosed 
and digested. AECs do not phagocytose bacteria, nor do the bacteria infect the 
AECS. Therefore, presentation of PAMPS to the AECs may be more limited to 
innate immune cells such as macrophages. However, if insufficient TLR activation 
by bacteria were the case then both TLR agonists should be inducing the 
expression of these AMPs, but generally they do not. We only found AMP induction 
using a more virulent S. pneumoniae strain, but AMP induction was neither 
enhanced nor suppressed by viral co-stimulus.  
AECs upregulated secretory leukocyte protease inhibitor (Slpi) in response 
to co-stimulation (Figures 16, 17. Appendix Tables 4, 5). It has been documented 
to be produced by the epithelia of the lung (Abe et al. 1991), and its role as an 
antimicrobial peptide has been described (Fahey and Wira 2002). Interestingly, 
calgranulin A (S100a8) and calgranulin B (S100a9) are differentially expressed 
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during X31 and TLR4 co-stimulation (Figure 16D and E, Appendix Table 4). These 
AMPs form a heterodimer to form calprotectin which has been shown to have 
microbicidal activity against many bacteria (Abtin et al. 2010), by inhibiting bacterial 
adhesion to mucosal epithelium and bacterial growth through zinc chelation. 
S100a8 and S100a9 are induced at high levels within the first 24 hours after 
bacterial infection in vivo (Raquil et al. 2008). They are also known to be 
upregulated by the cytokines IL-1α, IL-6, TNF-α, some of which have been found to 
be significantly increased by viral and bacterial co-exposure of the mTECs. S100a8 
and S100a9 not only show bactericidal properties but have also been described to 
have chemotactic and proinflammatory properties. Treatment of mice with anti-
S100a8 and anti-S100a9 antibodies had no effect on bacterial load or survival, but 
did however cause a reduction in the recruitment of neutrophils and macrophages 
(Raquil et al. 2008). The three defensins Defb1, and Defb3 show an increase in 
messenger levels following certain co-stimulations. Defensins have also been 
characterised to be chemotactic for monocytes and neutrophils (Raquil et al. 2008).  
The increase in expression of these AMPs contradicts our hypothesis of 
suppression during co-exposure. This may suggest that during co-stimulation, the 
virus does not hinder their expression. It may also be possible that their increases 
are contributing to the proinflammatory and immune cell recruitment responses of 
the AECs rather than acting as conventional AMPs. However, we have assessed 
only expression levels of these few AMPs, and therefore cannot conclude whether 
the same is true for all AMPs. 
As we saw no great indication of AMP production from the AECs following 
any sequence of stimulation we decided not to pursue this any further. As we only 
measured transcriptional induction of these AMPs it may be useful to measure 
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protein levels before drawing concrete conclusions, and direct quantification of 
bactericidal properties of AEC supernatants might allow for a functional 
assessment of antibacterial activity without prior knowledge of the mechanisms 
involved. Innate immune cells also have the ability to express antimicrobial 
peptides, with neutrophils known to express S100a8 and S100a9 (Raquil et al. 
2008), and there is the possibility that immune cells are the major contributor of 
these molecules in the lung. This would be in contrast to reports in the gut of strong 
AMP production by epithelial cells. Alternatively, immune-cell derived cytokines 
such as IL-22 or other, maybe cell contact-dependent signals, may be required on 
top of bacterial stimuli to induce AMP induction in lung epithelia. Therefore, a co-
culture system may be useful to determine the effect of the innate immune cells on 
the airway epithelial production of antimicrobial peptides. As greater effects are 
seen in vivo compared to in vitro, immunofluorescence detection of antimicrobial 
peptides on lung sections may show directly whether airway epithelia produce 
these peptides.  
We next hypothesized that co-stimulation of the AECs would result in 
increased production of type I and III IFNs and subsequently ISGs. We found that 
the induction of IFNs and ISGs were mainly driven by the antiviral response and 
remained unchanged following co-stimulation. IFN production is traditionally 
associated with antiviral immunity, however the role of type I IFNs in S. 
pneumoniae infections have also been studied (Parker et al. 2011; Koppe et al. 
2012). IFNβ was been shown to be produced following S. pneumoniae infection 
(Koppe et al. 2012). The role of type I IFN during bacterial infections is 
controversial. One study which utilised mice lacking the Ifnar gene showed 
increased susceptibility to disease, where the mice succumb to S. pneumoniae 
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bacteraemia (LeMessurier et al. 2013). In contrast, other studies showed that Ifnar-
/- mice were more resistant to Listeria infection (Auerbuch et al. 2004), and type I 
IFN promoted bacterial infection and pathology (Carrero et al. 2004; O'Connell et 
al. 2004; Osborne et al. 2016). Listeria is an intracellular pathogen whereas S. 
pneumoniae is extracellular and so cannot be directly compared. Therefore, it is not 
yet known whether type I IFNs are protective or pathogenic during IAV-S. 
pneumoniae co-infections but Shahangian et al. propose that type I IFNs contribute 
to lack of bacterial control (Shahangian et al. 2009).  
IFNa4 messenger levels were not induced by either the virus or bacterial 
stimulus, but this is just one of 11 subsets of IFNα within a mouse and hence the 
right IFNα may not have been tested. Nevertheless, an induction in IFNα proteins 
as tested by ELISA was found for the virus and for the HK and live S. pneumoniae 
(D39) stimuli. This discrepancy may be due to early induction of IFNa4 which is not 
detectable anymore by mRNA levels at the time of testing. There is rarely any 
significant increase in type I or III IFNs during co-stimulation in comparison to the 
two single stimuli; their induction is rather driven by the virus alone. Given the lack 
of an increase in production of type I and III IFNs following co-stimulation, it is not 
surprising that there is also no significant increase in ISG production. ISGs are 
driven also by the antiviral response, which is further confirmed in the AEC 
transcriptional profiles.  
This dominance of the virus stimulus for IFN and ISG induction is hardly 
surprising since IFNs and ISGs are predominately an antiviral response potently 
induced by the RIG-I signalling, and less so by bacterial PRRs. It has been 
reported that the pneumolysin of S. pneumoniae interacts with TLR4, which 
activates TRIF to induce type I IFN (Malley et al. 2003; Srivastava et al. 2005; 
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Parker et al. 2011). However, one study suggests it is not the TLR4 pathway that is 
required to initiate an immune response to S. pneumoniae, but rather the NLRP3 
pathway (McNeela et al. 2010).  
Our results of no significant induction of type I IFNs following co-stimulation 
disagrees with our hypothesis and the findings from Nakamara and associates, 
who showed a synergistic increase in type I IFNs following co-infection (Nakamura 
et al. 2011). The Nakamara et al. study however reverses the order of infection by 
giving S. pneumoniae before the virus, PR8 - the more virulent strain of influenza. 
This completely changes the response to the two infections and as such cannot be 
directly compared to our study. Nonetheless, the lack of significant amplification of 
IFNs and ISGs may be due to the different timings discussed earlier. Peak IFN 
levels are usually seen 4 hours following infection whereas we measured the IFNs 
and ISGs 48 hours after the initial viral infection and 24 hours after the secondary 
stimulus. The levels of IFN may therefore be decreased and the ISGs may have 
already reached plateau. Furthermore, the lack of innate immune cells such as 
pDCs, which are potent IFN producers, may also explain the lack of increased 
production during co-stimulation. Koppe et al. suggested that it is not the lung 
epithelial cells themselves which produce type I IFNs after S. pneumoniae infection 
but are activated to induce ISGs by type I IFN produced by macrophages in a 
paracrine manner (Koppe et al. 2012). The contribution of innate immune cells to 
the production of type I IFN may also explain the synergistic increases observed in 
the Nakamara et al. study. Future studies could employ a co-culture system and 
test earlier for IFN and ISG production. Overall, these results suggest that it is not 
the AEC response alone that is driving increased IFN production within co-infection. 
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Primary viral infection causes damage within the lung, which can be 
mediated by the cytotoxic effects of the virus or by the antiviral response. We 
therefore hypothesised that the induction of apoptosis related genes would be 
increased following co-stimulation in relation to the two single stimuli. Type I IFN 
has been described to cause damage to the lung via DR5-TRAIL interaction 
following IAV infection (Herold et al. 2008; Davidson et al. 2014) and it is via this 
signalling pathway that the outgrowth of the secondary bacteria is facilitated (Ellis 
et al. 2015). The airway epithelia do upregulate both type I and type III IFNs 
following IAV, however there was no corresponding induction of DR5 on the 
epithelia. Neither bacterial stimulation nor co-stimulation induced DR5. FAS, 
another apoptotic receptor on the epithelia was also not induced by any stimulation 
(Waring and Müllbacher 1999). The lack of DR5 or FAS upregulation may be due 
to type I IFN indirectly causing DR5 expression through the induction of cytokines 
that are not present within mTEC cultures. Again this could be explained by a 
contributing factor missing from the cultures. Innate immune cells may be providing 
this contributing factor, which may be soluble or provided via cell-cell contact, and a 
co-culture system may be able to address this question.  
On the other hand there is a significant increase in their corresponding 
ligands: TRAIL and FASL. TRAIL can be expressed by a variety of cell types such 
as B cells, DCs, gut epithelia, and macrophages (Wiley et al. 1995). FASL is a 
transmembrane protein which can be cleaved to be a soluble ligand (Hohlbaum et 
al. 2000). This suggests that when death receptors are induced, AECs may 
contribute to the increased induction of apoptosis and lung damage. However the 
increased epithelial cell death is not orchestrated by the AECs alone. Since we saw 
no induction of death receptors we did not test further for the induction of apoptosis. 
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Future experiments could however test for apoptosis induction and integrity of the 
epithelium by quantifying bacterial migration through the epithelium, or tracking the 
transepithelial electric resistance (TEER) levels throughout the experiment. Another 
way to quantify damage of the epithelia is by measuring the levels of caspase since 
this an important mechanism of cell death. 
The massive increase in innate immune cell recruitment along with 
proinflammatory cytokine production within co-infected mouse lungs lead us to next 
hypothesise that this is orchestrated by the AECs. Neutrophils and other 
phagocytic cells in co-infection are essential for the control and elimination of 
bacteria. The airway epithelia do very clearly induce significantly increased 
amounts of CXCL1 and CXCL2 in response to a co-exposure versus during single 
exposure, which could correlate with the increased neutrophil numbers found in 
vivo (Ellis et al. 2015). These findings also disagree with studies that found the 
CXCL1 and CXCL2 were blocked in co-infection by type I IFNs (Shahangian et al. 
2009; Schliehe et al. 2014), as IFN is clearly present in these cultures. It could be 
that IFN-mediated CXCL1 and CXCL2 suppression is more prevalent in immune 
cells whose chemokines may contribute strongly to the overall neutrophil 
recruitment into the lung. Schliehe et al. showed that Setdb2, a type I interferon-
stimulated protein, repressed CXCL1 expression which in turn had a negative 
effect on early neutrophil recruitment, tissue damage and bacterial burden during 
IAV-S. pneumoniae co-infection (Schliehe et al. 2014). This study therefore 
highlights the protective role of early CXCL1 signalling and neutrophil recruitment. 
TNF-α which is essential in during IAV - S. pneumonia co-infection for bacterial 
control and clearance was also found to be significantly induced by the AECs thus 
contributing to the beneficial innate immune response (Ellis et al. 2015). However, 
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high concentrations for prolonged periods of these cytokines and chemokines may 
have the potential to be pathogenic. TNF-α and activated neutrophils can induce 
apoptosis of epithelial cells, which may contribute to lung injury and disease 
outcome (Abraham 2003; Chau et al. 2004; Moraes et al. 2006).  
Many other cytokines and chemokines do appear to be more highly 
expressed in co-exposure such as CCL5, GMCSF, GCSF, IL-1β and IL-1α that 
function to recruit and activate phagocytic cells to eradicate the pathogens and 
potentially contribute to pathogenesis. IL-6 was not significantly induced when HK 
S. pneumoniae was used as the secondary stimulus, and interestingly there 
appears to be a suppression of this cytokine when the live bacteria is used during 
co-stimulation. This could be due to a late peak in mRNA that has not been 
translated at the time of measuring. On the other hand, a protease, SpyCEP, 
released by Streptococcus pyogenes has been described to inhibit chemokines 
(Zingaretti et al. 2010). S. pneumoniae could therefore potentially be releasing 
similar proteases which are cleaving cytokines and chemokines, although this 
remains to be proven. Nonetheless, IL-6 was significantly increased in co-exposure 
with TLR agonists compared to the two single exposures. IL-6 has both pro- and 
anti-inflammatory roles, with one study reporting its role in neutrophil survival 
during influenza infection (Dienz et al. 2012). Therefore, this increased response to 
co-stimulation could be acting in tandem with CXCL1 and CXCL2 to recruit and 
promote the survival of neutrophils, which, as discussed, may or may not be 
protective. One study demonstrated that the control of inflammation was essential 
for the protection of mice during co-infection (Damjanovic et al. 2013). This 
however was only effective if the bacterial infection was controlled by antibiotic 
treatment. This highlights the requirement of the induction of these proinflammatory 
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cytokines and chemokines for the control of the bacteria, however an unchecked 
inflammatory response along with an outgrowth of bacteria can severely damage 
the lung.  
Overall, the AECs can contribute to the induction of proinflammatory 
cytokines and chemokines which induce the recruitment of the innate immune cells. 
It is unlikely that it is the AEC response alone that is responsible for the 
documented massive increase of immune cells and proinflammatory cytokines in 
co-infection. We find however that the increased epithelial response in vitro to co-
stimulation closely reflects the stronger in vivo response to co-infection. In 
particular, data within the lab found that after IAV-S. pneumoniae co-infection in 
vivo, showed similar increases in these proinflammatory cytokines and chemokines. 
The different timings of co-exposure in vivo and in vitro, as discussed earlier, 
however render direct comparison between in vivo and in vitro results difficult. 
Since it was thought that D39 might be a poor stimulator of the epithelium, 
the more virulent strain TIGR4 was also used. TIGR4 stimulation induced AMPs far 
greater than TLR agonists or D39. However, comparisons between single stimuli 
and co-exposure did not show the same significant synergies as when D39 was 
used. TIGR4 is a capsulated virulent serotype 4 strain, whereas D39 is a 
capsulated clinical serotype 2 strain of S. pneumoniae (Lanie et al. 2006). Whether 
these strains keep or lose their capsule during growth and within the mTEC culture 
is not known. Variability in the expression and accessibility of surface proteins 
resulting from either keeping or losing their capsule may explain the differences in 
the AEC responses (Bogaert et al. 2005). Major genetic differences have been 
found between the two strains such as a single sortase gene in D39 compared to 
four in TIGR4 (Tettelin et al. 2001; Lanie et al. 2006). Such genetic differences may 
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also explain the divergence in disease outcomes in vivo and why the same 
synergistic effects are not observed when the same genes were analysed. 
The antiviral response dominates the overall innate immune response of the 
airway epithelia to infection. However, it has been possible to identify significant 
synergies in the AEC response to co-stimulation. AECs do appear to contribute to 
the proinflammatory cytokine and chemokine responses seen in vivo. These 
chemokines are involved in recruiting neutrophils whose antibacterial function is 
crucial in co-infection (Ellis et al. 2015). Co-exposure of co-cultures may however 
offer a more realistic scenario, or migration assays could be set up to test if 
increased chemoattractant production by co-exposed epithelia translates into 
stronger immune cell recruitment.  
In conclusion, the epithelial barrier is crucial to protect the host from the 
outside environment and many different invading pathogens. The airway epithelia 
do respond to both viral and bacterial stimulation, and the increased levels of some 
apoptosis related peptides, cytokines and chemokines observed following co-
stimulation agrees with previous findings. We find evidence for increased 
proinflammatory activity of co-exposed epithelia, and while these effects are less 
strong than those observed in vivo, epithelia might be important to initiate a 
stronger inflammatory response in co-infection which is subsequently amplified by 
positive feed back loops such as more chemokine production by the recruited 
innate immune cells. Therefore, airway epithelia may not be the main driving force 
but the initiator of the documented massive increase in inflammation, lung damage 
and immune cell recruitment during co-infection that is associated with morbidly 
and mortality.  
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Chapter 4. Airway epithelia from IAV susceptible 
129S8 mice differ from C57BL/6 epithelia in 
responses, cell composition and regeneration  
4.1 Background 
Differences between hosts in influenza severity or protection can be attributed to 
varying adaptive immune response depending on the history of previous exposures, 
to the virus strain’s virulence, or to defined medical preconditions that represent 
risk factors for severe influenza. However, apart from these differences, there may 
also be a role in the host-dependent variations in anti-influenza innate immune 
responses. Growing evidence indicates that lung damage and epithelial cell death 
in influenza depends on immune-mediated effects. Fatal disease may therefore be 
a result of pathology associated with an excessive immune response (Tisoncik et 
al. 2012), and the degree of the immune response may be at least partly 
determined by host genetics.  
Recently, host genetics have gained momentum as playing a major role in 
the outcome of disease (Horby et al. 2012). In humans, a correlation has been 
made between MHC haplotypes and the outcome of infectious disease (Blackwell 
et al. 2009; Ruiz-Hernandez et al. 2016). Specifically in influenza, a study by 
Albright and associates found that in a specific population from Utah, USA, there 
was an inheritable predisposition to influenza mortality. Examining the genealogy of 
this population indicated that a close or distant relation of an individual who had 
succumbed to influenza infection in the past, was more likely to succumb 
themselves (Albright et al. 2008). The familial clustering of the HPAI H5N1 and H7 
N9 has furthermore increased the awareness of genetic susceptibility to infection 
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(Ungchusak et al. 2005; Kandun et al. 2006; Sedyaningsih et al. 2007).  Fortunately, 
the virus as of yet has not displayed efficient human-to-human transmission (Xiao 
et al. 2014). 90% of the reported human-to-human transmission cases that have 
occurred are between genetically related family groups (Hu et al. 2014).  
Genetic predisposition to disease has also been confirmed in animal studies. 
Similarly to humans, chickens displayed a strong association with the MHC 
haplotype and resistance or susceptibility to pathogens (Banat et al. 2013). 
Hernandez and associates showed two genetically different in-bred lines of 
chickens, which diverged in the outcome of infection, with one resistant and the 
other susceptible. Their resistance to infection was independent of the adaptive 
immune response, however the innate immune response was not studied (Ruiz-
Hernandez et al. 2016).  
Susceptibility to IAV also varies between inbred mouse strains. An important 
influenza restriction factor that varies between mouse strains is Mx1. Susceptible 
mice have a nonsense point mutation or deletions in the Mx1 genes resulting in 
non-functional Mx1 protein (Staeheli et al. 1988). Mx1 is a potent ISG capable of 
inhibiting IAV replication (Lindenmann 1962; Haller et al. 1979; Staeheli et al. 1988). 
Further mouse studies have confirmed that host genetic background determines 
susceptibility to IAV-induced disease with susceptibility correlating with high viral 
loads, excessive inflammation and severe lung damage (Boon et al. 2009; 
Srivastava et al. 2009; Blazejewska et al. 2011; Trammell et al. 2012). Our lab 
utilized a resistant mouse strain – C57BL/6, and a susceptible mouse strain - 
129SvEv, and showed that differences in the innate immune response to IAV 
played a direct role in the outcome of disease. High type I IFN levels correlated 
with disease severity where the viral loads remained unchanged. Susceptible 
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129SvEV mice that lacked the IFNαβ receptor displayed reduced morbidity and 
mortality, confirming the contribution of excess IFNαβ to disease. High levels of 
IFNαβ also correlated with high levels of DR5 on epithelia and TRAIL on 
inflammatory monocytes, whose interaction resulted in lung epithelial damage 
(Herold et al. 2008; Davidson et al. 2014). This pathogenic potential of type I IFNs 
is in stark contrast to the potent antiviral abilities associated with this family of 
cytokines (Isaacs and Lindenmann 1957; Garcia-Sastre et al. 1998; Koerner et al. 
2007). Type I IFNs however are known to induce many other cytokines, which 
contribute to the hypercytokinemia or ‘cytokine storm’ that has been well 
documented from past pandemic IAV strains (de Jong et al. 2006; Peiris et al. 
2009; Mauad et al. 2010). 
 Since IAV preferentially replicates within the airway epithelium of the lung, 
and some of the first cytokines to be released by the epithelia post IAV infection are 
the type I IFNs (Crotta et al. 2013), the host genetic background could determine at 
the level of the epithelia how the host response initiates and thus the outcome of 
disease. 
 The lung is a complex organ consisting of an upper respiratory tract – nasal 
cavity and trachea, and a lower respiratory tract – bronchioles and lungs. Since we 
breathe in a plethora of microbes every day, the immune system of the lung is vital 
in protecting the host from disease. The airway epithelium plays an essential role in 
this defence. Not only must the airway epithelium respond to an infection by 
recruiting and activating the innate and adaptive immunity, it must also repair itself 
from such exogenous and endogenous insults and injury.  
The lung is a highly quiescent organ which was traditionally associated with 
a low cell turnover. However, upon injury, lung epithelia can proliferate rapidly to 
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repair damage and return to homeostasis (Blenkinsopp 1967; Rawlins and Hogan 
2006). The tracheal epithelium consists of three major cell types: basal, secretory, 
and ciliated cells. The basal cells are progenitor cells for the airway epithelium, 
capable of self renewing and differentiating into both secretory and ciliated cells 
(Rock et al. 2009; Whitsett and Alenghat 2015). Basal cell proliferation is important 
following damage to the lung, such as that initiated by IAV infection, to repair the 
lung and return back to its pre-infection state, allowing the host to recover. 
Secretory cells such as club cells produce mucus and other proteins able to trap 
and potentially kill pathogens. Ciliated cells constantly move in a co-ordinated 
fashion to expel any invading pathogens from the lung. Studies have also shown 
the potential of the secretory club cells to self renew, differentiate into ciliated cells 
and dedifferentiate back to basal cells (Donnelly et al. 1982; Breuer et al. 1990; 
Watson et al. 2015).  
In some cases, proper repair and regeneration following damage does not 
occur but rather a remodelling of the lung takes place, resulting in in fibrosis that is 
associated with a spectrum of chronic lung diseases such as: Interstitial 
pneumonitis (IPF), ciliopathies, cystic fibrosis (CF) or chronic obstructive pulmonary 
disease (COPD) (Chilosi et al. 2002; Randell 2006). In ciliopathies, a defect in the 
ability of the cilia to move or even a lack of cilia can occur (Waters and Beales 
2011). COPD and cystic fibrosis often associate with increased mucus production 
due to goblet cell metaplasia (Rock et al. 2010). Such chronic lung diseases have 
also been associated with a hereditary component (Marciniak and Lomas 2010) 
pointing to a possible genetic link to remodelled airway epithelia. Any deviation of 
the repair process from rapidly reaching the pre-injury homeostasis of the lung will 
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greatly impact the host’s ability to recover fully from an infection, resulting in 
increased morbidity and mortality or in long-term alterations of the lung. 
Given that genetic differences determine the host’s ability to detect, respond 
to, and eliminate infections, all of which correlates with the outcome of disease, it 
remains to be elucidated whether such genetic differences determine responses to 
infection at the level of the airway epithelium.  
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4.2 Hypothesis and Aims 
The airway epithelium is the first host target of IAV infection. It can respond to this 
infection by orchestrating the innate and adaptive immune response to clear the 
virus, and it must repair any infection-related damage. Differences in the host 
genetic background have been associated with disease outcome and could be 
playing a role in epithelial responses and repair. To test the contribution of genetic 
differences in airway epithelia to the outcome of disease caused by IAV, epithelia 
from different in-bred mouse strains were utilised to quantify the response to 
infection and the regenerative capabilities. Primary mouse tracheal epithelia from 
resistant low IFN and susceptible high IFN responders were used for this. 
 
I hypothesize that: 
• The high and low IFN response found in vivo will be recapitulated by the 
corresponding mouse airway epithelia, resulting in higher IFN production 
from the 129S8 AECs compared to C57BL/6 AECs 
• The 129S8 epithelia, due to inducing more IFNs, will consequently express 
higher levels of ISGs 
• 129S8 epithelia may have increased cytokine and chemokine production 
contributing to the cytokine storm found in vivo in 129 mice 
• Alternatively or additionally, the epithelium of the susceptible 129S8 mouse 
strain may be less capable of repairing 
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4.3 Results 
4.3.1 129S8 mice are not high IFN responders in vitro 
129SvEv and other sub strains of 129 mice, such as 129S8, were found to be more 
susceptible to influenza disease, which correlated with high type I IFN levels in the 
lung. Upon infection, airway epithelia release type I IFNs, thus 129S8 epithelia 
could be producing more IFN than their resistant counterpart epithelia from 
C57BL/6. However, following infection of the two genotypes of epithelia this 
phenomenon was not discovered, but rather the opposite (Figure 20). IFNa4 
messenger levels were not induced 6, 24 or 48 hours post infection by epithelia of 
either genotype (Figure 20A). This is only one of 11 subsets of IFNα in mice and 
thus the right IFNα may not be tested here. There is an induction in protein levels 
however by C57BL/6 epithelia at both 24 and 48 h.p.i. This is not recapitulated in 
the 129S8 epithelia which do not appear to be producing IFNα in response to 
infection, resulting in a significant difference between the two genotypes at both 
time points (Figure 20B). IFNb1, another type I IFN, was also quantified. For this 
IFN, a significant induction by C57BL/6 epithelia at 24 h.p.i can be observed, but at 
no other time-points. 129S8 epithelia again display no mRNA induction of type I 
IFNs (Figure 20A). IFNβ protein production by C57BL/6 epithelia is only detectable 
at 48 h.p.i, whereas again it is not produced by the 129 epithelium (Figure 20B). As 
the epithelium of the 129S8 mice do not seem to be producing any type I IFNs, the 
type III IFNs were tested, which are known to be expressed by the epithelia and 
play a redundant role with type I IFNs in epithelial cells (Crotta et al. 2013). Both 
C57BL/6 and 129S8 epithelia do induce messenger of IL-28A, albeit a significantly 
more robust induction by C57BL/6 than by 129S8 epithelia (Figure 20A). IFNλ 
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protein levels are more strongly induced by C57BL/6 epithelia at both 24 and 48 
h.p.i, however only minimal amounts are detectable by 129S8 at 48 h.p.i.  
 Overall, this indicates that the in vivo phenotype is not recapitulated in 
airway epithelia in vitro. C57BL/6 generally induce significantly more IFNα, IFNβ 
and IFNλ than the 129S8 epithelium. The low production of IFNs from the 129S8 
AECs could be due to the lack of innate immune cells within the culture, such as 
pDCs which are known to be potent type I IFN producers and show differential IFN 
production between the mouse strains in question (Asselin-Paturel et al. 2003; 
Davidson et al. 2014). IFNλ induction is far greater than any type I IFN induction, 
which could indicate a greater role for IFNλ within the epithelium against influenza 
infection. 
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Figure 20 C57BL/6 epithelia are greater type I and III IFN producers compared to 
129S8 epithelia 
C57BL/6 and 129S8 epithelia were infected with X31 at a MOI of 0.1 for 6, 24 and 
48 hours. cDNA from the cultures were analysed for IFNa4, IFNb1 and IL-28A (A). 
Supernatants were collected after 24 and 48 hours and quantified for IFNα, IFNβ 
and IFNλ (B). Significance was assessed by unpaired t-test where * represents X31 
infected:corresponding media ctrl, and o represents C57BL/6:129S8. * P<0.05, ** P 
<0.01, *** P< 0.001 and **** P< 0.0001 Graphs show mean ± SEM. Data pooled 
from two independent experiments, n=6-11.  
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4.3.2 129S8 epithelium are more responsive to infection than C57BL/6 
epithelium 
Although the 129S8 epithelium only induced small amounts of IFNs, the induction 
of ISGs was tested nonetheless. Davidson and colleagues found that susceptibility 
follows the stromal IFNAR1 genotype, with chimeric mice more susceptible to 
influenza virus only if the stromal cells express the IFNαβ receptor (Davidson et al. 
2014). Therefore, it may not be the amount of IFNs released but rather the 
responsiveness of the epithelia to immune-cell produced IFNs, which may be 
different between 129 and B6 epithelia and could determine susceptibility. Upon 
stimulating both C57BL/6 and 129S8 epithelia with equivalent doses of type I 
(IFNβ) and type III (IFNλ), as determined by titration (shown in Chapter 6, Figure 
38), there is a significant induction in the epithelia of both genotypes in messenger 
levels of Rsad2, Oasl2 and Ifi203 (Figure 21A). Intriguingly, for Rsad2 and Oasl2, 
129S8 epithelia have a significantly higher expression than C57BL/6. Although 
there is a higher expression of Ifi203 by 129S8 epithelia upon stimulation with IFNβ, 
this is not significant.  
 To verify if this occurs following a proper viral infection, C57BL/6 and 129S8 
epithelia were infected with X31 and levels of matrix, a viral protein used to 
measure viral replication, and ISG levels were analysed after 6, 24 and 48 hours 
(Figure 21B). For C57BL/6 epithelia, there appears to be a proliferation of the virus 
between 6 and 24 hours, which declines at 48 hours, whereas the viral matrix 
expression slowly declines from 6 hours onwards within the 129S8 epithelia. An 
induction of all three ISGs in both genotypes can be observed following IAV 
infection. Furthermore, 129S8 epithelia are generally expressing significantly more 
of the three ISGs, specifically at 48 h.p.i. This higher expression in ISGs by 129S8 
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epithelia could explain the discrepancy in matrix levels, since higher ISG levels 
induced early, as seen with Rsad2 at 6h.p.i, could be indicative of a stronger or 
more rapid antiviral response that reduces virus and therefore the matrix levels. 
However, this is just a small subset of the hundreds of ISGs induced by IAV 
infection and thus these along with viral titres would need to be quantified before 
concrete conclusions can be drawn. These results nonetheless indicate that 129S8 
epithelia, although not higher IFN producers, are in fact higher IFN responders in 
the production of ISGs. 
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Figure 21 129S8 AECs respond more strongly to stimuli by expression of ISGs 
than C57BL/6 AECs 
C57BL/6 and 129S8 epithelia were treated with media control or IFNβ (30 U/ml), or 
with IFNλ (30 ng/ml) for 4 hours. cDNA from the cultures were analysed for Rsad2, 
Oasl2 and ifi203 (A). C57BL/6 and 129S8 epithelia were infected with X31 at a MOI 
of 0.1, or media control for 6, 24 and 48 hours. cDNA from the cultures were 
analysed for Matrix, Rsad2, Oasl2 and ifi203 (B). Significance was assessed by 
unpaired t-test where * represents induction:corresponding media ctrl, and o 
represents C57BL/6:129S8. * P<0.05, ** P <0.01, *** P< 0.001 and **** P< 0.0001 
Graphs show mean ± SEM. Data pooled from three independent experiments, n=3-
11. 
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 Hypercytokinemia and hyperchemokinemia have been well established in 
severe influenza infections and are associated with increased mortality (de Jong et 
al. 2006). Therefore, 129S8 epithelia were tested for increased responsiveness to 
IAV infection by expression of cytokines and chemokines, compared to C57BL/6 
epithelia (Figure 22). 129S8 epithelia showed increased levels of CXCL1 
expression throughout infection, whereas C57BL/6 epithelia appear to induce 
CXCL1 only at 24 h.p.i. The higher expression of CXCL1 by 129S8 at 48 h.p.i. is 
statistically significant. TNF-α seems to be induced at similar levels by both 
genotypes at 24 h.p.i, however at 48 h.p.i. the 129S8 epithelia are inducing 
significantly more than C57BL/6 epithelia. For IL-6, 129S8 epithelia have a 
statistically significant increased expression at 6h.p.i compared to C57BL/6 
epithelia, however the levels are similar at 24 and 48 h.p.i. The expression of 
CXCL2 remains similar between the genotypes at 6 and 24 h.p.i, whereas at 48 
h.p.i. there is a greater expression in 129S8 epithelium. This indicates that 129S8 
have a higher expression of chemokines and cytokines following IAV infection, 
compared to C57BL/6 mice. However, these are a small set of cytokines and 
chemokines. Furthermore, protein levels may give a better indication of whether the 
cells are actually producing these cytokines, hence a cytokine multiplex would give 
a better overview of whether 129S8 epithelia are more responsive to infection in 
terms of cytokines and chemokines. 
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Figure 22 129S8 AECs have a higher expression of some cytokines after IAV 
infection, compared to C57BL/6 AECs 
C57BL/6 and 129S8 epithelia were infected with media control or X31 at a MOI of 
0.1, for 6, 24 and 48 hours. cDNA from the cultures were analysed for CXCL1. 
TNF-α, IL-6 and CXCL2. Significance was assessed by unpaired t-test where * 
represents X31 infected:corresponding media ctrl, and o represents 
C57BL/6:129S8. * P<0.05, ** P <0.01, *** P< 0.001. Graphs show mean ± SEM. 
Data representative of two independent experiments, n=3. 
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4.3.3 129S8 epithelia have higher resting levels of death receptors 
In the lungs of 129 mice high type I IFN production in vivo also correlated with 
increased DR5 expression on the epithelia, and its corresponding ligand TRAIL on 
inflammatory monocytes, thus increasing lung tissue damage in comparison to the 
resistant C57BL/6. This increase in lung tissue damage also associated with 
increased morbidity and mortality. To investigate if this increase in DR5 expression 
on 129 epithelia also recapitulated in vitro, DR5 expression was assessed on 
C57BL/6 and 129S8 epithelium after IAV infection (Figure 23). There was no 
significant DR5 induction in epithelia of either genotype after influenza infection. 
There is an increase however by C57BL/6 epithelia at 24 h.p.i, which correlates 
with the peak in matrix levels (Figure 21B). Interestingly, there is a significant 
increase in resting levels expression of DR5 on 129S8 epithelium. The opposite is 
true for the ligand TRAIL, where 129S8 have lower resting levels compared to 
C57BL/6. Both genotypes induce TRAIL expression following IAV infection, except 
for 129S8 epithelia at 24 h.p.i, where there appears to be a decrease in expression.  
 There is also an increase in resting state levels of FAS, another apoptosis 
inducing receptor, in 129S8 epithelia. Following infection, both genotypes generally 
have unchanged levels of FAS, except for a downregulation at 24 h.p.i in 129S8 
epithelia, and 48 h.p.i. in C57BL/6 epithelia. FASL, the ligand for FAS, is induced 
by C57BL/6 at 6 h.p.i. only, whereas FASL expression is reduced at 6 h.p.i and 
unchanged at the other two time points for 129S8. The trend for TRAIL is also seen 
for FASL, with the resting expression levels lower in 129S8 epithelia compared to 
C57BL/6.  
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Figure 23 129S8 epithelia express higher apoptosis related receptors at resting 
state 
C57BL/6 and 129S8 epithelia were infected with X31 at a MOI of 0.1, or media 
control for 6, 24 and 48 hours. cDNA from the cultures were analysed for DR5, 
TRAIL, FAS and FASL. Significance was assessed by unpaired t-test where * 
represents X31 infected:corresponding media ctrl, and + represents C57BL/6 media 
ctrl:129S8 media ctrl. * P<0.05, ** P <0.01. Graphs show mean ± SEM. Data 
representative of two independent experiments, n=3. 
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 Since DR5 expression was not induced in either genotype, while in vivo 
DR5 expression increased in an IFNαβ-dependent manner (Davidson et al. 2014), 
it was considered that MTEC cultures may not respond to influenza in the same 
manner as epithelia in lower airway tracts or in alveoli do, since they are obtained 
from the trachea of mice. As primary cultures of lower airway epithelia cells are 
difficult to grow and maintain, we used the human lung carcinoma epithelia-like cell 
line, A549. This cell line represents alveolar epithelia, which can become infected 
in severe influenza infections. Upon infection, the human apoptosis-inducing TRAIL 
receptors DR5 and DR4 (TRAIL-R2 and TRAIL-R1, respectively), along with TRAIL, 
are significantly induced after 24 and 48 hours (Figure 24). FAS is also significantly 
induced, whereas its ligand FASL is only significantly increased 24 h.p.i, with a 
reduction in levels 48 h.p.i. This corroborates the DR5 induction on epithelia by IAV 
infection, in which DR5 binding to TRAIL can result in apoptosis resulting in 
increased damage to the lung.  
Although this induction of DR5 is not seen within the 129S8 epithelium, the 
higher resting levels of apoptosis receptors suggest an apoptosis prone state of the 
129S8 epithelium, and lack of induction following IAV infection may be due to lack 
of sufficiently high levels of IFN present in the cultures. However, the lack of DR5 
up regulation by C57BL/6 which have previously been shown to induce high 
amounts of type I IFN (Figure 20) points to another contributing factor that is 
missing within the cultures. Future co-culture experiments could address this 
problem or supplementing the culture with the broncoalveolar lavage (BAL) fluid 
from infected 129S8 mice. 
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Figure 24 IAV infection induces the expression of death receptors and ligands on 
a human epithelial cell line 
A549 cells were infected with X31 or media control and assessed for expression of 
TRAIL receptors 2 and 1 (DR5 and DR4, respectively), TRAIL, FAS and FASL by 
qPCR at specified time points. Graphs show mean ± SEM. Significance was 
assessed by unpaired t-test where * P<0.05, ** P <0.01, *** P<0.001, **** 
P<0.0001. Data pooled from two independent experiments, n=3-8. 
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4.3.4 129S8 epithelia are morphologically different to C57BL/6 epithelia, with 
reduced potential for repair 
Interestingly, 129S8 MTEC cultures often fail to grow. Since the setting up of these 
mTEC cultures can be seen as a model of epithelial damage, in which to reach 
confluence again the epithelia must ‘repair’ by proliferating and re-creating tight 
junctions, we hypothesised that 129S8 epithelia may not repair as efficiently as 
C57BL/6. This could be due to a reduced frequency or proliferative capacity of 
basal cells. In addition, differentiation of basal cells may be altered, leading to 
epithelium remodelling as seen with ciliopathies and with goblet cell metaplasia that 
are associated with COPD and other chronic inflammatory lung conditions. 
To establish if the epithelia of 129S8 and C57BL/6 are morphologically 
similar, a flow cytometry protocol of cell surface markers to stain basal, ciliated and 
secretory cells was designed. Since most cell markers for basal cells: p63 and 
KRT5 (Rock et al. 2009), ciliated: FoxJ1 (You et al. 2003), Ccno (Wallmeier et al. 
2014), Mcidas (Boon et al. 2014) and goblet cells: Scgb1a1 (Zheng et al. 2014) are 
intracellular or secreted, their quantification by flow cytometry is difficult. A set of 
cell surface markers were used to quantify the different cell subsets: nerve growth 
factor receptor (NGFR) (Rock et al. 2009), integrin alpha 6 (CD49f) (Guo et al. 
2012; Höfner et al. 2015), ceacam1a (CD66a) (Nikolai Belyaev, GSK, personal 
communication), prominin-1 (CD133) (Nikolai Belyaev, GSK, personal 
communication). NGFR, CD49f double positive, CD133 and CD66a negative were 
classified as basal cells (Figure 25A-gate 1). NGFR and CD49f negative, CD133 
positive were classified as ciliated cells (Figure 25A-gate 2), with CD66a positive as 
goblet cells (Figure 25A-gate 3). NGFR, CD49f, CD133 and CD66a negative cells 
were classified as undifferentiated cells (Figure 25A-gate 4). An unexpected 
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population of NGFR negative, CD49f positive, CD133 and CD66a double-negative 
existed, which could be classified as a type of progenitor cell, which has not yet 
differentiated into a basal cell, however this has not been confirmed by PCR 
(Figure 25A-gate 6). Mixed populations where cells may be in transition between 
differentiation states also exist (Figure 25A-5). The total percentage of the different 
subsets is also displayed (Figure 25B). To confirm this classification of the different 
cell subsets is indeed correct, these different subsets were sorted and analysed for 
the different cell lineage markers known to be associated to them. The subset of 
cells classified as basal cells do express levels of the Krt5 protein and Trp63, a 
transcription factor associated with basal cells (Rock et al. 2009), more highly than 
any other population (Figure 25C). This confirms that the gating strategy based on 
NGFR and CD49f identifies a population highly enriched for basal cells. The 
population classified as ciliated cells did express more Ccno, Mcidas and Ccdc67 
than any other cell type. However, FoxJ1 was also seen in the putative goblet cell 
fraction (Figure 25D). Next, the putative goblet cells were analysed for the goblet 
cell markers: Scgb1a1, Muc5b and Muc5ac. These were mostly expressed in the 
putative ciliated fraction (Figure 25E). This indicates that CD133 and CD66a are 
not able to distinguish between ciliated and goblet cells and are expressed by both 
populations, thus identifying a mixed population. Subsections 2 and 3 were 
combined and classified as differentiated cells, comprising both ciliated and 
secretory cells. It is reassuring that the undifferentiated subset expressed little no to 
none of the basal, ciliated or goblet cell markers, thus confirming these are in fact 
an undifferentiated subset of cells, and not basal cells. 
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Figure 25 Determining epithelial cell sub populations 
Gating strategy by flow cytometry for basal cells (1), ciliated cells (2), goblet cells 
(3), undifferentiated (4), mixed cells (5) and CD49fhi population (6) in C57BL/6 
AECs (A). Percentage subset of live cells (B). Flow cytometry sorting of these 
different cell populations allowed for cDNA generation of each cell subset, which 
was quantified for basal cell markers: Krt5 and Trp63 (C), ciliated cell markers: 
FoxJ1, Ccno, Mcidas and Ccdc67 (D), and goblet cell markers: Scgb1a1, Muc5b 
and Muc5ac (E). Data representative of five independent experiments (A, B), n=5 
(B). Data pooled from two independent experiments. Basal cells n=2-3, ciliated 
cells n=2-3, goblet cells n=1, undifferentiated cells n=3. CCNO n=1 for all subsets.  
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 Using this validated flow cytometric analysis panel to analyse the different 
subsets of epithelial cell populations, 129S8 epithelia display drastically different 
amounts of the different cell subsets. When compared to C57BL/6 AECs, 129S8 
AECs displayed a significantly higher percentage of undifferentiated cells and the 
unusual CD49fhi population (Figure 26A). They also had significantly lower basal 
cell and differentiated cell subsets, confirming the earlier hypothesis of a reduction 
of basal cells in 129 cultures. Since this flow cytometry antibody panel cannot 
distinguish which differentiated cell 129S8 epithelia are lacking, β-tubulin IV 
staining was performed directly on the mTEC cultures of both genotypes. Tubulin is 
the major constituent of microtubules and thus this antibody allows us to quantify 
ciliated cells. Intriguingly, 129S8 epithelia show significantly lower β-tubulin IV 
staining (Figure 26B, C). C57BL/6 AECs have many multiciliated cells whereas 
129S8 epithelia have far fewer multiciliated cells and instead show a tendency for a 
single cilium per cell if at all (Figure 26B). This confirms that 129S8 have a 
phenotypically different epithelium to C57BL/6 when grown in vitro. If one argues 
that mTEC cultures model repair post injury (i.e. growth to confluence after 
digestion), these results could be interpreted as 129 epithelia reform differently to 
C57BL/6 epithelia in response to damage and as such display characteristics 
reminiscent of a diseased remodelled epithelium as seen in patients with 
ciliopathies. Mucins and goblet cell staining or PCR assays for mucin genes are 
needed to determine if there is also a lack of goblet cells within the 129S8 
epithelium, or goblet metaplasia, as has been identified in some lung diseases. 
However, the whole trachea from each of these mice was removed and stained for 
β-tubulin IV and club cell secretory protein (CCSP). Here we do not find differences 
between the different hosts in the amount of ciliated or goblet cells. This therefore 
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illustrates that the effect we see in vitro may be brought about through the 
regeneration process.  
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Figure 26 129S8 and C57BL/6 AECs are phenotypically different, with 129S8 
AECs displaying a lack of cilia 
Quantification of undifferentiated cells, mixed cells, basal cells, differentiated cells 
and CD49fhi cells by flow cytometry in C57BL/6 and 129S8 AECs (A). 
Immunofluorescence of C57BL/6 and 129S8 AECs for β-tubulin IV and DAPI (B). 
Quantification of percentage area of β-tubulin staining of C57BL/6 and 129S8 
AECs (C). Whole tracheas from C57BL/6 and 129S8 mice were stained for β-
tubulin IV, DAPI and CCSP (D). Significance was assessed by unpaired t-test 
where * P<0.05, ** P <0.01, *** P<0.001, **** P<0.0001. Data pooled from five 
independent experiments, n=4-17.  
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 We hypothesised that 129S8 epithelium may have a repair defect which 
may explain the increased morbidity and mortality after IAV infection. To determine 
if this was true, fully-grown cultures were scratched and the transepithelial electrical 
resistance (TEER) was recorded to determine the time at which the cultures reach 
confluence again (R>1000 mΩ/cm2). Scratching the cultures induces damage 
which they need to repair to re-establish confluence. The cultures were also re-
scratched until they could no longer repair the scratch (Figure 27A). Upon the first 
scratch there was no significant difference between the two genotypes in the time 
taken to reach confluence (Figure 27B), however around 20% of 129S8 cultures 
were unable repair the scratch and reach confluence again (Figure 27C). Upon the 
second and third scratch, 129S8 epithelia have a significantly reduced ability to 
reach confluence. 129S8 take longer to repair the scratch, with 20 - 60% of the 
cultures failing to repair the scratch at all (Figure 27B, C). To further confirm that 
129S8 epithelia have reduced ability to repair, EdU was added to un-scratched and 
scratched cultures and analysed after 24 and 48 hours. At both time points 129S8 
AECs had fewer EdU positive cells than C57BL/6 AECs in the unscratched cultures 
(Figure 27D). Upon scratching the cultures, the percentage of EdU positive cells do 
not increase after 24 hours post scratch (h.p.s.), but the difference between the two 
genotypes is still evident. 48 h.p.s EdU positivity does increase in both genotypes 
however the levels in 129S8 AECs do not reach those of C57BL/6 AECs. 
However, the extent of a scratch injury can vary between transwells, and future 
methods that will introduce a uniform level of injury to a transwell should be 
used. 
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Figure 27 129 epithelia undergo less proliferation and delayed repair after 
mechanical injury in comparison to C57BL/6 epithelia 
C57BL/6 and 129S8 AEC cultures were scratched and re-scratched with the 
transepithelial resistance measured until confluence is reached (R>1000 mΩ/cm2) 
(A). The time taken to reach confluence (B) and percentage of cultures that don't 
reach confluence is graphed (C). Un-scratched and scratched cultures were 
analysed for EdU+ cells by flow cytometry 24 and 48 hours post scratch (h.p.s). 
Graphs show mean ± SEM. Arrowheads indicate when the AEC cultures where 
scratched. Significance was assessed by unpaired t-test where * P<0.05, ** P 
<0.01. Data representative of seven independent experiments, n=3 (A). Data 
pooled from seven independent experiments, n=3-21 (B, C). Data representative of 
three independent experiments, n=3-4 (D).  
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 To determine if this lack of repair is recapitulated in vivo, C57BL/6 and 
129S8 mice were infected with X31, and EdU positivity of lung cells was quantified. 
Pre-determination of lung damage of these mice following IAV infection and before 
EdU administration could not be performed without first removing the lung for 
staining with damage markers such as TUNEL, which stains apoptotic cells. Due to 
the higher susceptibility of 129S8 mice to IAV-induced disease, the IAV doses 
administered to C57BL/6 and 129S8 mice were modified to levels previously found 
within the lab to induce similar weight loss. Thus, C57BL/6 mice were infected with 
2.4 x104 TCID50, whereas 129S8 mice were infected with 800 TICD50. Weight loss 
is one clinical symptom of IAV disease, however, it is does not conclusively indicate 
the levels of damage induced.  
There is no significant difference between 129S8 and C57BL/6 EdU 
positivity levels be it in their hematopoietic or non-hematopoietic cells (Figure 28A, 
B). Although infected with less IAV, 129S8 mice had increased weight loss and 
showed no signs of recovering like the C57BL/6 mice (Figure 28C). This divergent 
response to IAV infection demonstrates how difficult it is to normalise for damage 
using IAV as the damage inducer. As it is not possible to assess lung damage in 
the individual mice used for EdU treatment, this type of experiment was not further 
pursued. Future in vivo experiments could implement another method of inducing 
lung damage such as naphthalene, to measure damage and repair capabilities 
between these mice strains.  
 Overall, it is clearly evident that 129S8 epithelia are not only more 
responsive to IFN exposure and IAV infection but have a reduced potential for 
repair and show impairments in basal cell numbers and epithelial cell differentiation 
reminiscent of epithelia remodelling in chronic inflammatory diseases. These 
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results demonstrate that genetic changes can impact the biology of airway epithelia 
resulting in different epithelial responses and regeneration. In particular, the 
epithelial differences observed in 129S8 epithelia are consistent with 
hypercytokinemia and decreased repair of the lung following IAV infection, thus 
potentially contributing to morbidity and mortality. 
  
Chapter 4 Results 
 
172 
 
 
Figure 28 Proliferation of cells following IAV-induced damage does not differ 
between C57BL/6 and 129S8 mice 
C57BL/6 and 129S8 mice were infected with X31 (2.4 x 104 TCID50 and 800 TCID50 
respectively) and treated with EdU on days 6, 7, 8 and 9 post infection. Whole 
lungs were taken and analysed for EdU positivity in CD45+ (hematopoietic cells) 
(A) and CD45- cells (non-hematopoietic cells) (B) 10 d.p.i. by flow cytometry. The 
weights of the mice were recorded throughout infection (pink: C57BL/6, blue: 
129S8) (C). Graphs show mean ± SEM. Data pooled from four independent 
experiments, n=9-10 (A, B). Data representative of four independent experiments, 
n=3 (C). 
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4.4 Conclusions and Discussion 
Severe influenza infection correlates with rapid development of lung injury and a 
vigorous inflammatory response (Cate 1987; Kaufman et al. 2009; Mauad et al. 
2010). However, individuals differ in their response to infection, which may be due 
in part to differences in host genetics (Peiris et al. 2009). We hypothesized that the 
airway epithelia may play a role in the divergent response to IAV. We have shown 
that AECs generated from an IAV susceptible and a resistant in-bred mouse strains 
diverge in the response to IAV, in the production of IFNs, ISGs, and 
proinflammatory cytokines and chemokines. The composition and regenerative 
capabilities also differ between these two host strains. 129S8 AECs have a 
reduced ability to repair compared to the resistant C57BL/6 AECs. When 129S8 
AECs do repair, we see an epithelial phenotype that is drastically different to 
C57BL/6 epithelia – fewer basal cells, and fewer differentiated cells. We therefore 
believe that genetic differences can determine the response of the epithelia to IAV 
infection, and contribute to the ability to repair lung tissue injury. This change in the 
ability to respond to infection and repair may contribute to the increased morbidly 
and mortality following IAV infection in vivo.  
IAV preferentially infects and replicates within the airway epithelium, which 
responds by inducing the antiviral cytokines type I and III IFNs. Although historically 
type I IFNs were shown to be protective during IAV infection, studies have shown 
that they can be pathogenic in high quantities as in the 129 mice (Boon et al. 2009; 
Davidson et al. 2014). We therefore postulated that this in vivo phenotype would be 
recapitulated in vitro, with a higher production of IFNs by the 129S8 AECs in 
comparison to the C57BL/6 AECs. However, 129S8 AECs were not found to be 
high IFN producers but were in fact scarcely inducing IFNs at all. This lower 
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amount of IFNs at the level of AECs may be detrimental in itself for these cultures. 
This contrasts the in vivo findings, but this may be due to lack of the IFN producing 
innate immune cells in the system, such as pDCs, which have been described to 
induce robust amounts of type I IFN and be recruited in large numbers to the lung 
following influenza infection. In fact, depletion of PDCA-1+ cells protects 129 mice 
from severe influenza (Davidson et al. 2014). It would therefore be interesting to 
quantify IFN production from a co-culture of AECs and pDCs and/or other innate 
immune cells.  
The in vivo results only describe severity correlating with a high type I IFN 
response. In our system type III IFN, a second totally independent, yet redundant 
IFN system, which acts exclusively on epithelial cells (Kotenko et al. 2002; 
Onoguchi et al. 2007; Crotta et al. 2013) is the most upregulated IFN in both 129S8 
and C57BL/6 AECs. This could indicate that type III IFN may play a bigger role 
during influenza infection in AEC cultures as compared to the situation as a whole 
lung.  
We did not find the high IFN response by the 129S8 epithelia as is observed 
in vivo in the whole lung. However, the greatest peak of IFN induction in vivo is 2/3 
d.p.i. (Davidson et al. 2014). It would therefore be interesting to repeat this 
experiment at later time points. Unfortunately, the cytolytic effect of IAV could 
potentially kill the entire culture and therefore, the results may not fully recapitulate 
what is observed in vivo. Intriguingly, a study pointed to endothelial cells, a cell type 
only infected in severe IAV, as orchestrating the excessive cytokine response to 
influenza infection (Teijaro et al. 2011). This would suggest that it is not the 
epithelia from the proximal lung that are inducing the excessive IFNs in severe IAV 
but rather another cell type, be it stromal or non-stromal. However, to see so little 
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IFN induction is surprising and may therefore be due to the remodelling of the 
epithelium after injury which will be discussed at length later in this chapter. 
In vivo results from the lab have shown that bone marrow chimeras of 129 
mice reconstituted with type I IFN knock out bone marrow have low IFN levels and 
yet are more susceptible to IAV infection. Therefore, the production of IFN may not 
be the limiting factor, but rather the responsiveness of the cells to it. Severe IAV 
infection correlates with a ‘cytokine storm’ leading to excessive lung damage and 
ultimately death of the host (de Jong et al. 2006; Taubenberger and Morens 2006; 
Vigneswaran et al. 2007; Zeng et al. 2007; Peiris et al. 2009; Stary et al. 2009; 
Bernardo et al. 2013). This lead us to hypothesize that 129S8 AECs would be more 
responsive to IAV by producing more ISGs, proinflammatory cytokines and 
chemokines, and apoptosis related genes than the resistant counterpart strain. We 
found that this was somewhat the case with 129S8 AECs producing more ISGs, 
and proinflammatory cytokines and chemokines. However, we did not find any 
induction of death receptors on the AECs in either genotype after IAV infection. 
This lack of death receptor induction in the 129S8 AECs may be due to the 
absence of type I IFNs which have previously been shown to induce DR5 on the 
lung epithelia (Herold et al. 2008; Davidson et al. 2014; Brauer and Chen 2016; Hui 
et al. 2016). Previous findings within the lab have shown that 129 mice have higher 
numbers of apoptotic epithelial cells following IAV infection due to the higher IFNαβ 
production (Davidson et al. 2014). However, if type I IFN alone is required to induce 
DR5 on epithelia, we should see an induction in the C57BL/6 AECs, where we do 
not. We do however find death related apoptosis genes significantly induced in a 
different culture system: A549 cells, following IAV infection. This suggests that 
another contributing factor may be missing from the mTEC cultures, such as innate 
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immune cells or type I IFN indirectly causing DR5 expression through the induction 
of cytokines that are not present in these cultures. Therefore incorporating innate 
immune cells into the culture could induce the needed IFN and/or other cytokines 
leading to up regulation of DR5 on the epithelia. BAL fluid collected from IAV 
infected 129S8 mice would provide another way to add the missing recruited 
immune cells and cytokines and chemokines that would normally be acting on the 
AECs. Utilizing the two genotypes again in these experiments could further 
delineate the genetic contribution to severity of disease. Apoptosis is not only 
induced by DR5 expression, and therefore TUNEL staining of the epithelium could 
be carried out to fully decipher the epithelium integrity before and after IAV infection. 
Nevertheless, the higher resting state level of death receptors on 129S8 AECs 
compared to C57BL/6 AECs is interesting and suggests a possible apoptosis prone 
state of the epithelium.  
We have shown that 129S8 epithelia do not recapitulate the high type I IFN 
phenotype as observed in vivo. However, they are more responsive to infection and 
IFNs in the production of ISGs, and proinflammatory cytokines and chemokines. 
These responses from the 129S8 AECs are not massive and do not fully reflect the 
‘cytokine storm’ observed in vivo. 
 A hallmark of infection by respiratory viruses is productive infection of and 
the subsequent destruction of the airway epithelium. Following resolution of the 
infection, this airway damage must be repaired to allow for total recovery of the 
host. Digesting and plating out the AECs is a form of damage and repair model 
without the complication of an active influenza infection, thus allowing us to easily 
decipher any differences following injury between the phenotype of 129S8 versus 
C57BL/6 AECs. We hypothesized that the 129S8 AECs would be less capable of 
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repairing. We confirmed this hypothesis, but we also discovered that the 129S8 
epithelium has a remodeled phenotype following injury showing less basal and 
differentiated cells. 
To quantify the different cell types of the AECs we had to set up an antibody 
flow cytometry panel. The upper airway epithelium is made up of three main cell 
types: basal cells, ciliated cells and secretory cells. Although NGFR and CD49f are 
well known as basal cells markers (Rock et al. 2009; Guo et al. 2012), there are no 
known cell surfaces markers for ciliated or secretory cells, making flow cytometric 
analysis of these cells difficult. Our antibody panel employed here is an attempt to 
use cell surface markers to quantify these cell types. However, as of yet it is not 
fully known what the CD49fhi single positive population is, as they were not easily 
sortable due to their lower number in C57BL/6 cultures. Sorting of 129S8 AECs 
may allow for sorting of this population and quantifying for the expression of known 
markers of the different cell subsets. However, we found it difficult to obtain 
sufficient cell numbers from this sorting process for downstream analysis. 
Comparing the different cell subsets it was surprising to find significant differences 
between the two genotypes. 129S8 AECs displayed more undifferentiated and 
CD49fhi single positive cells, and less basal and differentiated cells than in the 
C57BL/6 AECs. The increased undifferentiated and CD49fhi single positive cells, 
and the lower amount of basal cells could suggest that there may be a reduced 
ability of basal cells to proliferate. The lower percentage of differentiated cells also 
suggests a block in differentiation.  
Interestingly, in a study comparing B6 to 129 responses to IAV, basic 
fibroblast growth factor (bFGF), a growth factor important for epithelial repair, was 
found to be the only cytokine downregulated in 129 mice compared to the B6 mice 
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(Zhou et al. 2016). Other known proliferation factors such as epidermal growth 
factor (EGF), and transforming growth factor alpha (TGF-α) should also be tested 
for blockade within these 129S8 cultures (Aaronson et al. 1990; Ferriola et al. 
1991). 
The current flow cytometry panel employed here does not allow us to 
distinguish differentiated cells into either ciliated or secretory cells within the 129S8 
culture. We therefore used immunofluorescence of the cultures with β-tubulin IV to 
quantify ciliated cells. Here we show a striking lack of ciliated cells within the 129S8 
culture. We did not see this effect in vivo when the whole trachea was stained, 
however such phenotypes may be stronger in vitro than in vivo, and more subtle 
effects may occur in vivo. This may also tell us that this effect only occurs when 
damage and repair is initiated. 
A normal ciliated cell should display many cilia on its surface, whereas in 
most cases the 129S8 epithelia show rather a trend for one or few cilia. To fully see 
if there is a defect in multiciliogenesis electron microscopy should be carried out. 
This could nonetheless point towards a blockade in the downstream mechanism for 
the formation of cilia. For the formation of cilia, MCIDAS and CCNO must be 
expressed for basal cells to exit the cell cycle and allow for centriole amplification. 
CCNO and FOXJ1 induce apical docking of the centrioles and FOXJ1 induces the 
expression of motile ciliate proteins (Boon et al. 2014). Notch functions as a 
repressor of MCIDAS and could potentially be overexpressed in regenerating 
129S8 epithelium. The aryl hydrocarbon receptor (AhR) is downstream of Notch 
signalling and has been shown to not only be required for detoxification but also for 
the generation of multiciliogenesis, as blockade of AhR resulted in reduced cilia in 
mTEC cultures (Villa et al. 2016). Interestingly, 129 mice are AhR hypomorphs and 
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thus this may account for the reduction in ciliated cells. Overall, any mutations or 
blockade of MCIDAS, CCNO, FOXJ1 or AhR could result in reduced generation of 
cilia; therefore they may be interesting factors to quantify within the 129S8 
epithelium. 
Since the 129S8 often do not grow when plated, we hypothesized that they 
would have a decreased ability to repair. To confirm this the cultures were injured 
by scratch assays repeatedly. Indeed 129S8 cultures took longer to repair the 
scratch and quite often failed to do so, which likely is due to the lower amount of 
proliferation we find. This could reflect the lower amounts of basal cells and 
potentially club cells within these cultures. The reduced ability of 129S8 epithelium 
was not recapitulated in vivo when mice were infected with X31 and treated with 
EdU. However, this system is difficult to control as a method of damage induction 
since the mouse strains under comparison respond differently to IAV infection. It 
was therefore difficult to normalize for damage as there is no reliable measure of 
damage inflicted on the epithelium before the EdU is administered, without first 
culling the mice. To fully assess the amount of damage inflicted, mice would have 
to be culled and the lungs stained for damage markers or lack of the 
aforementioned cell subsets. Influenza infection also causes many secondary 
effects, which could be affecting the ability of the epithelium to repair as discussed 
in Chapter 6. 
 Another method of lung epithelium damage should be carried out such as 
naphthalene treatment. Naphthalene is already extensively used to induce damage 
to the airways and quantify repair (Lawson et al. 2002; Carvalho-Oliveira et al. 
2009). Naphthalene is a chemical which, when metabolized by club cells ablates 
them. Ciliated cells squamate and cover the basement membrane. The lung 
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epithelium must then repair by progenitor and basal cell proliferation, which starts 
24 hours after injury. Differentiation occurs allowing for full restoration of the 
epithelium and function of the lung, which can take up to several weeks (Carvalho-
Oliveira et al. 2009). Lawson et al. used this method to quantify repair in C57BL/6 
and 129/SvEv mice and showed that 129SvEv had a delay in the formation of cilia, 
reduced cell density, and proliferated for longer compared to C57BL/6 mice 
(Lawson et al. 2002). This is highly encouraging and somewhat confirms our own 
findings. We plan to employ this method in future studies 
Overall, it is evident that genetic differences of the airway epithelium can 
determine the outcome of disease. Epithelia from the IAV-susceptible mouse strain 
displayed an increased responsiveness to IFNs and IAV infection, remodeling of 
the epithelium and reduced potential for repair after injury. This reduced potential 
for repair and changes in the different cell subsets is interesting as it reflects what 
is observed in chronic lung illnesses. This may highlight that there may be a 
genetic contribution to the generation of chronic lung illnesses where repeated lung 
insult and injury leads to remodeling of the epithelia in some individuals. 
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Chapter 5. Therapeutic potential of IFNs during IAV 
infection 
Work in this Chapter was undertaken with Dr Sophia Davidson as a joint project. 
Where indicated, experiments were carried out co-operatively. Much of the 
experimental results in this chapter have been published: ‘IFNλ is a Potent Anti-
Influenza Therapeutic without the Inflammatory Side Effects of IFNα Treatment’ 
Sophia Davidson1, Teresa M McCabe1, Stefania Crotta, Hans Henrik Gad, Edith M 
Hessel, Soren Beinke, Rune Hartmann and Andreas Wack. EMBO Mol. Med. DOI 
10.15252/emmm.201606413 (2016). 1Joint first authors 
 
 
5.1 Background 
IAV can cause up to five million cases of severe illness and up to 500,000 deaths 
annually (Krammer et al. 2015). IAV can also cause pandemics, such as the 1918 
“Spanish Flu” in which an estimated 50 million people died globally (Johnson and 
Mueller 2002). At present, there exists the constant threat of highly pathogenic 
H5N1 and H7N1 avian influenza strains, which demonstrate the burden of IAV and 
the need to better protect from and treat IAV infections.  
 Currently, the best method for protection from IAV is immunization with 
inactivated or live attenuated vaccines. However, existing vaccines rarely induce 
broadly neutralizing antibodies, thus they cannot provide protection against 
heterologous IAV strains (Krammer et al. 2015). Therefore, each year new 
vaccines must be made to match the current circulating strain in addition to 
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predicting viruses that are the most likely to circulate in the upcoming influenza 
season. This has a number of potential problems. Many influenza virus strain 
candidates grow poorly in eggs making it difficult to obtain the vaccine. Vaccines 
require six months to prepare, thus they must be made well before the upcoming 
influenza season. Incorrect predictions of which strains are likely to circulate could 
potentially be made, thus rendering the vaccines partially inefficient. Furthermore, 
some IAV strains do not appear until late in the season and as such may be missed 
when the vaccine candidates are chosen. Due to the long time frame for creating a 
vaccine, creating an additional vaccine late in the season is impractical.  
  Once infected with IAV, the main treatment options are antivirals. The 
prophylactic efficiency of antivirals varies between 80 to 90%, and ideally need to 
be administered within 48 hours of the onset of symptoms to reduce severe 
complications and deaths (Davies et al. 1964; Younkin et al. 1983; Reuman et al. 
1989; Spagnuolo et al. 2016). There are two classes of antivirals: ion channel 
blockers (amantadine and rimantadine), and inhibitors of influenza neuraminidase 
(oseltamivir, zanamivir, peramivir and laninamivir), which act directly on viral 
proteins (Jefferson et al. 2006). However, emergence of drug resistance, due to the 
high natural mutation rate of IAV, has been observed. In fact since 1994, reports 
have described adamantine-resistant A (H3N2) (Bright et al. 2005), rimantadine-
resistant strains of influenza A virus (H3N2) (Hayden et al. 1989), oseltamivir-
resistant seasonal A (H1N1) viruses and adamantine-resistant pandemic A(H1N1) 
(Pizzorno et al. 2011). This resistance has also been found to be transmissible, 
which is worrying as they may widely replace susceptible strains. Thus there is a 
need to target novel IAV and strains that cannot be vaccinated against, without 
driving drug resistance. Antiviral host factors would provide ideal treatment options, 
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since they avoid the issue of drug resistance. Type I and III IFNs could represent 
one such family of immune activated antivirals. 
 As previously mentioned, type I IFNs are a family of cytokines which are 
known for their antiviral properties but are also strong immunostimulants. Binding to 
IFNAR results in the transcription of hundreds of ISGs (Randall and Goodbourn 
2008). Importantly, two of these ISGs have been known to be significant restriction 
factors of IAV: IFN regulator factor 7 (IRF7), and orthomyxovirus resistance gene 
(Mx). IRF7 is essential for the amplification of type I and III IFNs during IAV 
infection (Ciancanelli et al. 2015). MxA, the human homologue of Mx1, can also 
restrict IAV replication by interfering with viral protein transport, synthesis or 
translocation (Pavlovic et al. 1995).  
Type III IFNs, another more recently discovered family of IFNs, are also 
induced during viral infection which initiate the same JAK/STAT signalling cascade 
to induce the same ISGs as type I IFN. They however do not bind through the 
IFNαβR, but through their own heterodimeric receptor complex composed of IL-
10R2 and IFNλR1 subunits. This receptor, unlike IFNαβR, is not ubiquitously 
expressed, but rather is expressed primarily at mucosal epithelia such as the lung 
and gut (Kotenko et al. 2002; Sheppard et al. 2002).  
 Mice deficient for both IFNαβR and IFNλR were found to be highly 
permissive to a number of respiratory and other viruses (Mordstein et al. 2008). Not 
only did mice deficient for both receptors display increased viral titres compared to 
Wt mice, but also to mice deficient for just IFNαβR or IFNλR. These increased viral 
titres correlated with an increase in disease burden and host mortality. The IFNαβR 
deficient mouse controlled the virus better than the double knock out mouse, 
demonstrating the redundant role of type I and III IFNs within the AECs. This was 
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further confirmed by Crotta et al. who showed that only AECs deficient for both type 
I and III receptors in AECs resulted in high IAV loads and as such host morbidity 
and mortality, even with an intact Wt hematopoietic immune response (Crotta et al. 
2013). The lung epithelium, the first host target of IAV infection, is therefore 
essential in the induction of antiviral ISGs and thus the control of IAV. 
 IAV has evolved ways to antagonize type I and III IFN induction and 
signalling through the action of the viral NS1 protein (Jia et al. 2010). As such 
treatment by the exogenous addition of more of these cytokines to an infected host 
may serve to bypass this virus-mediated block of IFN induction. Type I IFNs have 
previously been suggested as a possible treatment for IAV during infection (Finter 
et al. 1991). However, type I IFNs, although they are excellent inducers of antiviral 
genes, also have the potential to induce immunopathology, resulting in 
exacerbated disease (Davidson et al. 2014). Type III IFNs have previously been 
shown to have a less adverse effect compared to type I IFNs in clinical trails for 
hepatitis C (Muir et al. 2014). Therefore its therapeutic potential in IAV is clinically 
relevant. However, the Davidson et al. study was undertaken on Wt in-bred mice 
which have been shown to carry nonfunctional alleles for Mx1 (Staeheli et al. 1988).  
Therefore, given the potent antiviral capability of Mx1, it could be argued that the 
pathogenic, rather than protective, effect of a high IFNαβ response is due to the 
lack of the Mx protein. Indeed pretreatment of congenic mice, which are genetically 
backcrossed to express a functional Mx1 protein: A2G-Mx1, with IFNα displayed 
complete protection from lethal 1918 H1N1 infection, whereas only partial 
protection was observed in non-IFN pretreated, IAV infected controls (Cilloniz et al. 
2012). Furthermore, pretreatment of A2G-Mx1 mice with IFNα also protected mice 
against infection from the highly pathogenic H5N1 strain (Tumpey et al. 2007). 
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 As the world’s population continues to expand rapidly, and contact with 
natural avian IAV hosts increases, the potential for novel IAV strains to cross the 
species barrier also escalates. This, along with the difficulty of developing the right 
vaccines, the high mutation rate of IAV, and the antiviral resistance demonstrates 
the urgent need for a protective host-immune mediated treatment option. IFNs, a 
host induced family of antiviral cytokines, therefore become very interesting as a 
treatment option and their role as therapeutics is assessed here. Given the known 
potent immunomodulatory effects of type I IFNs, type III IFNs, which have not 
previously been assessed as a potential treatment option for IAV, are also studied 
here. As the IFNλR is only expressed on mucosal epithelia, the addition of IFNλ 
may not stimulate the hematopoietic system and therefore may not drive the 
immunopathology ascribed to IFNα. 
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5.2 Hypothesis and Aims 
Severe IAV induced disease is characterised by a robust immune response and 
lung tissue damage. Type I (IFNα) and type III (IFNλ) IFNs are potent antivirals 
rapidly induced following infection. Given the vaccine difficulties, IFNα4 and IFNλ2 
were used to assess their potential as viable treatment options against IAV-induced 
disease in B6.A2G-Mx1 mice. A viable treatment option would be one that protects 
the host from viral and host-induced tissue damage, does not induce 
immunopathology, and lowers the overall disease burden. MTEC cultures will be 
used to identify equivalent doses of IFNα4 and IFNλ2. 
 
I hypothesize that: 
• Due to the different distribution of type I and III receptors, IFNα4 will induce 
immunopathology by stimulating the innate immune cells, whereas IFNλ2 
will not 
• Therefore, IFNλ2 may be the better option as a therapeutic in influenza 
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5.3 Results 
5.3.1 IFNλ and IFNα are protective if given before IAV infection, but only 
IFNλ is protective in an on-going infection  
To ascertain equivalent doses of type I IFN, IFNα, and type III IFN, IFNλ, the 
induction of ISGs were assessed on AECs. AECs were treated with a serial dilution 
of either IFNα or IFNλ and the ISGs Rsad2, Oasl2, ifi203 and Mx1 (Figure 29A) 
were quantified. As expected, AECs respond to both types of IFN. The dose 
response curves were then used to determine EC50 values, which allowed us to 
calculate a conversion ratio to establish equipotency between IFNα4 and IFNλ2 
(Figure 29B). The final conversion ratio of 0.558 was determined by the geometric 
mean of the ratios obtained for all ISGs assessed and applied to treat mice 
expressing the functional Mx1 gene (B6.A2g-Mx1) and of various cell types with 
equivalent doses of IFNα4 and IFNλ2. 
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Figure 29 Determination of equivalent doses of type I and III IFNs using AECs 
AECs were stimulated for 4hrs with IFNα4 or IFNλ2, and induction of ISGs was 
assessed by qPCR. Prism 6 software was used to perform a curve fit (Sigmoidal, 
4PL), generate a dose response curve and calculate a half-maximal effective 
concentration (EC50) for each gene assessed for each treatment. A conversion ratio 
was then generated using the indicated formula for each ISG and a final conversion 
ratio was taken from the average of all ISGs assessed. Values represent means ± 
SEM. Data is pooled from 2 independent experiments, n=3-7. 
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 Intranasal IFN treatment with either IFNα4 or IFNλ2 of mice prior to infection 
with the pathogenic IAV strain, PR8 (strain A/Puerto Rico/8/34 H1N1), protected 
mice from morbidity and mortality, as has been previously shown within the 
literature (Tumpey et al. 2007; Mordstein et al. 2008; Cilloniz et al. 2012) (Figure 
30A). This protection correlated with undetectable viral titres within the lung at 4 
days post infection, whereas the vehicle control groups displayed higher viral tires, 
weight loss and over 55% mortality (Davidson et al. 2016). This indicates that both 
types of IFNs can induce an antiviral environment within the lung, preventing IAV 
infectivity and replication. 
 As patients only seek medical help when they display symptoms of IAV 
disease, it is not feasible to pre-treat the entire population during a pandemic. 
Therefore intranasal IFN treatment during an on-going IAV infection represents a 
more realistic clinical option and as such the effectiveness of IFNα4 and IFNλ2 
administered after IAV infection is assessed. B6.A2g-Mx1 mice were infected with 
PR8, and treated intranasally with vehicle control, IFNα and IFNλ on days 2, 4 and 
5 post infection (figure 30B). Here we see a divergent outcome depending on the 
type of treatment. IFNλ2-treated mice were better protected against IAV-induced 
disease, exhibiting decreased morbidity and mortality compared to the vehicle 
control group. IFNα4 treatment however resulted in increased morbidity and 
mortality. This divergence in disease outcomes did not however correlate with a 
difference in viral loads. IFNα4 and IFNλ2 treatment both resulted in significantly 
lower viral loads compared to vehicle control treated groups (Davidson et al. 2016). 
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Figure 30 IFNα4 and IFNλ confer protection if given before IAV, however only 
IFNλ is protective during an active IAV infection 
B6.A2G-Mx1 mice were pre-treated with equivalent doses of IFNα4 (1.45 µg/50ul) 
or IFNλ2 (2.6 µg/50ul), or Veh Ctrl (50ul) 24 hrs. prior to infection with PR8. Weight 
loss and survival was assed throughout infection (A). B6.A2G-Mx1 mice were 
infected with PR8 and treated with equivalent doses of IFNα4 or IFNλ2, or Veh Ctrl 
2, 4 and 5 days post infection. Survival and weight loss was monitored throughout 
(B). Significance was assessed by Log-rank (Mantel-Cox) test (survival), and 2-way 
ANOVA (weight loss). * indicates IFNα4:Veh Ctrl, + indicates IFNλ2:Veh Ctrl and o 
indicates IFNα4:IFNλ2. Symbols to the right indicate statistical significance of the 
whole curve. * P<0.05, ** P<0.01, *** P<0.001, ****P<0.0001. Data is pooled from 
two independent experiments, n=5-7 (A). Data (n=17-34) is pooled from six 
independent experiments that were performed by myself and by Dr Sophia 
Davidson. 
  
0 3 6 9 12
70
80
90
100
110
Days post infection
%
 o
f s
ta
rt
in
g 
w
ei
gh
t
PBS
IFNα
IFNλ
Pretreatment
**+++
***+++ ****+++
***+++ **++ **++
*++
0 2 4 6 8 10
0
20
40
60
80
100
Days post infection
%
 s
ur
vi
va
l
Veh Ctrl
IFNα
IFNλ
Pretreatment
*+
A
B
0 5 10 15
0
20
40
60
80
100
Days post infection
Pe
rc
en
t s
ur
vi
va
l
Veh Ctrl
IFNα
IFNλ
Post-treatment
**
oo
0 2 4 6 8 10 12 14
70
80
90
100
110
Days post infection
%
 o
f s
ta
rt
in
g 
w
ei
gh
t
Veh Ctrl
IFNλ
IFNα
Post-treatment
++
****
oooo
Chapter 5. Results 
 
191 
 
5.3.2 Overlapping and divergent effects of IFNα and IFNλ 
Given the divergent outcome between IFNα and IFNλ treatment following IAV-
induced disease, which does not correlate with differences in viral load, there must 
be another host immune aspect responsible for IFNλ protection. High IFNα levels 
following IAV have already been associated with immunopathology, epithelial cell 
damage, and mortality (Davidson et al. 2015). Therefore, the effect of IFNα and 
IFNλ treatment on innate immune cells and AECs was assessed. Bronchoalveolar 
lavage (BAL) fluid throughout IAV infection was collected and measured for the 
inflammatory cytokines: IL-6, CXCL10, CCL2, Eotaxin and CCL3 (Figure 31). IFNα 
significantly altered the proinflammatory cytokine response in comparison to Veh 
Ctrl and IFNλ2 treatment groups. The cytokine response between Veh Ctrl and 
IFNλ2 groups were however comparable from day 4 post infection onwards. This 
suggests that in the context of on-going IAV infection, further administration of IFNα 
results in decreased viral loads, but also drives immunopathology. In striking 
contrast, IFNλ does not induce this immunopathology, as it does not modify the 
proinflammatory cytokine secretion. 
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Figure 31 IFNα4 treatment causes increased proinflammatory cytokine secretion 
during IAV infection 
B6.A2g-Mx1 mice were infected with PR8 and treated with IFNα4 (1.45 µg/50µl), 
IFNλ2 (2.6 µg/50µl) or Veh Ctrl (50ul) as per Figure 30B. IL-6, CXCL10, CCL2, 
Eotaxin and CCL3 were measured by multiplex cytokine assay from BAL fluid. 
Arrowheads represent days of treatment. Significance was assessed by 2-way 
ANOVA with Bonferroni post tests. * indicates IFNα4:Veh Ctrl, and o indicates 
IFNα4:IFNλ2. IFNλ2:Veh Ctrl was not significant. Symbols on the right of the 
graphs indicate statistical significance of the whole curve (2-way ANOVA) while 
those above indicate significance of individual time points (Bonferroni post test). * 
P<0.05, ** P<0.01, ***P<0.001. Graphs show mean ± SEM and are representative 
of two independent experiments, n=3. Samples collected and processed in 
collaboration with Dr Sophia Davidson. 
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IFNα, IFNβ and IFNλ levels were also measured throughout infection 
(Figure 32A). The peak of endogenous IFNs is at 2 days post infection and is 
comparable between the three groups. After administration of IFNα or IFNλ on day 
3 post infection, their levels subsequently drop on day 4 post infection. IFNα protein 
levels on day 5 post infection are significantly increased, whereas they are not in 
the Veh Ctrl or IFNλ groups. Similarly, IFNλ levels are increased at 5 days post 
infection, but these are unchanged in the Veh Ctrl and IFNα groups. This may be 
due to the IFN positive feedback loop or, more likely, to the detection of exogenous 
IFNs administered on day 5 post infection. To understand if the IFN positive 
feedback loop is in fact playing a role, IFN transcript levels over time post treatment 
were assessed (Figure 32B). There is no evidence of a positive feedback loop for 
endogenous IFN production since the transcript levels for all three IFNs tested are 
essentially unmodified by IFNα or IFNλ treatment. Also, to ensure the IFNs 
administered are reaching the lung and show that there is no basal level of IFNs 
within a naïve mouse, BAL was taken from mice 5 minutes after treatment and 
measured for IFNα, IFNβ and IFNλ (Figure 32C). We see only protein levels of 
IFNs corresponding to the treatment administered, whereas we see no IFNβ, as 
expected. These results indicate that it is the exogenous IFN administered that is 
driving the observed divergence in disease and proinflammatory cytokine induction. 
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Figure 32 The exogenous administered IFNα4 rather than endogenous IFNα4 is 
driving the exacerbated disease 
B6.A2G-Mx1 mice were infected with PR8 and treated with IFNα4 (1.45µg/50µl), 
IFNλ2 (2.6µg/50µl) or Veh Ctrl (50ul) as per Figure 30B. IFNα, IFNβ and IFNλ were 
assessed by ELISA (A). Whole lungs were taken at day 3 and 5 post infection and 
analysed by qPCR for IFNa4, IFNb1 and IL28A (B). B6.A2G-Mx1 mice were 
treated with IFNα4 (1.45µg/50µl), IFNλ2 (2.6µg/50µl) or Veh Ctrl (50ul) and BAL 
fluid taken 5 minutes later and assessed by ELISA for IFNα, IFNβ and IFNλ (C). 
Arrowheads represent days of treatment. Significance was assessed by 2-way 
ANOVA with Bonferroni post tests. * P<0.05, and ** P<0.01. Graphs show mean 
Graphs show mean ± SEM and are representative of two independent 
experiments, n=3. Data for A was collected and processed in collaboration with Dr 
Sophia Davidson 
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 To determine why the different types of IFN resulted in a divergent ability to 
protect the mice from IAV, the response of different innate immune cells were 
assessed. In vitro stimulation of whole splenocyte cultures with IFNα, but not with 
IFNλ, resulted in increased ISG expression: Rsad2 and Oasl2 (Figure 33A), and 
proinflammatory cytokine secretion: IL-6, CXCL9, CXCL10 and CCL2 (Figure 33B). 
IFNλ did not induce these ISGs and cytokines due to the lack of IL28Ra on 
hematopoietic cells (Figure 33C), thus confirming the literature on the distribution of 
the IFN receptors (Sommereyns et al. 2008; Mordstein et al. 2010).  
 As the IL28Ra is present on the non-haematopoietic cells, the response to 
IFN stimulation on AECs was assessed. AECs are the primary infection targets of 
IAV and as such are the first responders to infection. Upon stimulation AECs 
respond comparatively to both types of IFNs by the induction of ISGs, as expected 
(Figure 34A). However, neither IFNα nor IFNλ induced expression or secretion of 
proinflammatory cytokines (Figure 34B, C). Together, these results suggest that 
AEC upregulation of antiviral ISGs upon stimulation with IFNα or IFNλ is sufficient 
to inhibit IAV replication in vivo. As IFNλ does not induce proinflammatory cytokines 
by either innate immune cells or by the AECs, it appears that they are unnecessary 
to control infection and therefore are only contributing to immunopathology. 
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Figure 33 Splenocyte treatment with IFNα, but not with IFNλ, results in ISG and 
proinflammatory expression 
Whole splenocytes isolated from C57BL/6 mice were stimulated with IFNa4, IFNλ 
or Veh Ctrl for 4 hours. ISG expression was measured by qPCR (A) and 
proinflammatory cytokine production was analysed from supernatants by multiplex 
cytokine assay (B). Whole lungs were collected and separated for hematopoietic 
(CD45+) and non-haematopoietic (CD45-) cells, and IL28Ra expression was 
measured by qPCR (C) Significance was assessed by unpaired t-tests where * 
P<0.05, *** P<0.001 and **** P<0.0001. Graphs show mean ± SEM. Data is 
representative of two independent experiments, n=2-12. Samples were collected 
and processed with Dr Sophia Davidson. 
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Figure 34 IFNα and IFNλ treatment of AECs induces comparable ISG expression, 
but no proinflammatory cytokines 
C57BL/6 derived AECs were treated with IFNα, IFNλ or Veh Ctrl for 4 hours then 
assessed for ISGs (A) and proinflammatory cytokines (B) by qPCR. Supernatants 
were collected and analysed for proinflammatory cytokines by multiplex cytokine 
assay (C). Graphs show mean ± SEM. Data is representative of two independent 
experiments, n=2-4.  
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5.3.3 Human primary epithelial and immune cells show the same divergence 
in IFNα versus IFNλ responsiveness as mouse cells 
To be able to extend our study to human cells, the same determination of 
equivalent doses of human IFNα and IFNλ had to be carried out. To do this, 
primary human AECs were generated and treated with a serial dilution of human 
IFNα or IFNλ, and antiviral ISGs were assessed (Figure 35A). The human AECs 
responded to both IFNs in a dose-dependent manner. Dose-response curves were 
then used to determine EC50 values, which allowed for calculation of a conversion 
ratio of 17.5, for equipotent treatment with IFNα4 and IFNλ2 on human cells, as per 
Figure 29 (Figure 35B).  
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Figure 35 Determination of equivalent doses of IFNα and IFNλ on primary human 
AECs 
Human AECs were stimulated for 4hrs with IFNα4, IFNλ2 or Veh Ctrl, and induction 
of ISGs were assessed by qPCR. Prism 6 software was used to perform a curve fit 
(Sigmoidal, 4PL), to generate a dose response curve and to determine a half-
maximal effective concentration (EC50) for each gene assessed for each treatment. 
A conversion ratio was then generated using the formula from Figure 29 for each 
ISG and a final conversion ratio was taken from the average of all ISGs assessed. 
Values represent means ± SEM. Data is representative of 2 independent 
experiments, n=3. 
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 Human peripheral blood mononuclear cells (PBMCs) were collected from 
healthy donors and assessed for ISG and proinflammatory cytokine induction in 
response to IFNα and IFNλ after 4 and 24 hours (Figure 36). IFNα induced 
expression of ISGs (Figure 36A) and proinflammatory expression and secretion 
(Figure 36B, C) at both time points. Messenger levels of TNFα were not induced by 
IFNα treatment, however an increase in protein levels was observed, indicating that 
TNFα expression may have peaked before the first time point tested. IFNλ on the 
other hand did not induce any of the ISGs or proinflammatory cytokines tested, in 
accordance to what we saw when mouse cells were used.  
 To further corroborate that IFNλ treatment during an infection does not 
induce immunopathology, human PBMCs were infected and treated with IFNα or 
IFNλ for 24 or 48 hours. PR8 infection of PBMCs induces both ISGs and 
proinflammatory cytokines at both time points (Figure 37). Further treatment with 
IFNα or IFNλ along with IAV infection does not enhance ISG expression at 24 or 48 
hours (Figure 37A). Similarly IL-6 expression is not enhanced following IFNα or 
IFNλ treatment (Figure 37B). Cytokine secretion is also not enhanced following 
IFNα or IFNλ treatment (Figure 37C). Here we are seeing no IFNα driven 
immunopathology, however these time points differ from the in vivo infection and 
treatment model, as IFNs are given earlier, and ISGs and proinflammatory 
cytokines are assessed earlier. An in vitro model should be set up to completely 
mimic the in vivo model, however the viral-induced apoptosis of the PBMCs is of 
concern and may thus not fully represent the in vivo scenario. Collectively, these 
results further confirm that IFNλ treatment is unlikely to drive the immunopathology 
observed with IFNα, making it a more attractive treatment option for humans. 
Chapter 5. Results 
 
201 
 
 
Figure 36 IFNα4 treatment induces ISGs and proinflammatory cytokines in 
human immune cells, whereas IFNλ does not 
ISG (A) and proinflammatory cytokine induction (B) in human PBMCs was 
assessed at 4 and 24hrs post IFNα (21 U/ml) or IFNλ (1.2 ng/ml) stimulation. 
PBMC proinflammatory cytokine secretion was measured by multiplex cytokine of 
supernatants (C). Significance was assessed by 2 way ANOVA where * P<0.05, ** 
P<0.01, and *** P<0.001. Data shown is representative of 6 independent donors, 
n=6. 
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Figure 37 IFN addition during IAV infection on human immune cells does not 
enhance ISG or proinflammatory cytokine responses 
ISG (A) and IL-6 cytokine induction (B) in human PBMCs was assessed at 24 and 
48 hours post PR8 infection and treatment with IFNα (21 U/ml) or IFNλ (1.2 ng/ml) 
stimulation. PBMC proinflammatory cytokine secretion was measured by multiplex 
cytokine assay of supernatants(C). Significance was assessed by unpaired t test 
where * P<0.05, ** P<0.01, *** P<0.001 and **** P<0.0001. Data shown is pooled 
from 6 independent donors, n=3-6. 
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5.4 Conclusions and Discussion 
An ideal treatment option for IAV should stimulate the induction of antiviral genes in 
AECs to control the spread of the virus, without driving immunopathology. Both 
IFNα and IFNλ, if given prior to infection, can control the spread of IAV, however 
only IFNλ is protective if given during an on-going infection. IFNα treatment 
resulted in increased proinflammatory cytokine production, recruitment of innate 
inflammatory cells and apoptotic AECs (data shown here and Davidson et al. 2016), 
thus promoting IAV-induced morbidity and mortality. Treatment of human AECs 
and PBMCs showed the same dichotomy, with IFNα resulting in increased cytokine 
production by hPBMCs. Overall, this highlights IFNλ as a stronger candidate for 
therapeutic application against IAV in humans.  
 The IFN induced production of ISGs prior to IAV infection blocks the virus 
from establishing an infection, as seen by the reduced viral loads within the lung 
compared to the Veh Ctrl group (Davidson et al. 2016). Previous studies also 
showed that pre-treating mice with type I IFNs protected against a variety of IAV 
strains (Beilharz et al. 2007; Tumpey et al. 2007), although within the Beilharz et al. 
study, mice displayed increased morbidity if they were given higher doses of IFNα 
(Beilharz et al. 2007). Pre-treating an entire population before a serious IAV 
outbreak is not realistic. Mice were thus treated from the onset of IAV-symptoms, 
such as weight loss, at day 2 post infection onwards. Again we see reduced viral 
loads after treatment from both types of IFN compared to the Veh Ctrl group 
(Davidson et al. 2016). IFNα, IFNβ and IFNλ concentrations within the lung 
following infection are low. This is likely due to either the B6.A2G-Mx1 mice being 
on the B6 background which have already been shown to be low IFN responders to 
IAV (Davidson et al. 2014) or to IAV induced blockade of IFNs. NS1 protein of IAV 
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is known to inhibit IFN induction by interfering with upstream pathways such as 
blocking RIG-I ubiquitination or IRF-3 activation (Gack et al. 2007; Hale et al. 2008). 
The addition of exogenous IFN may therefore control IAV replication through the 
increased expression of ISGs or by bypassing the blockade induced by IAV NS1 
protein (Ehrhardt et al. 2010).  
 Virus control following treatment did not always correlate with disease 
outcome, as IFNα treated mice showed increased morbidity and mortality despite 
reduced viral load. Within humans, severe IAV disease is characterised by a 
‘cytokine storm’ and pulmonary tissue destruction, which can be host- or immune-
mediated (Peiris et al. 2004; de Jong et al. 2006; Louie et al. 2009). Exogenous 
IFNα treatment provoked increased secretion of proinflammatory cytokines such as 
IL-6 and CCL2 when compared to the Veh Ctrl or IFNλ treatments. Increased 
recruitment of immune cells such as pDCs and inflammatory monocytes, and AEC 
apoptosis was also observed following IFNα treatment (data shown in Davidson et 
al. 2016). pDCs and IMcs can secrete proinflammatory cytokines and chemokines 
such as CCL2 and IFNαβ following infection. Therefore, enhanced recruitment 
could propagate the proinflammatory cytokine secretion, resulting in amplified lung 
inflammation leading to AEC damage and ultimately mortality of the host. 
Furthermore, in vitro treatment of whole splenocytes with IFNα, but not with IFNλ, 
drives proinflammatory cytokine secretion.  
Type I IFN induced inflammation and epithelial cell death is designed to be 
protective for the host. Recruitment of immune cells and subsequent cell death of 
infected cells should contribute to viral clearance. However, if this system becomes 
over activated, such as from the addition of more IFNα, then increased recruitment, 
cytokine production and lung damage occurs. To identify the overlaps and 
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differences in the lung transcriptional response to both IFNα and IFNλ, we 
performed microarray analysis on whole lungs treated with Veh ctrl, IFNα or IFNλ. 
Samples were normalized to the average of the Veh ctrl and filtered for a fold 
change of 1.5 which yielded 553 genes differently expressed between the two 
treatments, of which 429 were upregulated. Upon K-means clustering of the genes 
upregulated we obtained six gene clusters induced by IFNα alone and the 
remaining genes were induced by both IFNα and IFNλ. IPA analysis of the IFNα 
specific genes revealed the we have found that the “Role of 
hypercytokinemia/hyperchemokinemia in the pathogenesis of influenza” as one of 
the top pathways induced, while the pathways common to both treatments were 
strongly related to IFN signalling pathways (Davidson et al. 2016). These genes are, 
unsurprisingly, primarily proinflammatory cytokines, thus concurrent with human 
studies which found mortality associated with hypercytokinemia (Hayden et al. 
1998; Peiris et al. 2004; de Jong et al. 2006; Yang et al. 2012). IFNα and IFNλ 
treatment induce a highly similar set of genes in AECs (Crotta et al. 2013), in fact 
we see similar ISG expression but no proinflammatory cytokine secretion by either 
treatment of AECs in vitro. Restricted IFNλR allows IFNλ treatment to target the 
cells most at risk to IAV infection, without exacerbating the production of 
proinflammatory cytokines. Therefore, it may also be advantageous within this 
system to block type I IFN signalling late in infection.   
Collectively, these results suggest that it is the IFNα driven proinflammatory 
cytokine production by immune cells that is driving AEC damage during an active 
IAV infection resulting in host mortality. In contrast, IFNλ treatment does not drive a 
cytokine storm, and the ISG induction in AECs is sufficient to control IAV replication 
and protect the host from IAV-induced disease. To completely conclude that it is in 
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fact the exaggerated proinflammatory cytokine response that leads to mortality of 
the host, a blocking antibody such as anti-mouse Ly-6C/G (Gr-1) or anti-PDCA1, 
could be used along with IFNα treatment. Since this should block immune cells 
recruitment, IFNα treatment should lose its immunostimulatory effect and lead to 
the same outcome as with IFNλ treatment. Generating bone marrow chimeras of 
B6.A2G-Mx1 mice reconstituted with an IFNαβR sufficient or deficient 
hematopoietic system would be an alternative strategy to assess whether IFNα4 
treatment drives the excessive immunopathology specifically in immune cells. 
Chimeras reconstituted with IFNαβR-/- hematopoietic system should be protected 
whereas mice receiving a Wt immune system would have increased morbidity and 
mortality. A caveat to this is that radio-resistant myeloid cells may still be present 
within the lung, which could potentially contribute to epithelial cell apoptosis. 
However a study by Hogner et al. showed that Wt C57BL/6 mice reconstituted with 
TRAIL-/- or IFNαβR-/- immune system were protected from IFNαβ/TRAIL induced 
cell death (Högner et al. 2013). Another caveat is the possibility that pulmonary 
endothelial cells may be a source of IFNαβ driven proinflammatory cytokines 
(Sommereyns et al. 2008; Teijaro et al. 2011). If this is possible then IFNα4 
treatment could still induce inflammation by stimulating these endothelial cells to 
induce immunopathology.  
 Pre-treating with IFNα or IFNλ does not confer protection against all viral 
infections. Pre-treatment with IFNα was more effective against 
encephalomyocarditis virus (ECMV) and LCMV, whereas IFNλ was more effective 
against herpes simplex virus type 2 (HSV-2) (Ank et al. 2006). This variation in 
protection is likely due to the virus tissue tropism as IFNλR is restricted primarily to 
mucosal surfaces such as the lung epithelial layer (Sheppard et al. 2002; Mordstein 
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et al. 2008). IFNλ is thus effective against viruses that preferentially replicate within 
the epithelium, whereas it is less effective against viruses that replicate in other cell 
types. Thus in our system of IAV infection, IFNλ is the preferential treatment as IAV 
replication is restricted to the AECs. Although IFNα stimulation over-activates the 
immune response in this setting, it may be protective in other virus infections that 
preferentially replicate within immune cells. Furthermore, we treated mice that had 
a complete, healthy immune system, whereas many fatalities from influenza 
infection occur in immunocompromised individuals who may benefit from immune 
cell stimulation, in which IFNα could be the appropriate treatment option. A number 
of studies have shown that some strains of IAV can replicate within immune cells 
such as AMs and DCs in vitro, however this is usually non productive (Rodgers and 
Mims 1982; Perrone et al. 2008). Human monocyte derived macrophages or DCs 
have also been reported to be infected by highly pathogenic H5N1 or 1918 IAV 
strains (Perrone et al. 2008; van Riel et al. 2011).  
A number of studies have shown that some immune cells do indeed 
respond to IFNλ stimulation (Jordan et al. 2007), such as DCs, NK cells and 
macrophages (Ank et al. 2008; Liu et al. 2011). IFNλ was also found to reduce 
neutrophil numbers and IL-1β production in Th17-driven diseases (Blazek et al. 
2015). Neutrophils express IFNAR, as all immune cells do, however they are 
unique in their expression of the IFNλR (ImmGene database). The IFNλ effects 
Blazek and colleagues describe would equally be mediated by IFNα (Davidson et 
al. 2015) and are most likely not important in our system since we found no 
significant changes in neutrophil numbers or IL-1β levels by either IFN treatment. 
To fully assess the role of IFNλ and its potential protective abilities, different strains 
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of IAV, particularly those capable of replicating within the immune cells, such as 
highly pathogenic H5N1, should also be studied. 
 The pathogenic potential of type I IFNs has been previously reported in mice 
that lacked a functional Mx1 protein (Davidson et al. 2014). As the human 
homologue of Mx1, MxA, has been shown to be a potent restrictor of IAV both in 
vivo and in vitro (Pavlovic et al. 1995), the mice used in this study are a more 
appropriate model for comparisons to human IAV infections. IFNα driven 
immunopathology was nonetheless demonstrated to outweigh the protective effect 
of the IFN-induced anti-IAV Mx1 protein (Horisberger 1995). However, mouse 
models, unlike humans, are naïve to a multitude of pathogens and it is 
consequently unknown whether this study will translate into a clinical application. 
Natural mutations within humans that are linked to IFN production, for example 
IRF7 and IFITM3 (Everitt et al. 2012; Ciancanelli et al. 2015), could impair the 
effectiveness of IFNλ treatment, whilst other mutations which enhance STAT1 
(Yamazaki et al. 2014) activity could over activate the IFN response, thus rendering 
IFNλ useless. IFNλ has already been utilised as a treatment against hepatitis C 
patients, in which it was found that IFNλ was just as effective as IFNα, but with 
reduced hematologic toxicities such as neutropenia or thrombocytopenia and fewer 
influenza-like symptoms such as chills, pyrexia or pain (Ramos 2010; Donnelly et 
al. 2011; Muir et al. 2014). Since many influenza-like symptoms are caused by 
proinflammatory cytokine secretion and inflammation (Eccles 2005), this further 
validates the lower direct immunomodulatory effect of IFNλ compared to IFNα also 
in humans.  
 As IFNλ has been employed as a treatment in other diseases but not with 
IAV, we therefore replicated our data on human AECs and human PBMCs. Both 
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IFNα and IFNλ induced ISG expression in AECs as expected, but only IFNα 
induced cytokine secretion from PBMCs, as was observed with the mouse cells. 
IFN treatment of IAV infected PBMCs did not result in enhanced ISG or cytokine 
secretion regardless on the type of IFN given, but a longer time point should be 
assessed. Interestingly, there appears to be a slight modulation of CCL2 following 
IFNλ treatment of IAV infected PBMCs. This could hint at the possible 
responsiveness of some immune cells to IFNλ, in agreement with previous studies 
mentioned (Ank et al. 2008; Liu et al. 2011; Blazek et al. 2015). Although immune 
cells may be responsive to IFNλ under some circumstances, it is encouraging that 
IFNλ treatment does not contribute to a ‘cytokine storm’ within these cells. Overall, 
our human data suggests that IFNλ does not induce cytokine production within 
human immune cells, unlike IFNα. 
 In conclusion, from the results presented in this chapter, it is clear that IFNλ 
is a preferential IAV treatment option, and that IFNα treatment should only be used 
with caution. IFNα acts on all cells types to induce an excessive immune response 
resulting in a ‘cytokine storm’ and host pathology. IFNλ, owing to its receptor 
distribution, only acts upon the first host cell target of infection to induce a sufficient 
antiviral response within these cells to control infection, without inducing immune-
mediated pathology. 
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Chapter 6. Antiproliferative effect of IFNs on 
regenerating epithelia 
 
6.1 Background 
Since its discovery in 1957, type I IFNs were classically described as antiviral 
cytokines (Isaacs and Lindenmann 1957). However, since it was first described in 
1962, the antiproliferative effect of type I IFNs has been extensively studied 
(Paucker et al. 1963). Paucker and colleagues showed a temporary decline in the 
growth of cells following a 24 hour exposure of L-cells to either IFN or UV-irradiated 
Newcastle Disease Virus (Paucker et al. 1963). Furthermore, IFN addition was 
found to inhibit the growth of the oncogenic Friend virus, Rauscher virus and 
Mouse Sarcoma virus (MSV) along with inhibiting the cellular transformation 
induced by these viruses in vitro (Oxman et al. 1967; Fitzgerald 1969).  
 These mouse studies prompted considerable work on the effects of 
interferon on human malignancies. An example of this translational research is the 
delay in mammary tumour development found when female mice were treated with 
IFN (Came and Moore 1972). Balkwill and colleagues then advanced from there to 
discover that two out of three human breast cancers were susceptible to IFN 
treatment following xenograft implantation in athymic nude mice (Balkwill et al. 
1980). Prompted by these encouraging results, clinical trials were conducted on the 
effect of type I IFN treatment on malignant melanoma, acute granulocytic leukemia, 
multiple myeloma and chronic lymphatic leukemia, all of which displayed some 
tumour regression or delay in tumour growth following IFN treatment. The first 
licensed interferon for anti-tumour applications was IFNα2 for the treatment of Hairy 
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Cell Leukemia (HCL) in 1986 (Golomb et al. 1986). Subsequently, IFNα2a 
(Roferon-A, Hoffman-La Roche, Nutley, NJ) and IFNα2b (Intron-A®, Schering-
Plough, Kenilworth, NJ) have been licensed for the treatment of: Chronic 
Myelogenous Leukemia (Talpaz et al. 1987; Kikawa et al. 1993; Guilhot et al. 2004), 
Follicular Lymphoma (Aurora and Winter 2006), Malignant Melanoma (Sabel and 
Sondak 2003), and AIDS-Related Kaposi’s Sarcoma (Krown et al. 2002). 
 The mechanism(s) by which these IFNs induce their antiproliferative effects 
have yet to be fully elucidated and are a matter of continuous study. Type I IFNs 
are known to affect different phases of the mitotic cell cycle, specifically during the 
S phase in solid tumours and G1 arrest in Daudi Burkitt’s lymphoma cells (Roos et 
al. 1984; Garrison et al. 1996; Qin et al. 2001). The downregulation of the 
transcription factor c-myc by type I IFN was also found to induce cell-cycle arrest 
(Einat et al. 1985). Furthermore, IFN treatment was shown to upregulate the 
tumour suppressor gene p53 which is known to initiate cycle-arrest or apoptotic 
pathways (Oren 1994; Takaoka et al. 2003). Other pro-apoptotic effect of IFNs are 
the upregulation of apoptotic proteins such as DR5 and TRAIL resulting in 
apoptosis of DR5 expressing cells (Herold et al. 2008; Davidson et al. 2014). 
Not only can IFNs be directly antiproliferative or pro-apoptotic but they can 
also result in modulation of growth factor expression. Epidermal growth factors 
(EGF) and fibroblast growth factors (FGF) are required for the proliferation of cells, 
which is particularly important for repair. The production of basic fibroblast growth 
factor (bFGF) and vascular endothelial growth factor (VEGF) was found to be 
reduced following IFN treatment (Singh et al. 1995; Marshall and Swain 2011). 
Growth factors of the EGF family exert their action through the Epidermal Growth 
Factor Receptor (EGFR) and IFNα treatment of renal carcinoma cells was found to 
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downregulate EGFR to induce its antiproliferative effect (Eisenkraft et al. 1991; 
Scambia et al. 1991). In contrast, other studies have found that EGFR expression 
was enhanced following IFNα and IFNβ treatment in some tumour cells, which 
antagonized the antiproliferative effect of type I IFNs (Martyré et al. 1990; Caraglia 
et al. 1995; Yang et al. 2004). These conflicting reports may be due to the different 
cancer cells studied, different IFNα subtype and concentrations used, and also 
different timings of treatments. Nonetheless, Zoon et al. also found that IFNα 
treatment reduced the ability of EGF to bind to EGFR leading to the antiproliferative 
effect of IFNα (Zoon et al. 1986). The effect of type I IFN on innate immune cells 
which have cytotoxic effects has already been discussed in Chapter 3. Whether it is 
anti-proliferative, pro-apoptotic, immunmodulatory effects, or a combination of all 
three that underlie the anti-tumour action of IFN is not precisely known, and the 
effect of type I IFN to elicit these mechanisms may change according to the type of 
tumour and the varying responsiveness of different cell types to type I IFN.  
 The recently discovered type III IFNs (Kotenko et al. 2002), IFNλ1 (IL-29), 
IFNλ2 (IL28A), IFNλ3 (IL28B) and IFNλ4 have previously been discussed to induce 
the same signalling pathways as the type I IFNs, and their antiproliferative and anti-
tumour abilities have recently gained attention (Dumoutier et al. 2004; Brand 2005; 
Maher et al. 2014). The mechanisms of the antiproliferative effects of IFNλ are still 
unclear, and have not been as extensively researched as type I IFN effects. Not 
only was IFNλ found to be antiviral against murine cytomegalo virus (MCMV), but 
was also found to decrease the proliferation of intestinal epithelial cells in vitro 
without an effect on apoptosis (Brand 2005). Maher and colleagues found that IFNλ 
treatment resulted in stronger and prolonged downstream signalling compared to 
IFNα treatment, and in contrast to the previous study, this prolonged signalling 
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resulted in apoptosis rather than growth inhibition of human keratinocyte HaCaT 
cell line (Maher et al. 2014). This divergence in results could be due to the different 
cell types studied: intestinal epithelial cells and keratinocytes, in which IFNλ may be 
mediating different effects. Dumoutier and colleagues did not quantify apoptosis of 
cells but suggest that STAT2 activation is required for the antiproliferative effects of 
IFNλ (Dumoutier et al. 2004). IFNλ as an anti-tumour treatment has as of yet not 
been employed in clinical trials. 
  A hallmark of influenza is productive infection by IAV and the subsequent 
destruction of the airway epithelium (Mauad et al. 2010). The AECs respond to 
infection by the induction of type I and III IFNs, a family of pleiotropic cytokines 
which subsequently induce antiviral ISGs to control the spread of the virus (Randall 
and Goodbourn 2008; Vareille et al. 2011). Once the virus is eliminated, the airway 
epithelium must undergo extensive mitosis in order to repair and return back to 
homeostasis. Currently, the antiproliferative effects of IFNs have largely only been 
studied as anti-tumour therapies. However, the known antiproliferative effect of 
IFNs poses the question of whether it can affect the repair of lung AECs, which at 
present has not been assessed. As repair of the lung epithelium after infection is 
essential, the prolonged presence of IFNs with antiproliferative and pro-apoptotic 
effects may therefore prove to be detrimental to the host. The genetic contribution 
to this repair process has already been discussed in Chapter 4 where 129S8 mice 
were shown to have reduced ability to repair following injury. Since these mice are 
known to be high type I IFN producers (Davidson et al. 2014), how this repair 
process is affected in the presence of high type I IFN levels is of interest. Due to 
the tissue tropism of IFNλR, the role of IFNλ on regenerating epithelia becomes 
particularly intriguing since IFNλ acts primarily on AECs, and shown in Chapter 5 it 
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is the most suitable antiviral therapeutic in IAV infection. Could the additional 
exogenous IFNλ treatment potentially disrupt repair of AECs? As such the effect of 
type I and type III IFNs on regenerating AECs was assessed. 
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6.2 Hypothesis and Aims 
Given the antiproliferative role of type I and III IFNs, their presence may interfere 
with the repair process following IAV-induced lung damage. Any disruption to the 
ability of the lung to repair could lead to impaired lung function, or could potentially 
leave the host vulnerable to other pathogens. Both of the scenarios could lead to 
increased morbidity and mortality of the host. Plating of AECs can be considered a 
model of epithelial repair, a process to reach confluence again and differentiate into 
the constituent cell types. To determine the antiproliferative effect on the repair 
process of epithelia, type I and III IFNs will be added to C57BL/6 AEC cultures from 
start of culture. 
 
I hypothesize that the addition of type I and III IFNs to growing epithelia will inhibit 
the growth of the AECs through a reduction in EGF signalling. 
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6.3 Results 
6.3.1 Antiproliferative and remodelling effects of IFNs on regenerating AECs 
Before the antiproliferative effects of type I and III IFNs can be tested and 
compared on regenerating epithelia, equivalent amounts of IFNα, IFNβ and IFNλ 
must be determined. The mouse IFNλ used in Chapter 5 was purified and 
generously gifted by Dr R. Hartmann, whereas the IFNλ used for this Chapter (and 
also in Chapter 3) was purchased from R&D systems. Therefore, another serial 
dilution of the three IFNs to assess equivalent induction of ISGs was performed 
(Figure 38). The serial dilutions were not performed concurrently. AECs were 
treated with a serial dilution of either IFNα or IFNβ (Figure 38A), or treated with a 
serial dilution of either IFNβ or IFNλ (Figure 38B). All AECs respond to the three 
types of IFN by their induction of Rsad2, Oasl2 and ifi203. The dose response 
curves were then used to determine EC50 values, which allowed for generation of 
a conversion ratio of equipotency as per Chapter 5, Figure 30. The conversion ratio 
for IFNα:IFNβ:IFNλ is 2:1:1 (U/ml:U/ml:ng/ml). 
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Figure 38 Determination of equivalent doses of type I and III IFNs 
C57BL/6 AECs were stimulated for 4hrs with a serial dilution of IFNα4, IFNβ or 
Media Ctrl (A), and IFNβ, IFNλ or Media Ctrl (B), and induction of ISGs were 
assessed by qPCR. Prism 6 software was used to perform a curve fit (Sigmoidal, 
4PL), and generate a dose response curve and a half-maximal effective 
concentration (EC50) for each gene assessed for each treatment. A conversion ratio 
was then generated using the formula from Figure 29 for each ISG and a final 
conversion ratio was calculated as the geometric mean of all ISGs conversion 
ratios determined. Graphs show means ± SEM. Data is pooled from 10 
independent experiments, n=5-34 (A). Data is representative of 8 independent 
experiments, n=3-17 (B). 
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 To determine the antiproliferative effect of type I and III IFNs, cells on 
regenerating airway epithelia, cells were digested out of the trachea and plated in 
the presence of IFNα, IFNβ, IFNλ or Media Ctrl (Figure 39A). Upon treatment with 
a serial dilution of IFNβ or IFNλ we find the AECs were unable to reach confluence 
at any concentration used. However, this effect was not seen when an IFNα 
concentration equivalent to the highest IFNβ or IFNλ concentration was used, i.e. 
60 U/ml IFNα versus 30 U/ml IFNβ and 30 ng/ml IFNλ. (Figure 39B). This effect 
also correlates with a reduction in cell number on day 14 of culture (Figure 39C). 
Digesting cells out of the trachea and subsequent plating results in the outgrowth of 
an initially small subset of basal cells, while differentiated cells most likely undergo 
apoptosis after plating. These initially infrequent basal cells proliferate allowing the 
culture to reach confluence. IFNβ and IFNλ addition is preventing this small subset 
of cells from proliferating. Therefore, to generate a culture where the effect of IFNβ 
and IFNλ directly on basal cells can be studied and fully quantified, the cultures 
were allowed to grow as normal without any IFN addition. This allows for the basal 
cells to proliferate unimpeded, resulting in a large subset of basal cells (Figure 
39D). These AECs are digested off the transwells and re-plated at defined numbers 
in the presence of IFNα, IFNβ and IFNλ (Figure 39E). Here we see a similar 
outcome following IFNβ and IFNλ addition during growth, although the effect is 
somewhat diminished, which is most likely due to the increased number of basal 
cells being plated per well with this approach. A subset of cultures do not reach 
confluence, which correlates with a reduction in cell number (Figure 39F, G). 
However, some cultures can reach confluence when the cell number is increased, 
although the time taken to reach confluence is slower and total cell number is lower 
than in the Media Ctrl and the IFNα treated cultures (Figure 39F, G). 
Chapter 6. Results 
 
219 
 
 
Figure 39 IFNβ and IFNλ prevent the AECs from proliferating and reaching 
confluence 
Tracheas from C57BL6 mice were digested, plated and treated with IFNα, IFNβ or 
IFNλ (A). Time taken to reach confluence (B) and cell number was quantified on 
day 14 after plating (C). Percentage of basal cells from cells digested out of trachea 
before plating (d0) and after the cultures are fully-grown (d14) was quantified by 
Flow Cytometry (D). AECs were grown as normal for 14 days then digested and re-
plated in the presence of IFNα, IFNβ and IFNλ (E). Time taken to reach confluence 
(F) and cell number was quantified at the end of the experiment (F). Significance 
was assessed by unpaired t tests where **** P<0.0001. Graphs show means ± 
SEM. Data is pooled from 2 independent experiments, n=3-11 (B, C), n=4-15 (D). 
Data is pooled from 8 independent experiments, n=7-24 (F, G). 
 
B
- 60 30 30 10 5 30 10 5
0
5
10
15
20
End of experiment
D
ay
s 
to
 c
on
flu
en
ce
Days to confluence
IFNα
(U/ml)
IFNβ
(U/ml)
IFNλ
(ng/ml)
d0 d14
0
20
40
60
80
%
 s
ub
se
t o
f l
iv
e 
ce
lls
Basal Cells
****
C D
- 90 30 90 30 90 30
0
2000
4000
6000
8000
100000
300000
500000
700000
900000
C
el
l n
um
be
r
Cell number
IFNα
(U/ml)
IFNβ
(U/ml)
IFNλ
(ng/ml)
F
- 90 30 90 30 90 30
0
5
10
15
20
End of experiment
D
ay
s 
to
 c
on
flu
en
ce
IFNα
(U/ml)
IFNβ
(U/ml)
IFNλ
(ng/ml)
Days to confluence
G
Media 60 30 10 5 30 10 5
0
20000
40000
60000
80000
100000
C
el
l n
um
be
r
Cell number
IFNα
(U/ml)
IFNβ
(U/ml)
IFNλ
(ng/ml)
A
E
Chapter 6. Results 
 
220 
 
 To further characterize the effect of IFN addition on the different developing 
cell types in the AECs, the re-plated cultures were analysed by flow cytometry as 
per Chapter 4, Figure 25. When equivalent amounts of the three IFNs were 
compared, we see little effect by IFNα on the frequency of basal cells, whereas 
IFNβ and IFNλ reduce the percentage of basal cells in the cultures (Figure 40A), 
with IFNλ inducing a statistically significant decrease. All three IFNs reduce the 
percentage of differentiated cells, with IFNλ again inducing the greatest effect. IFNβ 
induces an increased percentage of CD49f hi single positive cells, while the IFNλ 
induced increase is statistically significant (Figure 40A). These CD49fhi single 
positive cells were observed in Chapter 4 and are as of yet an unknown population. 
To determine if increased concentrations of IFNs change the phenotype further, a 
serial dilution was performed. Equipotent doses between all three IFN subtypes 
were used at the lowest doses: 10 U/ml IFNα, 5 U/ml IFNβ and 5 ng/ml IFNλ, but 
the highest doses were numerically the same. This is due to this experiment being 
carried out before the equipotent doses were determined. Increasing the 
concentration of IFNα does not induce a significant change in AEC subsets; in fact 
IFNα treated cultures generally appear very similar to the Media Ctrl cultures 
(Figure 40B). Although the highest dose of IFNα (270 U/ml) is not equipotent to any 
of the IFNβ and IFNλ doses used here, it is not inducing an effect on the cell 
subsets in comparison its closest equipotent dose of 90 U/ml of IFNβ and 90 ng/ml 
of IFNλ. IFNβ and IFNλ however show a dose dependent response with the highest 
equipotent concentrations having the greatest effect. High IFNβ concentrations 
cause a dramatic decrease in basal cells and an increase in CD49fhi and 
undifferentiated cells (Figure 40C). IFNλ also decreases basal cells and 
differentiated cells, along with an increase in CD49fhi cells (Figure 40D). These 
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effects start at a much lower concentration than with IFNλ than with IFNβ. This 
change in cell subsets is much more dramatically observed in the individual flow 
cytometric analysis plots when equipotent doses of the IFNs are used (Figure 40E). 
Here we see that in the presence of IFNα the different cell subsets are unaffected 
and look very similar to the Media Ctrl. IFNβ and IFNλ however show a loss of 
NGFR/CD49f double positive cells, which we have classified as basal cells (see 
Chapter 4), and a loss in NGFR/CD49f double negative cells, resulting in a 
dramatic loss of differentiated cells (NGFR/CD49f double negative, CD133 /CD66a 
high). There also appears to be a shift of the cells towards the CD49f hi single 
population. These results suggest that IFNβ and IFNλ addition reduces the 
proliferation of basal cells and the differentiation of the basal cells available, 
whereas IFNα does not strongly affect the AECs. IFNλ may have more of an 
antiproliferative potential as it induces a greater effect at lower concentrations 
compared to the concentrations of IFNβ.   
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Figure 40 IFNβ and IFNλ treatment causes remodelling of regenerating AEC 
Quantification of undifferentiated cells, mixed cells, basal cells, differentiated cells 
and CD49fhi cells by flow cytometry on AECs following equivalent doses of IFNα, 
IFNβ or IFNλ from day 0 of re-plating (A). A serial dilution of IFNα was added to re-
plated AECs and the different cell subsets were quantified by flow cytometry (B).  A 
serial dilution of IFNβ was added to re-plated AECs and the different cell subsets 
were quantified by flow cytometry (C).  A serial dilution of IFNα was added to re-
plated AECs and the different cell subsets were quantified by flow cytometry (D).  
Flow cytometry plots representative of one sample from AEC treated with 
equivalent doses of IFNα, IFNβ and IFNλ. The first flow cytometry plot shows how 
the cells are first subdivided for CD49f and NGFR. The second FACs plot is the 
CD49f/NGFR double negative population subdivided for CD133 and CD66a (E). 
Significance was assessed by unpaired t tests. * represents an increase compared  
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 Given the relative reduction of differentiated cells following IFNβ and IFNλ 
treatment, we wanted to define which of the differentiated cells are affected since 
our FACS panel cannot distinguish goblet cells and ciliated cells (see Chapter 4). 
We therefore stained these cultures for β-Tubulin IV, to quantify ciliated cells. 
Ciliated cells were reduced when the highest equivalent concentrations of IFNα, 
IFNβ and IFNλ are used. However, when concentrations are reduced, IFNα and 
IFNβ have less of an effect, whereas IFNλ continues to reduce ciliated cells (Figure 
41A). When this is quantified we see only a significant decrease in ciliated cells 
when the highest concentration of IFNα or IFNβ are used, while, even if the doses 
are equivalently titrated down further, IFNλ is still affecting the ciliated cells (Figure 
41B). This indicates that type I and III IFNs can reduce the differentiation of AECs 
into ciliated cells, with IFNλ having the greatest effect. 
 
 
 
 
 
 
 
 
 
 
 
to the equivalent cell subset from Media Ctrl. O represent a decreased compared to 
the equivalent cell subset from Media Ctrl. * P<0.05, ** P<0.01, *** P<0.001, **** 
P<0.0001. Graphs show means ± SEM. Data is pooled from 6 independent 
experiments, n=2-33 (A-D).  
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Figure 41 IFN addition during growth of AECs reduces the ability to differentiate 
into ciliated cells 
β-tubulin IV staining (white) of re-plated cultures grown in the presence of 
equivalent doses of IFNα, IFNβ, IFNλ or Media Ctrl (A). Quantification of 
percentage area of β-tubulin IV (B). Graph show means ± SEM. Significance was 
assessed by unpaired t tests where * P<0.05. Data representative of 3 independent 
experiments, n=1 (A). Data is pooled from 3 independent experiments, n=2-3 (B).  
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6.3.2 IFN addition to regenerating AECs can induce cell death and apoptosis 
pathways 
It is interesting to see a dose-dependent effect between the three IFNs used, with 
IFNλ having the greatest and IFNα having the least effect on multiciliation and IFNβ 
and IFNλ, but not IFNα, greatly reducing cell number increase. To discern whether 
the set of genes differentially expressed by IFNβ and IFNλ, and not by IFNα, 
correlate with an antiproliferative or apoptotic pathway, we analysed the epithelial 
expression profile in response to IFN exposure. 363 genes are induced in response 
to any of the three IFNs (Figure 42A). However, we see a much greater 
transcriptional response by IFNλ treated AECs (Figure 42A, B). To identify the top 
disease pathways represented by this gene set, the 363 genes were analysed by 
Ingenuity Pathway Analysis (IPA). Many of the top disease pathways induced are 
as expected, such as ‘Infectious disease’ and ‘Immunological disease’, since IFNs 
play a pivotal role in the immunological response (Figure 42C). Of interest however, 
is the appearance of ‘Tissue morphology’ and ‘Cell Death and Survival’ within the 
top disease pathways induced. As the bar chart does not show how these 
pathways are affected, a heat map of the ‘Cell Death and Survival’ pathway was 
created (Figure 42D). Intriguingly, here we see increased induction of apoptosis, 
cell death, necrosis, cytotoxicity (Figure 42D). The gene set associated with this 
increased cell death pathway (Figure 42D) was extracted and is shown in the 
Appendix, Table 7. Further analysis of the pathways induced will be undertaken to 
identify which induced genes are central in the anti-proliferative and/or pro-
apoptotic effects of IFNs on growing epithelia. 
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Figure 42 IFN addition to regenerating epithelia induces many anti-pathogen 
pathways, but can also induces cell death and apoptosis pathways 
Re-plated AECs were treated with IFNα (90 U/ml), IFNβ (90 U/ml), IFNλ (90 
ng/ml) or Media Ctrl from d0 of re-plating for 48 hours. RNA was collected for 
global analysis by Illumina.SingleColor.Mouse WG-6_V2_0_R0_1127 
microarrays. Samples (n=3) were normalized to the median of the Media Ctrl 
group and filtered for a fold change of 2, generating 363 genes differentially 
expressed (A). A Venn diagram was generated using the gene-set from A to 
show the number of genes most differentially expressed by IFNα, IFNβ or IFNλ 
(B).  The top disease pathways associated with the 363 gene-set were 
analysed by Ingenuity Pathway Analysis (C). Cell death and survival was 
amongst the top pathways induced. A heatmap showing the subcategories 
within this pathway and the IFN effect on them is displayed (D) One way  
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 Given that we observe an antiproliferative effect of IFNβ and IFNλ, and not 
of IFNα, we hypothesised that the gene set differentially expressed by the 
combination of IFNβ and IFNλ rather than the set induced by IFNα would be 
inducing the apoptotic pathways seen in Figure 42. We therefore examined the 
whole gene set induced by IFNα and analysed these 94 genes by IPA (Figure 43A). 
Again we see that immunological pathways are amongst the top disease pathways 
induced by IFNα, as expected (Figure 43B). We did not observe the induction of 
the ‘Cell Death and Survival’ pathway. Therefore, we analysed the heat map of the 
cell death and survival pathway and as expected we did not observe the great 
inductions in apoptosis and cell death as was the case in Figure 42D (Figure 43C).    
 As we expected that the gene set commonly expressed by IFNβ and IFNλ is 
inducing the apoptotic pathways, we analysed the 48 genes induced, by IPA also 
(Figure 44A). Many of the top disease pathways (Figure 44B) are unsurprising, and 
again we did not find the induction of the ‘Cell death and Survival’ pathway. The 
heat map for this pathway surprisingly did not show a great effect on apoptosis or 
the other pathways, which could be due to the low number of genes analysed 
(Figure 44C).  
 
 
 
 
 
 
 
ANOVA, P<0.01, Benjamini-Hochberg multiple test correction was carried out. 
Samples were analysed under the supervision of Dr Stefania Crotta. 
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Figure 43 The genes induced by IFNα do not induce the cell death and apoptosis 
pathways 
The Venn diagram from Figure 42 was used to generate the list of genes induced 
by IFNα (A). The 94 genes induced by IFNα was analysed by Ingenuity Pathway 
Analysis to determine the top disease pathways (B). The heatmap of the ‘Cell 
death and Survival pathway’ is displayed (C). 
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Figure 44 The common genes differentially expressed by IFNβ and IFNλ do not 
induce cell death and apoptosis pathways 
The Venn diagram from Figure 42 was used to generate the list of genes 
commonly induced by IFNβ and IFNλ (A). The 48 genes induced by IFNβ and IFNλ 
was analysed by Ingenuity Pathway Analysis to determine the top disease 
pathways (B). The heatmap of the ‘Cell death and Survival pathway’ is displayed 
(C). 
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Although the whole gene set induced by any of the three IFNs does 
associate with an apoptotic pathway within these cells, we do not find that the 
common gene set between IFNβ and IFNλ is responsible for this effect. In an 
alternative analysis, we therefore compared the full gene sets induced by IFNα, 
IFNβ and IFNλ separately and assessed the top disease pathways induced using 
IPA (Figure 45). Many of the top pathways, like before, are unsurprising since IFNs 
are known to induce an ‘Antiviral response’ and ‘Antimicrobial response’. However, 
we see ‘Cell death’, ‘Necrosis’, ‘Organismal death’, and ‘Proliferation of cells’ are 
affected by these IFNs. In fact, we can clearly see that in general IFNλ is having 
the greatest effect on these pathways, with IFNα having little to no effect. This 
confirms our previous findings of a greater antiproliferative effect of IFNλ. More in-
depth analysis of the transcriptional profiles obtained will be required to understand 
by which mechanisms IFNβ and IFNλ block proliferation and differentiation. 
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Figure 45 The top disease pathways induced by IFNα, IFNβ and IFNλ separately 
The total gene sets of IFNα, IFNβ and IFNλ treatment from Figure 42 were 
separately analysed and compared for the top disease pathways using Ingenuity 
Pathway Analysis. 
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6.3.3 Blockade of EGFR by IFNβ and IFNλ  
Given that we do not find the induction of an apoptotic pathway by the gene set 
differentially expressed commonly by IFNβ and IFNλ, we postulated that these 
IFNs may be antagonising a pathway required for these AECs to grow. As EGF is 
essential for the growth of AECs (Selman 2006) and is part of the culture medium, 
the addition of IFN could potentially block this signalling pathway. Zoon and 
colleagues showed that IFNα treatment of MDCK cells reduced the ability of EGF 
to bind to its receptor, EGFR (Zoon et al. 1986). WT C57BL/6 and Ifnar-/- cultures 
were grown and starved of EGF, then re-exposed to EGF in the presence or 
absence of IFNα, IFNβ or IFNλ (Figure 46). In the WT AECs, EGF addition alone 
induces phosphorylation of the EGFR as expected. This is unaffected by IFNα. 
However, both IFNβ and IFNλ significantly block the phosphorylation of EGFR (p-
EGFR) (Figure 46A, C). Total EGFR protein (T-EGFR) also appears to be reduced 
by IFNβ and IFNλ (Figure 46A, D). Quantifying the fold change of p-EGFR over T-
EGFR shows that even though the T-EGFR is reduced by IFNβ and IFNλ, only 
IFNλ induces a significant reduction of p-EGFR (Figure 46E). In the Ifnar-/- AECs, 
this block in phosphorylation of EGFR by IFNβ is not observed, as expected. 
Interestingly we did not see a reduction in phosphorylation of EGFR by IFNλ 
addition either, which is unexpected (Figure 46B, C). In fact the phosphorylation of 
EGFR appears to be increased by IFNλ, although this is not significant. T-EGFR is 
also not affected by any IFN in the Ifnar-/- (Figure 46C, D), and also no significant 
changes are observed when the fold change of p-EGFR over T-EGFR is analysed 
(Figure 46E). These results suggest that IFNβ and to a greater extent IFNλ, block 
the phosphorylation of EGFR, thus preventing the epithelia from proliferating. 
These results also suggest that IFNλ acts through the IFNαβR, maybe by inducing 
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type I IFNs or another downstream factor which is signalling through the type I 
receptor. Further studies will allow us to understand better the requirement of 
IFNαβR for IFNλ suppression of epithelial cell proliferation. 
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Figure 46 IFNβ and IFNλ block EGFR phosphorylation, which does not occur in 
Ifnar-/- AECs 
AECs from WT and Ifnar-/- mice were starved of EGF on d4 post ALI for 24 hours, 
and then treated with equivalent doses of IFNα, IFNβ, IFNλ for 2 hours, then with 
EGF for another 2 hours. Samples were collected from for the detection of p-
EGFR, T-EGFR and β-actin proteins by western blot. A representative blot from 
WT (A) and Ifnar-/- (B). A and B show 3 biological repeats per condition. The fold 
change in p-EGFR/β-actin (C), T-EGFR/β-actin (D) and p-EGFR/T-EGFR (E) was 
analysed. Graph show means ± SEM. Significance was assessed by unpaired t 
tests where * P<0.05, ** P<0.01. Data representative of 2 independent 
experiments, n=5 (C-E). 
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6.4 Conclusions and Discussion 
Following lung damage induced during IAV infection, the airway epithelium must 
regenerate to return to homeostasis. However, cytokines present within the lung 
following IAV infection, such as IFNs, may affect this regeneration process. A 
hallmark of lung disease is the remodelling of the lung leading to goblet cell 
metaplasia (Fahy and Dickey 2010; Danahay et al. 2015). Here we have shown in 
vitro that IFNs, a family of cytokines induced by IAV infection, can reduce the 
overall cell numbers and number of basal cells within the epithelia, and induce pro-
apoptotic pathways. We need to determine however if these lower cell numbers are 
due to decreased proliferation or increased apoptosis. IFNs also promote 
remodelling during regeneration of the airway epithelia by decreasing the 
differentiation of the basal cells. Our data suggest that IFNs may mediate these 
effects through blocking the epidermal growth factor pathway. 
 IFNα has been extensively used as an antiproliferative agent against 
tumours (Talpaz et al. 1987; Kikawa et al. 1993; Krown et al. 2002; Sabel and 
Sondak 2003; Guilhot et al. 2004; Aurora and Winter 2006). However, in our 
system IFNα did not affect basal cell numbers and did not block the 
phosphorylation of EGFR, unlike IFNβ and IFNλ. We utilized IFNα4 for this study, 
which is only one of eleven IFNα subtypes. It remains possible that we may not be 
using the right IFNα here, and other subtypes of IFNα should be used to see if they 
induce this effect. Other studies also found that IFNα did not downregulate EGFR, 
but rather enhanced its expression (Caraglia et al. 1995). We did not observe an 
increase of receptor levels, but this could be due to Caraglia and colleagues 
utilizing a human oropharyngeal epidermoid carcinoma KB cell line that may be 
responding to IFNα differently. Caraglia et al. also do not specify which subtype of 
Chapter 6. Results 
 
236 
 
IFNα they used in these studies. EGF addition although was found to exacerbate 
IFNα induced barrier disruption of LLC-PK1 porcine proximal tubular cells (Lechner 
et al. 2007). IFNβ however did elicit a greater antiproliferative effect than IFNα in 
regenerating AECs by significantly reducing the basal cell number and blocking 
EGFR phosphorylation. IFNβ was also seen to induce a ‘Cell death’ pathway within 
the regenerating epithelial, whereas again IFNα did not. These differing effects 
between the type I IFNs could be due to affinity for their corresponding receptors. 
IFNβ was found to have an approximately 50 fold higher affinity for IFNAR than 
IFNα2 (Lamken et al. 2004; Gavutis et al. 2005). Another study linked this higher 
affinity to increased antiproliferative effects (Jaitin et al. 2006). Type I IFNs are 
known to disrupt the cell cycle thus exerting their antiproliferative effect. Although 
recently, another mechanism has been proposed whereby type I IFNs activation of 
β-catenin lead to reduced proliferation of intestinal epithelial cells (Katlinskaya et al. 
2016). The blocking effect of type I IFNs on the EGFR pathway has to our 
knowledge not been shown before. 
The interest into the antiproliferative effect of IFNλ has gained momentum 
since its discovery in 2002 (Kotenko et al. 2002; Brand 2005; Maher et al. 2014). 
Since its discovery is more recent than that of type I IFNs, little is known about the 
antiproliferative mechanisms induced by IFNλ. Of the three IFNs, IFNλ induced the 
greatest antiproliferative effect on the basal cells, and induced more strongly the 
‘Cell death’ pathway as defined by IPA. The R&D IFNλ solution we used for this 
Chapter includes IFNλ3 and IFNλ2. Interestingly, IFNλ3 has been shown in the 
literature to induce greater expression of ISGs than IFNα following viral stimulation 
(Egli et al. 2014). A number of explanations have been put forward to account for 
this reported difference, including transcription factor differences; the presence of 
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SNPs regulating IFNλ expression or activity; receptor expression regulation; 
receptor binding affinity and feedback loops (Egli et al. 2014). A greater 
antiproliferative effect of IFNλ1 over IFNα-2a was found on a human keratinocyte 
cell line HaCaT by Maher and colleagues, who attributed this effect to prolonged 
JAK/STAT signalling (Maher et al. 2014).  
In our transcriptional analysis, we observed more genes differentially 
expressed by IFNλ than the other IFNs, in the face of a careful titration performed 
initially. This discrepancy needs to be resolved and may have to do with the fact 
that the initial titration was done on cultures grown to confluence from tracheal cells 
ex vivo, whereas the expression profiling was performed on expanding cultures 
started by replating low numbers of mTEC cells (as explained in Figure 39A versus 
E), to have a predictable and high content of growing basal cells. These latter 
culture conditions may lead to a higher IFNλ responsiveness, which may happen 
during proliferation of basal cells, or basal cells per se are more responsive to IFNλ 
than more differentiated cells. More work is needed to understand if IFNλ 
responsiveness differs between airway epithelial cell types or within basal cells 
during expansion versus confluence. 
We found IFNλ and IFNβ, but not IFNα, blocked phosphorylation of EGFR and total 
EGFR protein. There is conflicting reports on the action of type I IFNs on EGFR 
expression, but the effect of IFNλ on EGFR expression has not yet been studied 
(Martyré et al. 1990; Eisenkraft et al. 1991; Scambia et al. 1991; Caraglia et al. 
1995; Yang et al. 2004). EGF and EGFR are required to regulate epithelial repair 
and therefore IFN blockade of this signalling pathway would be detrimental to 
repairing epithelia (Selman et al. 2008). IFNα or IFNβ treatment of Ifnar-/- AECs did 
not block the phosphorylation of EGFR. Interestingly, when the Ifnar-/- AECs were 
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treated with IFNs and tested for phosphorylation of the EGFR, no IFN type induced 
this blockade. This would imply that IFNλ mediates its effect through the type I 
receptor. To ensure that this is indeed the case, AECs from IL28R-/- and 
Ifnar/IL28R-/- AEC should also be utilized. Furthermore, these four genotypes of 
AECs should be assessed for their ability to reach confluence and the effect on the 
different cell subsets following growth with IFNs. One study which ablated Ifnar1-/- 
specifically in the intestinal epithelial cells, found an increase in proliferating cells 
(Tschurtschenthaler et al. 2014), which along with our results suggests that type I 
IFN antagonizes epithelial growth and is potentially detrimental during epithelial 
wound healing. Overall, our results indicate that IFNβ and IFNλ can prevent wound 
healing through a blockade of EGF signalling. 
EGF is just one member of the epithelial repair family. Amphiregulin, 
transforming growth factor-α (TGFα), betacellulin, heparin-binding like EGF-factor, 
and epiregulin (EREG) are all ligands for EGFR (Yarom and Jonker 2011). 
Interestingly, the set of genes induced by any IFN treatment contains the gene for 
FGFR, which was downregulated. This is interesting as FGFR2b is expressed on 
epithelial cells and Fgf10, which signals through FGFR2b, can counteract IAV-
induced repair failure to restore barrier function in the lower lung (Igarashi et al. 
1998; Braun et al. 2004; Quantius et al. 2016). NGFR, a growth factor receptor, is 
also clearly downregulated by IFNβ and IFNλ as seen by flow cytometric analysis. 
These results may therefore highlight that IFN treatment not only blocks EGFR 
signalling, but can also potentially block other growth factor receptors. Blockade of 
EGFR has been found to induce increased secretion of amphiregulin and TGFα in 
colorectal cancer cells, protecting cells from the effect of EGFR blockade (Hobor et 
al. 2014). GM-CSF and IL-22 have also been identified as contributing to lung 
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repair following IAV induced damage (Wolk et al. 2004; Pociask et al. 2013; Rösler 
and Herold 2016). The effect of IFNs on these ligands, and vice versa whether 
addition of these ligands abolishes the antiproliferative IFN effects, should be 
determined.  
Not only can IFNs be antiproliferative and pro-apoptotic, but they may also 
drive remodelling of epithelium. This remodelling of the lung is common in many 
airway diseases as discussed in Chapter 4. We showed that IFNα, IFNβ and IFNλ 
had the ability to reduce differentiation of the cells, with IFNλ having the greatest 
effect and IFNα having the least. IFNα and IFNλ were found previously to reduce 
ciliated cells and increase goblet cells in human lung airway epithelia cells 
(Danahay et al. 2015), although IFNβ was not assessed in this system. This paper, 
unlike our results, did not find a discernable difference between the effects of IFNα 
or IFNλ on goblet or ciliated cells, nor did it detect any effect on the basal cells. 
Danahay and colleagues treated fully-grown human 3D epithelial organoid cultures 
and therefore the cultures may not be proliferating greatly, thus reducing the effect 
of the IFNs on the basal cells. Our flow cytometric analysis panel cannot distinguish 
between ciliated and goblet cells and so we do not know the effect on goblet cells 
and whether they are indeed increased here as they are in Danahay et al., 
therefore immunofluorescence staining for goblet cells or PCR analysis of goblet 
cell marker expression in this system would be helpful.  
 For the differentiation to ciliated cells aryl hydrocarbon receptor (AhR), a 
transcription factor best known for mediating the effects of toxins, signalling is 
required (Villa et al. 2016), and Notch signalling must be blocked (Boon et al. 2014). 
IFN may be antagonising or enhancing these signalling pathways respectively. In 
fact, interaction between AhR and type I IFNs has been previously described, 
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whereby AIP (aryl hydrocarbon receptor interacting protein) was found to be a new 
binding partner of IRF7, a key inducer of type I (Zhou et al. 2015) and III IFN 
expression (Osterlund et al. 2007). Administration of IFNβ was found to suppress 
inflammation within the central nervous system through activation of AhR 
(Rothhammer et al. 2016). In the context of a viral infection however, AhR 
signalling negatively regulated the type I IFN driven antiviral response (Yamada et 
al. 2016). Binding of the AhR and IRF7 proteins could potentially inhibit the 
induction of type I and III IFNs and thereby prevent the ciliopathy state induced by 
these IFNs. IFNα was found to block Notch signalling in human bone marrow 
mesenchymal stem cells (Su et al. 2015). Although this is a different cell type that 
is not present in the mTEC cultures, it may indicate why IFNα induces the least 
effect on ciliated cells. However, we do not know if IFNβ and IFNλ can initiate the 
same block on Notch signalling. Furthermore, increasing the concentration of IFNα 
does have an effect on ciliated cells, which may indicate that if the Su et al. study 
does recapitulate in mTEC cultures, higher concentrations of IFNα may supersede 
this blockade.  
 Whether these effects would still be seen in vivo is unknown. To do this we 
first need to set up a model of reproducible lung damage. IAV infection induces 
lung damage but is itself a strong IFN inducer, and thus does not allow for the 
modification of IFN levels independently from damage induction. Naphthalene 
treatment of mice would be a better way to induce reproducible lung damage. 
Naphthalene is a chemical which when metabolized ablates club cells so that 
ciliated cells squamate and cover the basement membrane. The lung epithelium 
must then repair by basal cell proliferation and differentiation. IFN addition to 
naphthalene-induced lung damage could not yet be performed. It is hypothesised 
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that naphthalene will induce damage within the lung, and IFNα will have little effect 
on repair, whereas IFNβ and IFNλ will impair or fully prevent regeneration of the 
lung, resulting in persistent damage. Furthermore, if the epithelia do repair, IFNβ 
and IFNλ could induce a remodelling of the lung resulting in decreased ciliated cells, 
creating an altered cellular composition of the epithelium, which may render the 
host more susceptible to subsequent infection, since there are fewer cilia to 
guarantee mucociliary clearance.  
 Overall, we have shown that the presence of IFNβ and IFNλ, but not IFNα, 
during epithelial repairing prevents proliferation of basal cells, induces a ‘Cell death’ 
pathway, and inhibits differentiation of AECs. We need to determine whether this is 
an antiproliferative or a pro-apoptotic effect and suggest that IFNβ and IFNλ 
mediate this effect through the prevention of EGFR signalling. There are indications 
that FGFR and NGFR are also downregulated in response to IFNs. All three IFNs 
can however induce a remodelled state of the AECs, if the epithelia have enough 
basal cells to grow, resulting in fewer differentiated cells. We observed a striking 
effect of IFN addition in the reduction of ciliated cells. Finally, we found that IFNλ 
induces a greater effect on each of these outcomes. Many fatalities from severe 
IAV infection have been associated with extensive pathology and epithelial damage 
(Herold et al. 2008; Mauad et al. 2010). While much attention is given immune-
mediated damage, we propose here that IFNs produced during viral infection could 
be preventing the lungs from repairing, thus contributing to the increased mortality. 
Furthermore, should the host repair the epithelium, the IFNs present during this 
process may have contributed to ‘remodelling’ of the epithelium, resulting in a 
diseased-prone state, which could potentially lead to susceptibility to other invading 
pathogens.  
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Chapter 7. Conclusions 
This thesis assessed in depth the response of AECs when exposed to different 
pathogens or immune stimuli. We investigated the contribution of AEC responses 
to severe disease caused by IAV-S. pneumoniae co-stimulation. We compared 
AEC responses and cell composition between IAV-resistant and susceptible inbred 
mouse strains. We studied how the restriction of IFNλR expression to AECs allows 
for a better treatment of influenza by IFNλ than by IFNα. Finally, we assessed how 
AEC repair and composition can be significantly affected by IAV-induced IFNs.  
We studied the response of the upper airway epithelial cells in these 
different scenarios and in some cases did not find what we hypothesized. This 
could be due to the lack of other cytokines and immune cells within the in vitro 
system. To better reflect the environment of AECs in vivo, co-culture systems with 
immune cells should be set up to study the different hypothesises posed in 
Chapters 3, 4 and 6. However, a co-culture system is not without its own 
complications. Deciphering which immune cell is responding, or whether the 
response is initiated by the AECs, or by the innate immune cells becomes a 
challenge as it would require re-separating cells prior to analysis. Also, owing to the 
position of the innate immune cells compared to the AECs in vivo (i.e. on the 
airway luminal side, which corresponds to the liquid free upper transwell chamber, 
or the stromal side, which corresponds to the lower, culture-medium filled transwell 
chamber) makes the set up difficult. 
The mTEC culture is a potent experimental system to study the response of 
the upper airway epithelium in isolation, however it too comes with limitations, as 
the cultures can be difficult to grow and can often fail. As the 129S8 AECs show a 
reduction in ciliated cells that is not found in vivo in 129 tracheas during steady 
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state, suggests that plating these cultures may lead to culture not fully reflecting the 
in vivo situation. Effects seen in vitro should always be confirmed in vivo, however 
the massive responses observed in vitro may be diluted when taken in vivo. The 
mTEC system we employed also only represents one type of epithelium: the upper 
airway epithelium. Some disease processes may happen in other lung cell types 
such as endothelia or alveolar epithelia. In fact Teijaro et al. suggest it is the 
endothelial cells that produce the bulk of IFNs following IAV infection and are 
responsible for the cytokine storm found in severe influenza (Teijaro et al. 2011). 
This may explain why we do not find high type I or III IFNs from the 129S8 AECs. 
Since primary influenza infection is an upper respiratory tract infection, we do think 
that mTEC cultures are the most appropriate primary cell model to study influenza-
related responses. 
In Chapter 3 we showed that airway epithelia do respond to both viral and 
bacterial stimulation. Our main hypothesis was that epithelial responses may 
contribute to the severe phenotype of lung damage, high cytokine responses and 
bacterial spread observed in co-infection. We first asked if the antimicrobial 
response by AECs was impaired by the previous virus or IFN exposure. We found 
little to no induction of AMPs by bacterial stimulation alone, which was generally 
not affected by co-stimulation. As we did not see an induction of AMPs, we did not 
pursue this hypothesis further. Future studies could however quantify many more 
AMPs and test bactericidal activity of epithelial supernatants in functional assays. 
We next asked if AECs contribute massively to the high proinflammatory cytokine 
and chemokine signature observed in vivo in response to the combined viral-
bacterial stimulus. We found that the viral stimulation alone drove the response of 
IFNs, ISGs, and the overall transcriptional response from AECs, which was only 
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slightly changed following co-stimulation. We did however see an increased 
proinflammatory cytokine and chemokine induction from the AECs during co-
stimulation in comparison to each single stimulus. Future chemotaxis assays could 
quantify how immune cell recruitment is affected following co-stimulation. Finally, 
we asked whether increased epithelial damage and death is induced by the 
combined stimulus. Much like the AMPs, we found that apoptosis related receptors 
were not induced following either single stimulus nor induced in co-stimulation, and 
the monitoring of mTEC cultures during co-exposure did not indicate major cell 
death occurring. This was however not formally measured by apoptosis assays or 
measurements of epithelial integrity. Overall, we found that the in vitro AEC 
cultures do not closely reflect the effects of co-infection we observe in the lung in 
vivo, however they appear to be contributing to the documented massive increase 
in inflammation and immune cell recruitment during co-infection.  
While this study was being undertaken, a parallel study was being 
performed in vivo within our lab. It was found that one of the drivers of the high 
cytokine response was the massive expansion of bacteria (Ellis et al. 2015). It is 
therefore unlikely that an increased epithelial response to co-stimulus alone 
explains the massively increased cytokine and chemokine production, but rather, 
that higher bacterial numbers in vivo are a main driver of this.  
We did not see an induction or suppression of AMPs during IAV infection 
that could in part explain this massive expansion of bacteria seen in vivo. The in 
vivo model however was carried out on specific pathogen free mice and therefore 
the airways are not free from bacterial colonisation. There is the possibility that it is 
not just S. pneumoniae that is disseminating during co-infection in vivo, and the 
presence of these other bacteria may be contributing to the overall response. The 
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lung flora present at steady state within these mice may also have a priming effect 
on the airway epithelia that gets lost in sterile cell culture conditions. This may 
explain aspects of the reduced responsiveness of mTEC cultures. Furthermore, the 
lack of innate immune cells in the mTEC culture could potentially be another 
reason for this. Innate immune cells can produce IL-22, a member of the IL-10 
cytokine family, which can bind to epithelial cells to induce many AMPs, and can 
augment the expression of S100A8 and S100A9 (Wolk et al. 2004; Liang et al. 
2006). These innate immune cells may also be primed by the lung flora at steady 
state to produce IL-22. However, IL-22 treatment of the epithelial cells alone did not 
induce a great response (data not shown), which may indicate that another 
cytokine is missing. This could potentially be IL-17 as Liang et al. showed that IL-22 
and IL-17 synergised in the production of AMPs (Liang et al. 2006), or the 
combination of IL-22 signals with TLR-mediated signals may be required for AMP 
induction. A co-culture system would allow us to determine the impact of the innate 
immune cells to the AMP response from the AECs.  
Results from the lab also showed that the immune-mediated damage was 
crucial for severity during co-infection. Although we did not find an increase in 
apoptosis related genes, this could also be due to the lack of the innate immune 
cells. pDCs are the main producer of type I IFN which is known to upregulate death 
receptors on the surface of AECs. Co-cultures would therefore allow us to 
determine if in the presence of innate immune cells, apoptosis related receptors are 
induced. 
If we look at the results obtained in Chapter 3 in the context of the findings 
from the thesis as a whole, a range of possible scenarios can be envisaged. A 
study by Kash et al. found a loss in epithelial cell proliferation and lung repair 
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mechanisms following co-infection (Kash et al. 2011). This is reminiscent of the 
results from Chapter 4 and 6. Therefore one could use the mTEC system to 
specifically determine if this loss in epithelial repair function in co-infection is 
orchestrated by the epithelium alone. One could measure epithelial permeability or 
epithelial repair after injuring the epithelia by scratch, or after replating low numbers 
of basal cells in co-exposure conditions, to understand if combined viral and 
bacterial stimuli can impair epithelial repair directly. The findings from Chapter 6 
demonstrate that in the presence of high IFNβ and IFNλ proliferation is hindered, 
leading to reduced repair of the epithelium. Development of differentiated cell 
subsets is also affected, leading to an altered epithelial cell composition. Any 
deviation from normal cell ratios within the lung epithelia can greatly impact the 
mucociliary action in the airways, hindering the ability to remove any pathogens. 
This may explain the increased epithelial damage and outgrowth of bacteria 
observed during co-infection.  
Kash et al. also showed a reduction in the epithelial repair factors HGF and 
FGF levels during co-infection (Kash et al. 2011). In Chapter 6, we describe the 
blocking effect of IFNβ and IFNλ on EGF signalling. Therefore, it would be 
interesting to determine if the reduction of HGF and FGF during co-infection is due 
to these IFNs. Blocking IFNs in vivo could be useful for the prevention of invasion 
of the bacteria. However, there are a number of caveats with this since the timing 
of antiviral vs. antiproliferative effect, and bacterial colonization are unknown. 
Blocking IFNs too early could be detrimental for the antiviral response of the 
immune system, leaving the host vulnerable to an unchecked IAV infection. 
Blocking too late may be superfluous as the damage has already occurred and 
bacteria have already disseminated. 
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IFNs were not the only cytokine reported to cause a remodelling effect. 
Danahay and colleagues reported a variety of cytokines which had an effect on the 
different subsets of the AECs (Danahay et al. 2015). This remodelled epithelium 
can result in ciliopathies or goblet cell metaplasia, which affects the proper 
mucociliary action of the lung. Many of these cytokines have not been tested for 
their antiproliferative abilities. Danahay et al. did not show an effect on basal cells 
by IFNα or IFNλ, yet in Chapter 6 the antiproliferative effect of IFNλ is quite striking. 
Owing to the massive proinflammatory cytokine signature in co-infected mouse 
lungs, there is the possibility that some of these cytokines are also affecting the 
repair of the lung epithelium, thus further increasing epithelial damage, epithelial 
remodelling and augmenting morbidity and mortality. Therefore, testing the 
antiproliferative effect of the described cytokines, and a better understanding of IFN 
effects on secretory cell differentiation, might also be interesting. 
In Chapter 4, we hypothesized that genetic differences at the level of the 
airway epithelium can determine the outcome of disease. We first asked if the high 
IFN response by IAV-susceptible mice, 129S8, was orchestrated or reflected by the 
airway epithelium in response to IAV. We showed that epithelial responses in vitro 
did not recapitulate the in vivo situation. 129S8 AECs induced little to no IFN in 
response to IAV infection. This may be due to the lack of innate immune cells 
within the culture. pDCs were found to be the main producer of IFN during IAV 
infection in vivo (Davidson et al. 2014). pDCs induce IFNs via a TLR7 pathway, 
whereas the AECs respond predominately via the RIG-I pathway (Diebold 2004; 
Lund et al. 2004; Iwasaki and Pillai 2014). These different recognition pathways 
may explain why 129 pDCs produce much higher IFN amounts upon IAV exposure 
than B6 pDCs, while epithelial cells don’t. We next asked if it was epithelial 
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response depended on the responsiveness to IFN and not the induction of it. We 
showed that 129S8 AECs had an increased responsiveness to IFN or IAV infection 
as measured by induction of ISGs and proinflammatory cytokines. However, we did 
not see any induction of death receptors following IAV infection. Again this could be 
explained by insufficient amounts of IFN induced by the epithelium itself and the 
lack of innate immune cells which can produce IFN in the culture system. It is also 
possible that other cytokines that are required for the induction of death receptors 
are missing from the in vitro culture system. Interestingly, the media control of the 
129S8 AECs had a higher resting state level of DR5 and FAS. Finally, we asked if 
the 129S8 epithelium had a reduced potential to repair following injury. We found 
that this was indeed the case. Additionally, the 129S8 AECs showed an altered 
cellular composition, displaying less basal and differentiated cells, reminiscent of 
remodeling in chronic disease states. 
Taking these findings together with other results in this thesis, it would be 
interesting to investigate if the higher levels of apoptosis-related receptors in the 
uninfected AECs is due to the regeneration process after plating, and therefore 
may not reflect the quiescent state in vivo. This apoptotic-prone state of the 129S8 
also fits with the decreased ability to repair. Since 129S8 AECs are taken from a 
high IFN producer, and cell damage is known to induce IFNs (Yu et al. 2015), could 
there be a higher tonic level of IFNs during the growth of the AECs, thus reducing 
the ability to grow and affecting the different cell subsets? We did not observe any 
IFN production by the 129S8 at resting state, but we do see slightly higher ISG 
levels. This was however analysed on fully differentiated AECs and as such the 
IFNs potentially present during growth are unknown. Furthermore, we have shown 
that even in the presence of low concentrations of IFNλ, the antiproliferative effect 
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can still be seen, thus the IFN amounts required to induce these processes may be 
below the limit of detection by ELISA. This is also corroborated by the slightly 
higher ISG expression on steady state 129S8 AECs.  
The fully differentiated 129 epithelium has reduced basal and differentiated 
cells compared to C57BL/6. It would be interesting to analyse if the lack of IFN 
production following IAV infection from these cells is due to this remodelling, thus 
leaving the AECs open to an unchecked IAV infection. The production of IFN was 
found to be somewhat decreased in AECs from patients with chronic lung diseases, 
such as COPD and cystic fibrosis, which have a remodelled state of the lung 
(Zheng et al. 2003; Mallia et al. 2011). It is unknown if the ability to produce IFNs in 
response to IAV infection varies between basal and differentiated cell subsets. It is 
also not known how long this remodelling lasts, or whether the AECs will stay 
remodelled. Further quantification of the cell subsets over time should therefore be 
undertaken. Although we showed that the different cell subsets do not appear to be 
affected in naïve 129S8 tracheas ex vivo, a more in-depth study is required to see 
if there are less basal and differentiated cells during steady state or even after 
infection in vivo compared to C57BL/6 mice. 
Blocking IFN during 129 AECs growth/repair could prevent the 
antiproliferative effect and allow for normal AEC homeostasis. However, 129 Ifnar-
/- AECs do not grow (data not shown). This may show that although high IFN levels 
can block growth, no IFN at all is also not conducive to growth of the AECs. The 
ifnar-/- may also have a tonic signal of IFNλ, which was shown to be the most 
potent IFN affecting AEC growth and differentiation. Therefore a blocking antibody 
against IFNλ may be helpful in this system. Alternatively, this growth defect could 
also be potentially due to a separate factor missing in 129 cultures, unconnected to 
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IFN, which is required for growth. Given these genetic differences observed 
between C57BL/6 mice and 129S8 mice, the 129S8 mice could potentially be more 
susceptible to not only primary IAV infection but also to co-infection. Utilising the 
129S8 epithelium may therefore indicate how an individual with a remodelled lung, 
such as in severe asthma, cystic fibrosis, or COPD, are more susceptible to co-
infections (Wark et al. 2013), thus allowing for better understanding and possible 
treatments. 
In Chapter 5, we hypothesized and confirmed that the restriction of IFNλ 
responsiveness and productive IAV replication to AECs allows IFNλ to limit IAV 
spread through antiviral gene induction in the relevant cells, without over 
stimulating the immune system and driving immunopathology as seen with IFNα. 
We therefore propose IFNλ as a superior treatment option for human IAV infection. 
 Along with the experiments proposed in Chapter 5, it would be of interest to 
stain for Mx1 protein in the lung, as has been elegantly shown in the intestinal tract 
of mice following treatment with IFNα and IFNλ (Mahlakoiv et al. 2015). Staining for 
Mx1 in the gut allowed Mahlakoiv et al. to show a compartmentalised IFN system, 
where the epithelium respond primarily to IFNλ, and other cell types require IFNαβ 
for induction of their antiviral defence. Staining of lung sections after IFNα or IFNλ 
treatment may allow us to identify if the immune cells are responding to IFNλ. 
Although we utilised both mouse and human cells, a translation of this study 
into ferrets would provide a better confirmation of the usefulness of IFNλ as a 
treatment option, as ferrets are considered a more clinically relevant model of IAV 
due to the distribution of sialic acid species on their lung epithelia which more 
closely reflects that of human AECs (Jayaraman et al. 2012). The ability of ferrets 
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to transmit the virus from one another could also theoretically highlight the 
effectiveness of IFNλ in preventing transmission (Herlocher et al. 2001). 
 IFNλ treatment reduces IAV-induced apoptosis of the AECs (Davidson et al. 
2016). However our results in Chapter 6 emphasise the importance of a strict 
treatment regime. IFNλ treatment should be stopped before repair of the lung 
commences to prevent the antiproliferative and remodelling effects of IFNλ from 
having deleterious outcomes. Since this effect is not observed by IFNα, it could be 
proposed that IFNλ should be only be used as a treatment early in infection shortly 
after onset of symptoms, and then replaced with small doses of IFNα, low enough 
to not induce immunopathology, but to ensure full IAV clearance without affecting 
repair of the lung. Unfortunately, the exact timings of this would be difficult to 
determine in a clinical setting, due to the fact that time of infection is mostly difficult 
to determine when patients present with their symptoms. Furthermore, given the 
increased AEC apoptosis following IAV in 129S8 mice (Davidson et al. 2014), and 
a lower ability to repair, the exogenous IFNλ may be exacerbate this apoptosis and 
reduce repair in patients that are represented by the 129S8 type of response to 
influenza. Since in vitro, 129S8 mTECs show changes in cellular composition that 
are reminiscent of those observed in human lung diseases, further careful study is 
required to elucidate how IFNλ treatment will affect the AECs of such patients. 
 The IFN-linked susceptibility difference between C57BL/6 and 129S8 mice 
may be due to timing of IFN induction rather than the total IFN amounts, as 129S8 
mice have prolonged IFN during IAV infection (Davidson et al. 2014). This 
prolonged IFN production in 129 mice could therefore hinder repair. To decipher if 
this is the case, treating IAV infected mice with IFNα or IFNλ only early or only late 
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during infection mice may allow a better understanding of the effect of mistimed 
IFN production clashing with repair processes. 
In Chapter 6, we hypothesised that the antiproliferative effects of IFNs would 
inhibit repair of AECs by restricting EGF signalling. We have shown that IFNβ and 
IFNλ have an antiproliferative or pro-apoptotic effect on repairing AECs whereas 
IFNα does not. We suggest that IFNβ and IFNλ mediate this effect through the 
prevention of EGFR signalling. All three IFNs can induce a remodelled state of the 
AECs, resulting in less differentiated cells. Finally, we show that IFNλ induces a 
greater effect on each of these outcomes. These effects may be especially relevant 
in high IFN producing individuals. During IAV infection of 129 mice, there is a 
second peak in IFN levels around day 6 post IAV infection (Davidson et al. 2014), a 
time in which the lung epithelium may have started to repair. Presence of these 
IFNs may disrupt the repair process leading to increased lung leakiness and 
potentially mortality of the host. Therefore, it may be beneficial to block IFNs during 
this time to allow for the lung to repair.  
These preliminary results need further work to understand the importance in 
vivo of the effects of IFNs and their mechanisms of action. We also do not yet know 
if IFNs specifically block only EGF and not other growth factors, such as FGF and 
amphiregulin, therefore these other growth factors need to be tested. GM-CSF, 
amphiregulin, and IL-22 have also been shown to be required for repair of the lung 
following IAV infection (Monticelli et al. 2011; Pociask et al. 2013; Rösler and 
Herold 2016). These cytokines are mostly induced by innate immune cells and 
therefore the mTEC system cannot fully model these effects without setting up a 
co-culture system or adding these cytokines to the culture. The effect of IFNs on 
GM-CSF and IL-22 should hence be tested in vivo. It is not known whether 
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blockade of only one of these growth factors is sufficient for prevention of repair or 
if a blockade in all is required in vivo. 
Type I IFNs have been shown to activate non-epithelial cells which respond 
by promoting increased epithelial cell proliferation and wound repair through the 
induction of the ISGs Apolipoprotein L9a and b (Sun et al. 2015). It may therefore 
be possible that the antiproliferative effect of IFNβ or IFNλ could be counteracted 
by this immune cell-induced signal for cell proliferation. This would be very 
interesting, and a co-culture system here would allow for further investigation into 
this. 
 Overall, we have shown in this thesis that airway epithelial responses to 
bacterial-viral co-exposure reflect some of the synergistic effects found in vivo in 
co-infection, in particular with respect to increased production of proinflammatory 
cytokines and chemokines. The AECs can also respond differently to infections 
depending on the host genetic background, which may contribute to reduced ability 
to repair the damage caused by IAV infections. Regeneration of the AECs in these 
individuals may also lead to a change in the cellular makeup of the epithelium 
which somewhat reflects the remodelling found in chronic inflammatory lung 
diseases. This remodelled state may affect the function of the lung and lead to 
increased susceptibility to other infections. The restriction of the IFNλR to the AECs 
also allows for a targeted treatment against IAV with IFNλ, which would not induce 
immunopathology as seen with IFNα. Finally, we have shown that IFNβ and IFNλ 
can affect the ability of the AECs to regenerate by blocking EGF signalling. The 
three IFNs tested can reduce basal and differentiated cells, with IFNλ inducing the 
greatest effect. These results show that studying epithelial responses and repair in 
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different scenarios can further our understanding of disease severity in lung 
infection and inflammation. 
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Chapter 8. Appendix 
RIPA Buffer Concentration 
TrisHCL 50 mM (pH 8) 
NaCL 150 mM 
EDTA 1 mM 
EGTA 1 mM 
Ne4P2O7 2.5 mM 
NeF 1 mM 
Ne3VO4 1 mM 
Trition-X-100 1% 
SDS 0.30% 
Protease 
inhibitors 1% 
Water   
Table 1 The constituents of Ripa Buffer 
 
 
Antigen 
Fluorochome 
Conjugate Company 
CD133 PerCp-eFluor® 710 eBioscience 
CD49f PE-Cyanine7 eBioscience 
CD66a APC eBioscience 
EdU Alexa 488 
Click-iT® EdU 
ThermoFisher 
NGFR FITC 
Advanced Targeting 
Systems 
Zombie 
live/dead Violet laser Biolegend 
Table 2 Flow cytometry antibodies for mTEC stains 
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Antigen 
Fluorochome 
Conjugate Company 
CD133 PerCp-eFluor® 710 eBioscience 
CD45.2 Pacific blue Biolegend 
CD66a APC eBioscience 
EdU Alexa 488 
Click-iT® EdU 
ThermoFisher 
Ep CAM APC-Cy7 Biolegend 
Zombie 
live/dead Violet laser Biolegend 
Table 3 Flow cytometry antibodies for whole lung stains 
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Table 4 List of the genes differentially expressed by co-exposed AECs 
compared to LPS or IAV exposure alone in Figure 16 
Symbol 
FC ([X31+LPS] vs. 
[mock]) 
4833436C18Rik -6.616498 
Itln2 -1.4508847 
2900009C16Rik -4.8684654 
Gstp2 -4.061549 
Kcnab2 -12.71074 
D930036B08Rik 18.017847 
2010001J22Rik -63.868076 
2010001J22Rik -24.506163 
Nfkbie 12.563931 
Nfkbie 17.378511 
Tmem171 26.628689 
Ldlr 5.5615287 
LOC237296 -17.377806 
4930449E07Rik -47.04908 
1700019F09Rik -36.782623 
Rorc -3.8320642 
Tcte1 -25.223228 
Cysltr1 -3.1573703 
2810022L02Rik 32.489597 
Galm -4.668308 
Plekha7 5.395251 
Ifi205 21.468693 
Ifi205 25.575924 
Ifi205 38.706608 
Ifi205 10.88376 
Fhad1 -4.909529 
H2-Bf 83.555016 
Timp4 -10.896376 
Iqca -17.10718 
A430065P05 111.68383 
Purg -1.1545076 
Spag8 -7.7218614 
Scgb3a2 -9.744204 
Ldlr 4.163194 
Plunc -4.050612 
Mpv17l -2.3889432 
0610010F05Rik -11.703206 
4930579J09Rik -37.58956 
Fxyd2 -106.14038 
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Aox3 -14.553607 
Cat -7.6073117 
1700011C14Rik -10.53248 
Cdsn 219.21442 
5930430M20Rik -13.364306 
Ehd1 4.3305926 
1700001C02Rik -48.244984 
B930008I02Rik -24.080448 
LOC381916 -15.685317 
Zbp1 64.08602 
Gsta1 -5.635457 
Gsta1 -6.7499123 
Slc26a4 45.52734 
BC013491 -20.588362 
Galc -2.4716873 
Gsdmdc1 9.479608 
Gsdmdc1 27.47724 
Jundm2 3.7208228 
Piga 7.6550226 
LOC434484 87.84375 
Tnf 90.47961 
Vcam1 23.509392 
Slc2a9 -2.2003636 
Gm1661 -112.55427 
LOC240672 14.989548 
BC038167 -24.324547 
Tnfrsf11b 9.097863 
Zzz3 -2.6000457 
Cxcl1 55.917324 
F630022B06Rik 11.188072 
LOC381256 -3.591229 
2900016B01Rik -19.04787 
Mlf1 -44.737885 
Slc9a4 13.76369 
Slc9a4 8.299932 
Ifi203 69.495346 
4933404M02Rik -5.480723 
9030623N16Rik 135.7164 
Hrc -3.0428936 
A630039F14Rik -3.4227674 
LOC380787 23.989973 
Dnahc2 -45.259487 
Cryz -2.1123452 
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Lpxn -13.401927 
D530004J12Rik -7.014247 
Edg7 -1.6235354 
6820408C15Rik -71.78285 
Ptpn8 12.074154 
LOC380842 -96.52662 
9330161C17Rik -3.6476393 
Pim1 17.399927 
1110018J23Rik -6.598663 
4933417K04Rik -22.079964 
LOC231462 1.7637912 
A830087P12Rik -6.3359547 
Ddo -52.8597 
4932415A06Rik -9.150352 
Slc22a17 -4.3561683 
Casc1 -45.03372 
Casc1 -4.098376 
9030418K01Rik -5.8692813 
LOC331595 -49.758327 
1700001O22Rik -14.378539 
C2 28.046274 
4933405I11Rik 5.5617485 
Slc5a8 16.147255 
1700066B19Rik 10.237174 
A330021E22Rik -21.889818 
A330021E22Rik -21.9644 
Ebi3 16.804497 
Ints6 10.819539 
1700007K13Rik -36.75222 
Rhof 11.151914 
Ak7 -22.122171 
B230363K08Rik -99.97411 
Card15 6.587546 
Slc35c1 -2.5983336 
BC029169 9.023405 
Acta1 -56.889294 
Lrsam1 -4.6719723 
Adh1 -2.258216 
2610028H24Rik -124.77361 
Gvin1 88.786835 
Isg20 4.583856 
5033414D02Rik 4.649564 
LOC384343 26.442842 
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Lrpb7 -32.796 
2900006K08Rik -23.98524 
A730054J21Rik -20.708189 
Sncg -1.5793785 
2210413P10Rik -3.1469152 
Ifitm6 36.36291 
Adamts4 300.66315 
Dnali1 -23.25053 
Grip1 -2.9057631 
1500015A07Rik 28.102886 
4933428F06Rik -52.27514 
Cd244 3.7681665 
4933430F08Rik 132.17178 
Aqp11 -6.6303277 
Tnfrsf19 -19.310022 
LOC381457 7.9593415 
C630016B22Rik 5.185207 
Mapk15 -20.624105 
2610028H24Rik -110.92721 
scl0003155.1_68 -2.891191 
4930528G09Rik -78.82128 
Cxcl2 264.14862 
E030019B06Rik -20.972475 
6430628N08Rik -3.7217908 
Ceacam1 4.4437914 
Chi3l4 -8.749407 
Itlnb -1.4597262 
1700016J18Rik -59.856785 
1110049B09Rik -38.420452 
D4Bwg1540e -73.22609 
Acaa2 -3.225109 
Acaa2 -3.9184122 
BC036961 27.2213 
Rtdr1 -34.40007 
Lhb -16.639118 
1700007J06Rik -32.029785 
4930534B04Rik -7.8614287 
Ttc18 -17.498028 
Csta 14.027455 
LOC333670 -17.393137 
A430073A17Rik 6.0253515 
Fn3k -21.116127 
4930438O03Rik -3.8284912 
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Trim44 -1.0726924 
2900052P03Rik -7.194705 
Ppp1r3c -5.756804 
Lrrc50 -66.95898 
Tcea3 -13.544936 
Azgp1 -13.210191 
Il6 6.570271 
BC010462 17.017906 
Aldh3b1 -10.930594 
Gp49a 79.96013 
Rab36 -5.5520024 
4931433A13Rik -4.344605 
Adamts9 24.222624 
2810422M04Rik -10.915428 
Kif9 -23.536377 
Spata17 -11.298378 
Rage -4.2983847 
Rage -15.949286 
Spag6 -28.453316 
Spag6 -38.839592 
Sprr2f 19.87772 
Serpina3g 55.48399 
Osbpl6 -132.87158 
1700123D08Rik -7.3263907 
LOC241084 -35.116776 
Ltf 12.904063 
Lrrc6 -9.372501 
LOC386463 74.38535 
3110040M04Rik 18.400597 
LOC237250 -4.581747 
Adrb2 6.7966495 
LOC546840 -10.911534 
D330022A01Rik -19.868681 
5730402C02Rik -19.478422 
Cd177 -3.1883702 
BC028975 -20.366316 
Sprr2b -3.4636607 
A230069H10Rik -1.5219984 
Frmd4b 4.5070868 
1700013F07Rik -37.376266 
9930023K05Rik 95.82212 
9930023K05Rik 105.071815 
4930451C15Rik -20.777159 
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2510015F01Rik -10.099755 
1110069O07Rik -36.470734 
Slpi 10.625102 
LOC381362 -9.328591 
4930442L21Rik -29.022951 
Tnfrsf1b 8.102031 
Tnfrsf1b 17.41249 
C330001K17Rik -26.115128 
AA467197 14.979809 
Tekt1 -60.483406 
Tekt1 -40.70461 
Ii 101.955 
4932425I24Rik -20.70129 
9030611K07Rik 9.642454 
LOC215949 -5.789652 
Mlh1 -11.270096 
Itga2 6.9616275 
Spag5 -11.966632 
S100a9 99.792145 
1700120B06Rik -40.166912 
Slc44a1 3.2074864 
Trim40 14.164214 
4930465M17Rik -5.745584 
1200009I06Rik 30.346096 
C330001K17Rik -76.19055 
Zmynd10 -16.34682 
Map3k5 -9.48425 
D630004K10Rik -4.734312 
Csf2 6.6795254 
Tsga10 -14.727856 
BC018371 -6.218881 
Acaa2 -3.5945487 
4933409I22 -53.44357 
4931415C17Rik -10.89132 
Wfdc12 52.06049 
LOC381737 -10.040842 
4932416A11Rik -3.2764194 
Pdgfc -4.7821374 
Mmp13 4.52152 
A530060O05Rik 74.501236 
Ppp1r9a -5.6219783 
4932415A06Rik -10.296492 
Slco1a5 4.04789 
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Lnpep -7.945842 
Ysk4 -11.651991 
Slc5a1 9.234197 
Saa3 26.291622 
4833426H15Rik -3.0473611 
1700010A17Rik -27.83073 
1700094D03Rik -25.349436 
Enpp4 2.9199724 
4933427G17Rik -5.886851 
D330014H01Rik -74.64089 
C86987 -10.863409 
Lincr 45.80014 
Lincr 61.500526 
Sdcbp2 5.7782617 
C230080I20Rik -4.917731 
Ch25h 4.627919 
B230328G18Rik -1.12808 
Plxdc1 -3.5408723 
Cte1 -20.435545 
1700007G11Rik -63.560345 
6330406P08Rik -6.3480644 
B230396O12Rik -14.911249 
Dnaic1 -61.12469 
1600029I14Rik -21.598225 
Sult1d1 -33.671505 
Mccc2 -9.44772 
Tmem20 -3.6095567 
Cxcl16 7.8353767 
Xylb -14.6778345 
AU021034 -31.521854 
Sprr2e 123.3557 
D11Ertd686e -87.69467 
BC004044 6.8603363 
BC004044 13.766559 
Dgat2 4.7578716 
2410116G06Rik -6.0053563 
Plxnb3 -33.048252 
LOC224813 -5.250548 
Slc27a2 -3.3052275 
LOC381284 -19.231024 
1700026D08Rik -30.082954 
Hey1 -4.37703 
LOC237891 -6.4645414 
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Mdm1 -20.532671 
Syt5 -8.666486 
0610009A07Rik -26.136206 
Clic4 5.730517 
Ccne1 8.374979 
1700018O18Rik 28.608704 
9130024O20Rik 14.546422 
Dfna5h 24.451979 
LOC381050 14.717464 
Wfdc13 -6.902324 
BC051019 -22.941721 
Tsga14 -15.265143 
Rwdd2 -6.1151185 
Rab4a -4.1549053 
Cxcl2 135.70998 
C130081G24 4.4336486 
Mak -4.7741446 
Tnfaip3 10.568073 
4732452L12Rik 9.553486 
BC013672 28.062946 
Sult1a1 -12.560923 
4931407K02Rik -19.263119 
Slfn4 9.825907 
Nos3 -4.1788535 
Il17c 264.16556 
Lrriq2 -3.8740726 
1700034E13Rik -8.3601465 
Ccna1 -51.234467 
Fxyd2 -107.00877 
Tcp11 -4.1918936 
Wdr31 -22.951315 
BC023105 35.56434 
C230080E09Rik -3.6145625 
Irg1 507.68845 
Irg1 390.2455 
9130008F23Rik 7.797466 
LOC195357 166.8272 
1110007F12Rik 2.7291656 
Fbxl13 -41.35467 
Fbxl13 -18.400396 
Ly64 3.6209624 
Ly64 3.5992072 
Dio1 -15.182323 
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Calcb 12.612391 
LOC381736 -72.9035 
Osmr 9.874561 
Nos2 10.429437 
Tnip1 6.3659554 
LOC381245 131.37732 
Casp4 8.567122 
AU020206 13.60617 
LOC382044 -12.625392 
Slc2a6 130.07884 
Il1a 37.127827 
Il1a 48.53383 
scl0002073.1_13 21.427965 
Tln2 -4.1522803 
0610037B23Rik 22.718325 
Pglyrp4 34.590633 
Nppb 12.309643 
Psors1c2 75.07662 
4430402I18Rik -1.4967674 
LOC384001 -1.6010369 
AY078069 12.758204 
BC036564 -52.573895 
Ctse -2.214388 
Stxbp4 -5.7624807 
Frk 2.9573557 
LOC381270 -12.905317 
Palm -11.56739 
scl000956.1_130 17.64839 
Pglyrp4 74.39592 
Slfn1 594.29346 
M32486 -3.1736796 
LOC240921 15.022007 
Pdcd1lg1 23.670366 
2510003B16Rik -1.7940722 
P2ry2 3.858005 
1600029D21Rik 7.5845146 
Hap1 6.7656994 
0610007L01Rik 13.443201 
Aifm3 -1.7380589 
9930020N01Rik 15.108525 
Ccdc39 -52.62793 
Ccdc39 -11.084942 
4930404N11Rik -12.427151 
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Mad 14.658037 
Mad 12.003484 
Tst -4.7814155 
9930032O22Rik 3.6618903 
4933428D01Rik -95.88333 
Pemt 4.6793065 
Muc4 9.326261 
Muc4 9.113364 
Nln -5.582543 
Dnali1 -3.5106113 
S100a8 3.9939768 
4930504H06Rik -4.5453143 
Ptp4a2 2.423661 
Cd40 189.85751 
Ccdc96 -18.526485 
3110023G01Rik -9.711737 
Aldh3a1 -3.4343762 
Tnfaip2 44.811302 
Tnfaip2 30.566004 
Tnfaip2 30.717188 
Slc7a4 -9.228412 
Plat 6.908556 
Fmo5 -9.574292 
Snai3 5.6178327 
Cbr3 -5.013678 
2310014L17Rik 13.174543 
6430537H07Rik -52.213806 
Chia -35.650204 
Indo 28.135294 
Vav3 1.2001798 
Tmem2 2.3640537 
3300002A11Rik -203.79768 
Nek11 -13.514322 
Stra6 10.800038 
Plk3 6.5460773 
Cd44 2.9366689 
Cd44 2.809089 
Stc2 -1.5616426 
5330439J01Rik -11.656634 
Adam8 4.101046 
Adam8 4.7410054 
1110017D15Rik -15.635389 
1110017D15Rik -14.668147 
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38047 -24.80307 
Tnfrsf5 93.69475 
3830408G10Rik 12.793762 
5730508B09Rik 26.740488 
Cry2 -3.788241 
Speer4c -26.022442 
Gzmm -4.2533712 
A530065I17Rik 4.8945932 
D15Wsu169e -6.6967854 
Hs3st1 6.0210423 
Tnfsf10 41.742878 
LOC381036 -46.774548 
Dusp13 25.177153 
Dusp13 12.620694 
Ly6g5b 6.9437537 
Eml1 -25.999874 
Pccb -9.281327 
LOC381697 -3.17976 
Lbh -3.0362144 
Cd59a -5.1362534 
3110032G18Rik -4.442849 
LOC328316 17.925676 
Tnf 100.95429 
Slc9a2 25.362368 
Serpina9 1.2381666 
Mogat1 -5.203873 
1700003M02Rik -25.30287 
4930526H21Rik -18.165352 
4921511C04Rik -10.323531 
1700086L19Rik -4.2145586 
Steap -1.4772114 
4831415H04Rik 5.3691263 
LOC195359 36.639946 
Rbpsuh 8.222415 
AI875199 -4.415329 
BC007180 -3.6139836 
Ldhd -3.2405431 
Gm1574 -78.98469 
Gm1574 -31.619984 
Pla1a 35.910603 
LOC382447 1.9882851 
Ttc29 -96.75366 
Tpd52l1 -5.0660233 
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Tpd52l1 -5.058146 
LOC381625 -5.017646 
4930430E16Rik -9.509059 
LOC269531 -19.910957 
Gbp5 79.894356 
Sema7a 25.952602 
Sema7a 66.42088 
Nat5 10.944688 
Smpdl3b 14.081125 
Tff1 19.382963 
Cldn10 -11.482289 
Tsnaxip1 -86.01117 
Tsnaxip1 -46.561455 
2410004P03Rik -17.128096 
Pml 24.989002 
B230373P09Rik -85.82554 
Ncoa2 4.969075 
2510015F01Rik -4.8195868 
4932443I19Rik -45.487377 
scl00319622.1_241 4.8749294 
1110049B09Rik -12.393307 
Dusp4 8.14277 
Dusp4 53.133057 
4930403G18Rik -2.6593335 
Gsta2 -6.8854537 
2610041P08Rik 10.766775 
Cldn10 -49.152927 
BC094916 9.565945 
1700003E16Rik -56.22664 
Slc25a18 -26.8294 
A530050E01Rik 48.088715 
Fmo3 -7.77887 
Tomm70a 1.3728225 
Rps6ka5 5.6027327 
Ifitm1 22.51026 
9530077C05Rik -21.402067 
Table 4 List of genes differentially expressed by co-exposed AECs compared to 
LPS or IAV exposure alone in Figure 16 
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Table 5 List of genes differentially expressed in co-exposed AECs compared 
to S. pneumoniae or IAV exposed alone in Figure 17 
Symbol FC ([x31+D39] vs. [mock]) 
Rnase1 -4.005454 
Spag8 -9.05239 
LOC381546 -3.2360406 
LOC380658 -3.1613936 
Adam7 19.34134 
LOC381916 -8.504549 
Irgm 9.037786 
5730410E15Rik -7.926718 
Cxcl1 5.8797297 
Ccl4 231.5049 
Ccl4 28.141367 
4833431D13Rik -2.8066792 
Casc1 -28.939758 
LOC381260 -28.315615 
Ak7 -5.942505 
Acta1 -14.186584 
LOC381165 -12.846548 
scl0001045.1_6 -11.609933 
Arrb1 -1.278096 
4831417L10 -24.942825 
Cxcl2 10.684248 
LOC381336 -6.008809 
scl0003377.1_167 -3.7938497 
D4Bwg1540e -4.565399 
4930534B04Rik -10.664519 
Ttc18 -14.206028 
Slc7a9 1.1069247 
2900090M10Rik -4.2518177 
4931433A13Rik -27.193962 
1700067I02Rik -23.424515 
B230396O12Rik -4.514424 
4930579J09Rik -4.5954247 
1110020C03Rik -7.340877 
4933429I20Rik -8.61118 
Slpi 3.0236628 
LOC381362 -5.5322275 
C330001K17Rik -7.423574 
Ii 26.057446 
Hs3st6 -1.9617084 
4930533K18Rik -8.717638 
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Zfp474 -4.7618046 
A530060O05Rik 45.8859 
Lnpep -5.507354 
Ii 14.868839 
Ii 15.477973 
Lincr 44.404655 
Ccdc11 -2.0554867 
Lnx1 16.161211 
2410116G06Rik -3.432547 
Klk11 -2.4229279 
Kcnq1 -3.7446623 
Zp3 -5.6077 
Vnn3 5.5073066 
Vnn3 5.0325937 
Cxcl2 12.230791 
4931407K02Rik -11.487261 
Bicc1 -12.917514 
Ubxd3 -3.5025134 
BC025206 -3.1898446 
Uox -9.287806 
Traf1 12.486707 
scl0002073.1_13 8.048939 
2410003A14Rik -8.605818 
Cxcl10 72.49143 
Bphl -3.0654972 
Cd40 68.38418 
Chia -4.1731677 
BC018465 15.089908 
Tnfrsf5 18.104614 
LOC226356 -33.549065 
A730062O07Rik -2.417968 
Emid2 -8.197315 
Ttc29 -8.052639 
Abca8 -6.130264 
3830422K02Rik 14.080281 
4933437K13Rik -3.1275494 
4921537F17Rik -4.2194486 
A430083B19Rik -15.520043 
1700003E16Rik -5.9079256 
A530050E01Rik 17.887083 
Table 5 List of genes differentially expressed in co-exposed AECS compared to 
S. pneumoniae or IAV exposure alone in Figure 17 
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Table 6 List of genes differentially expressed in co-infected whole lungs 
compared to S. pneumoniae or IAV infected alone in Figure 18 
Symbol 
FC ([5days + 48 hrs-
X31+D39] vs.  
[5days + 48 hrs-
PBS+PBS]) 
Aldh1a3 9.2532625 
Gpr4 -2.4762802 
Stfa2 14.25607 
Peg3 -4.241927 
Ccl1 11.8544445 
LOC381287 23.939367 
1700073K01Rik -5.651048 
Spic 7.586558 
Hr -3.8824863 
Paqr6 -2.2973847 
Cnfn 7.1827416 
G630023A01Rik -6.286888 
Thrsp -3.0482879 
Gm614 4.396164 
E230025N21Rik -4.683217 
E030040J04Rik 3.563552 
D230040N21Rik -1.9805455 
1600013E24Rik -2.841649 
Setdb2 5.626637 
Ldb3 -4.8544188 
Clk3 3.1310713 
1700111D19Rik -2.8481288 
Fech -4.291375 
Ftsj -4.265552 
Mx2 14.083483 
G7e-pending 4.5161843 
Ell3 2.934281 
C330016K18Rik -2.366802 
A530023O14Rik 19.344511 
A530023O14Rik 20.370556 
4933407I18Rik -11.14213 
6430514L14Rik -5.098839 
Il18rap 8.825821 
4933439C10Rik -4.0925436 
LOC328833 5.8336625 
Mtap4 1.5323141 
Slc7a11 18.059122 
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Slc7a11 14.081731 
1300013B24Rik 2.2533054 
Gsta1 -13.307004 
Daam1 -4.749987 
Tlr9 14.519885 
Hsd11b2 5.63653 
Hist1h2be -3.6725256 
4932425I24Rik -4.282527 
E430024F02Rik 6.1306915 
Atp7b -3.733271 
Tnf 48.616432 
G630009D10Rik -3.1447508 
LOC386545 16.019907 
Erdr1 -6.245958 
Rbp7 -2.569078 
LOC232875 -4.863572 
Stfa1 5.7176332 
Stfa1 18.351698 
Cxcl1 10.235682 
0710008A13Rik 4.2041783 
Cyp2e1 -4.951545 
Nr1d1 -5.9089603 
scl000034.1_162_REVCOMP 3.1244426 
LOC382154 4.3704066 
Krt1-13 10.807907 
D7Bwg0611e 6.2388325 
Ccl4 107.02748 
A930013B19Rik -4.1657777 
scl0003168.1_6 9.344341 
Gpr87 9.996748 
LOC278666 30.618946 
Zfpn1a1 9.0267725 
EG433016 9.802567 
Irs3 -7.2490907 
IGKV8-21_Y15982_Ig_kappa_ 
variable_8-21_114 4.76241 
Igfl3 5.1069446 
LOC212718 5.752527 
Fbln1 -5.9795547 
9030205A07Rik -13.992411 
9830169C18Rik -6.028699 
LOC381879 8.650268 
Krt2-6b 4.0608325 
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Acta1 45.53405 
LOC381165 -4.3269534 
Thy1 32.916348 
Agpt -10.409776 
Dixdc1 -6.4854984 
Aspn -3.690544 
LOC383860 -2.0231004 
Olfr56 7.0751095 
Pstpip2 13.208218 
Kcna6 -8.368392 
LOC278795 -2.5226665 
LOC213439 15.658827 
2610103H04Rik 3.8096554 
Ifitm6 5.9908385 
Ifnb1 41.085762 
Stx11 6.9277024 
Ccl3 87.47929 
Mup2 2.3990302 
Hspa1a -2.948982 
9430028F23Rik 8.407418 
Cyp3a13 -1.9303551 
Ambp 19.018637 
Cyp2a4 -21.613972 
Tff2 -60.54589 
scl000078.1_211_REVCOMP 2.3224747 
Pbp2 2.0175982 
Mov10 3.784699 
9030624G23Rik 4.0423946 
Serpinb2 40.018063 
1700023L04Rik -7.0663724 
Il8rb 4.689686 
Gp2 -10.0725355 
Prok2 5.0479474 
Cxcl2 46.488182 
2010002M12Rik 4.6770477 
AI324046 28.00435 
Vipr2 -2.7546325 
2310003M01Rik -3.085362 
Phf11 5.9159303 
Lhb -10.715599 
Slc7a11 6.443861 
Lcp2 9.1721525 
Il1rn 23.660025 
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Il1rn 4.5094924 
LOC386508 20.890017 
Grm6 2.2812102 
Car3 -4.680913 
Cspg2 4.072794 
D630039M01Rik -10.237084 
Por -6.7705603 
Gzmk 262.37027 
Slc39a12 -4.369838 
Serpinb12 4.9955826 
scl000085.1_5_REVCOMP 5.178832 
Hif1a 4.8273635 
BC018222 -3.2216098 
Gstm6 -2.6782017 
Csf2rb1 6.1862516 
A430079P20Rik -1.8763704 
Cxcl10 600.971 
C630002C17Rik 5.1121655 
Dner -9.2629 
Pdzk3 -4.710562 
Il10 64.81515 
Awp1-pending 6.92514 
D630040I23Rik -1.8495762 
2310003D02Rik -2.649386 
Lamc3 -5.04383 
LOC381948 6.6153135 
Gria1 -4.6646733 
Tgtp 3.6317859 
Slfn10 6.5077624 
Il27 13.790844 
Pkib 6.904138 
B930018B01 -8.343017 
Mb -8.1575 
Rptn -3.3160033 
Folh1 -21.115673 
Krt1-16 3.6016574 
Nptx1 -3.2138197 
Hist1h3h 3.0532596 
Avpr1a 1.3829854 
Gprasp2 -11.598816 
Mapt -5.0617537 
Clec5a 19.792244 
A330030K22Rik -2.407602 
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2310007F04Rik 5.5213084 
IL1RA 123.79579 
2610301F02Rik -7.2090883 
Osbpl1a -2.8101897 
Clecsf8 7.774864 
BC067047 2.6944954 
U46068 -32.76065 
Oas3 4.301259 
LOC228003 -3.5261433 
Trim6 5.434816 
A830094I09Rik -4.0341988 
4932415A06Rik -11.353266 
U46068 -25.698349 
Gpr84 142.95872 
Gpr84 59.014965 
Slc6a4 -10.887822 
Pamci -6.349332 
1700111A04Rik -2.7490196 
Lmnb1 7.577452 
LOC386169 7.31161 
Mlp 6.226706 
Mlp 4.034599 
Mlp 4.269826 
E030025D05Rik -9.970869 
Casq2 -5.8209553 
Car14 -4.271174 
Ptafr 9.604911 
Ccr8 10.151282 
Hist1h3c 8.145356 
LOC225609 -1.8443635 
2300002G24Rik 17.832056 
C130022C01Rik -4.956253 
9430028I06Rik 6.59567 
D830007F02Rik -4.5564327 
1810007P19Rik -3.8690012 
LOC382177 17.124071 
Dmn -2.6123834 
LOC239770 5.655685 
Clca3 -2.5009844 
Clca3 -6.8066072 
A330042I05Rik -7.794612 
Ccrl1 -7.520608 
2610302F08Rik 1.7147381 
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4632423N09Rik -2.263005 
Slc16a5 -5.0342126 
LOC268885 7.1519656 
Cxcl2 35.851307 
D10Bwg0791e -3.71564 
Cyp2a5 -13.809622 
Cyp2a5 -14.241847 
Cyp2a5 -17.870626 
C030003H22Rik -4.818498 
Pcdh20 -1.8066928 
BC013672 20.122505 
Smad7 -5.2284126 
4931407K02Rik -6.5050516 
Slfn4 38.502865 
Stfa3 23.420675 
Nudt12 -3.1915348 
Stfa1 17.068232 
LOC381113 -4.6668243 
scl000073.1_22_REVCOMP 7.5612593 
scl0003154.1_1 4.8555236 
2410076I21Rik -4.182957 
Ptx3 26.08214 
Ptx3 52.39555 
EG408196 18.178535 
Irg1 221.22397 
Irg1 774.8814 
Aass -2.4967082 
Cd226 18.478956 
2900079J23Rik -4.218969 
Trem3 4.121832 
E130209G04Rik -2.383037 
Mlh3 1.0759473 
LOC214531 -2.5398877 
Bcl11b 10.718304 
Cd14 2.9737172 
TRAV6-
1_AF259071_T_cell_receptor_ 
alpha_variable_6-1_5 6.254975 
LOC382866 -3.3937132 
Calml3 -2.6970205 
Slc7a11 15.205605 
E330039G21Rik -7.6393137 
4930438O05Rik -4.142868 
Appendix 
 
277 
 
Nos2 8.427788 
9130221D24Rik -4.8061395 
Slc2a6 9.100533 
9430014F16Rik 11.653433 
Il1a 8.436582 
Il1a 8.671223 
scl0002073.1_13 13.485202 
4632424B03Rik 5.787881 
2300003P22Rik 16.990446 
A630059M09Rik 6.741285 
Sct 18.352911 
9930115F03Rik -8.229764 
Pcdh7 -3.8082902 
scl0001330.1_10 -3.6544385 
2900074L10Rik 13.055641 
Lep -1.241542 
Mpp2 -4.273582 
Gpr109a 11.242366 
G430091H17Rik 19.282732 
Ear11 7.114176 
4933432B09Rik -4.10112 
Syn3 4.8498545 
LOC242805 -1.8072358 
Fgf18 -4.46005 
Ckm -12.961521 
A130002I06Rik 17.130575 
Aim1l -2.9392996 
scl0003476.1_2802 -1.9170756 
2810474C18Rik 4.0068674 
Il1b 10.79308 
Mad 7.5480456 
Mad 21.078764 
Vcan 4.748157 
Cxcl10 386.2294 
A030006P16Rik -14.371817 
Ctla4 60.410725 
9330175E14Rik 2.7309005 
Txlnb -2.91859 
G630052H11Rik -3.1527958 
2900093B09Rik -5.905076 
Sntb1 -1.1454355 
Oasl1 69.75825 
Oasl1 51.018208 
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BC057371 -2.2531562 
Myl3 -3.5659628 
scl000959.1_2 -2.207537 
Ifng 142.51643 
Ifng 45.64189 
Mrgpra2 15.591386 
1700012B09Rik -5.395898 
Clecsf9 29.983204 
Clecsf9 15.015002 
Hmox1 7.743844 
Jam3 -4.479632 
scl00009.1_36_REVCOMP 16.916739 
Klra15 1.5972623 
1700094J05Rik 2.2243679 
Foxd4 5.5384827 
Cd207 -12.154116 
Trem1 6.071018 
Fcrla -1.3692479 
Actb 5.7753654 
Actb 4.6799197 
Mmp8 6.8417115 
Ank1 -3.3346198 
Ank1 -3.3601944 
Alpk3 -2.58638 
A530017D12Rik 2.6464221 
Ccl24 9.937703 
Hcapg-pending 4.511475 
E030003B04Rik -2.6439447 
Phlda2 -3.7232912 
Syn3 -3.277085 
Kcnf1 -2.6912522 
Slc28a2 61.83259 
Cd69 8.470249 
A430056A10Rik 4.6036096 
AF085738 6.0249553 
C530008M17Rik -10.654587 
Tnf 74.86471 
1300013J15Rik -2.2643158 
Bsg -8.07679 
Bsg -5.726946 
Serpina9 -3.391256 
Scgb3a1 -47.363407 
C730016G14Rik -6.6665125 
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Edil3 -4.0142097 
2700033K02Rik -4.138234 
2810451K12Rik -6.4135146 
Gm1574 -7.906493 
mt-Nd5 12.727218 
Expi 10.941179 
Scgb3a1 -88.602585 
Spa17 -2.6221395 
Hspa1b -3.8559456 
A630012P03Rik 5.3480573 
Vstm2 -6.946604 
Usmg3 5.440463 
Igf2bp3 3.678903 
A830026L17Rik -4.6222897 
LOC386298 -6.8312926 
Pkp1 4.66488 
1700019G06Rik 5.820305 
4930553M18Rik 2.7334979 
1110012N22Rik -2.533811 
A530050D06Rik -2.1718853 
LOC381146 -7.3547177 
Gprk2l -5.474133 
Prom2 -4.3783746 
Tcf1 2.5104222 
BC094916 12.335565 
Mrgpra7 5.5885677 
Itgbl1 3.0382054 
Table 6 List of genes differentially expressed in co-infected whole lungs 
compared to S. pneumoniae or IAV alone infected alone in Figure 18 
 
  
Appendix 
 
280 
 
Table 7 The gene list from the cell death and survival pathway in Figure 42D 
Symbol 
FC ([Alpha] vs. 
[Media]) 
FC ([beta] vs. 
[Media]) 
FC ([lamda] vs. 
[Media]) 
Hap1 1.5368242 1.6429482 4.650505 
Psmb10 1.3218682 1.5655625 4.461529 
Psmb10 1.3302051 1.4910861 4.33169 
Nt5c3 1.0158954 -1.0787896 2.4042892 
Irf7 46.627216 146.663 828.19336 
Muc1 1.192938 1.2522265 2.0618737 
Muc1 1.139818 1.1713599 2.0833116 
Fgfr1 -1.1365047 7.1685767 -1.0663099 
Irgm 3.205464 4.28573 14.825324 
Gsta1 -1.1697929 -1.7688241 -4.289652 
Gsta1 -1.2170107 -1.8316518 -3.6169176 
Gsta1 -1.1584047 -1.6666508 -5.4789934 
Tnfrsf11b 1.2631515 1.4013133 6.1671166 
Irf1 1.1271989 1.2133054 2.2168913 
Irf1 1.0988456 1.1622128 2.088025 
Pml 1.2538916 1.2722906 2.503706 
Tdrd7 1.3670524 1.3958756 2.5815835 
Ifit2 1.2089369 2.0138652 35.108536 
Ifit2 1.2698854 2.7552 42.715237 
B2m 2.8235974 4.727805 9.850022 
B2m 3.009347 5.113851 10.285195 
Txnip 1.0627877 1.1859338 2.4460237 
Isg20 1.2627181 1.9371066 6.329873 
Scd1 -1.16213 -1.370751 -2.3313024 
Gadd45g 1.3798066 1.8352783 2.6689386 
Gadd45g 1.5746205 1.9802735 3.8099658 
Trim21 1.9199371 2.6484532 10.456548 
Lgals3bp 5.980614 8.171425 21.214617 
Lmo2 1.1730537 -1.0117885 7.1917257 
Casp1 1.2345303 1.1968346 2.6525166 
Optn 1.4300839 1.3557348 2.56553 
Tapbp 1.3910825 1.4895842 4.12192 
Parp14 3.755458 5.3035007 17.907188 
Sort1 -1.0998355 -1.3885114 -2.506992 
Tap1 3.341829 4.5298557 20.053694 
Adar 2.1189837 3.9119709 10.668044 
Cd47 1.2327391 1.1701299 3.4737177 
Sort1 -1.2232996 -1.4289604 -2.5285811 
Plcd1 -1.4457713 -1.7698541 -3.9379032 
H2-T23 1.5179851 2.0125878 8.31526 
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H2-T23 1.6318599 2.3127959 6.9104276 
H2-T23 1.5618751 2.148976 8.652974 
Il15 1.3950137 1.6807132 3.3993754 
Oas3 8.389993 14.457958 66.79426 
H2-K1 1.4208133 2.3953323 7.3155456 
Usp18 3.6112924 5.7998853 19.54635 
Usp18 3.401401 4.730425 14.133283 
Usp18 3.7943451 6.0265775 27.15867 
Ddit3 -1.0515045 1.2992167 5.2128167 
Ddit3 1.6529723 1.5567713 6.9476175 
Psmb8 2.5984392 4.568623 28.468575 
Psmb8 1.8362747 3.207279 25.738182 
Igfbp5 -1.1119783 -1.1305896 -2.5272732 
Igfbp5 -1.0542079 -1.1112237 -2.251628 
Clic4 1.4665444 1.5921469 2.3563085 
Cyr61 1.2197021 1.4718664 2.167132 
Mlkl 1.2147489 1.2303972 2.9012816 
Stat2 3.9967399 7.6267147 37.49118 
Tgm1 -1.299958 -1.5127536 -2.1610565 
Daxx 1.2571676 1.3861653 3.744458 
Igfbp5 -1.1425205 -1.2025253 -2.462872 
Lgals8 1.1556364 1.3102657 2.407126 
Lgals8 1.2180737 1.3407359 2.6079981 
Trex2 1.0123321 -1.071811 2.3668616 
Casp4 1.3045112 1.5389134 4.3948336 
Il1a 1.0248451 -1.2250439 2.3398027 
Txnip 1.0614768 1.1434577 2.3508062 
Rnf31 2.1212373 2.3792245 4.457319 
Rbm43 1.1655492 1.2214872 2.528525 
Adar 2.1739302 2.9827142 8.134632 
Adar 2.0044742 2.392418 3.3280604 
Cdc42ep3 1.1717758 1.2427976 2.113384 
Oas1b -1.1009653 5.3312135 73.88632 
Irf5 1.2627467 1.0022689 4.130327 
H2-M3 1.4727287 1.3134012 4.79143 
Btc 1.2036638 1.2286314 2.6748407 
Ifit3 10.296514 47.546497 934.8526 
Ifit3 9.554748 46.45387 1523.5782 
Ifit3 11.627982 51.944935 1667.002 
Trex1 1.194127 1.795586 9.617526 
Trex1 1.6882477 2.0657175 14.095984 
Aldh3a1 -1.2339481 -1.6135081 -3.7445908 
Tnfaip2 -1.2731305 -1.6087726 -2.8936818 
Appendix 
 
282 
 
Gch1 1.146738 1.1844139 2.6152468 
Gch1 1.1457549 -1.1357046 2.2476487 
Plat 1.1357344 1.2480022 2.1409032 
Lama1 -1.1629443 -1.3475317 -2.319883 
Gnpnat1 -9.133604 -10.3266535 -9.809605 
Atf3 -1.0624293 1.2637888 2.6643963 
Pcsk9 -1.0742208 -1.3455986 -2.3364913 
H2-K1 1.1868508 3.2084458 13.557327 
Ephb6 -9.782708 -9.662275 -8.637292 
Tap2 1.4973706 1.6387764 5.655904 
Gas6 -1.116394 -1.7596534 -2.2108812 
Plac8 1.0006844 1.0887637 2.5553946 
Prkcdbp 1.065209 1.3301984 3.43014 
Prkcdbp 1.0456362 1.3674774 4.0843987 
Stat1 2.7910256 4.0751166 16.041254 
Stat1 3.000436 3.8189561 17.763748 
Sema7a 1.0215431 1.3746121 2.6188538 
Spink2 1.9964968 2.2641604 6.470621 
Mt1 -1.1559778 -1.2769563 -2.058757 
Timp3 1.3815713 1.7367173 3.3761735 
Gsta2 -1.0847636 -1.5502074 -3.1348186 
Table 7 The gene list from the cell death and survival pathway in Figure 42D 
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